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Abstract 
Background: The bioavailability of BCS class II drugs used in non-small cell 
lung cancer (NSCLC) treatment is limited by low water solubility. Also, current 
therapies for NSCLC cause systemic side effects and sub-therapeutic levels of 
drugs at the target sites. Colloidal systems administered by the pulmonary route 
may overcome these problems.  
Method: A genistein-mPEG conjugate was synthesised and characterised for 
delivering erlotinib or curcumin in micelles. Liposomes co-loaded with genistein 
and erlotinib were developed as an alternative formulation approach and studies 
using DSC and HPLC analysis. The aerosol properties of micelles and liposomes 
were measured using the Next Generation Impactor (NGI). The Fast Screening 
Impactor (FSI) was investigated as an alternative to the NGI for aerosol 
characterisation of nebulised liposomes. Three parameters (nebuliser types, 
impactor operating conditions and liposome size reduction methods) were studied 
using the FSI.  
Results: Successful conjugation was confirmed by FT-IR, NMR and MS. 
Curcumin loading into conjugate micelles had mean size < 200nm, with ≈ 50% 
encapsulation efficiency (EE). However, the genistein conjugate was not 
appropriate for erlotinib delivery, having low EE (<3%). For liposomes, the mean 
size was ≈130 nm, with 10% EE (erlotinib) and 100% EE (genistein). DSC results 
showed incorporation of both drugs into the bilayer, giving a broadening of the 
main phase transition of DPPC with a decreased main phase temperature. The air-
jet nebuliser was superior to the vibrating-mesh device in terms of significantly 
higher fine particle dose (FPD) and fine particle fraction (FPF). The FSI (5± 3 ºC), 
with modification operated at 15 L/min, was found to be simple to use and labour-
saving for simple aerosol characterisation, giving comparable results to the NGI 
for FPD and FPF. Extruded liposomes showed greater size stability than sonicated 
vesicles during preparation and nebulisation. 
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Conclusions: Optimised micelles and liposomes with desired mean size and drug 
entrapments have the potential for nebuliser delivery of genistein, erlotinib and 
curcumin, and may be suitable for delivering other hydrophobic drugs. 
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Research Impact Statement 
Lung cancer accounts for almost 20% of total cancer-related deaths worldwide in 
both men and women. 85% of all lung cancer cases are classified as non-small 
cell lung cancer (NSCLC). The majority of NSCLC patients have experienced 
advanced local invasion and metastatic disease, as current therapies including 
chemotherapy are not sufficiently curative. Currently, chemotherapeutic 
molecules are administered via the oral or parenteral routes, causing systemic side 
effects and sub-therapeutic doses at the target sites. Thus, this study aimed to 
develop drug-carriers capable of pulmonary delivery, which may achieve the 
effective localised treatment of NSCLC. 
This study helps in our understanding of the potential of polymeric micelles and 
liposomes for the co-delivery of hydrophobic anti-cancer molecules by the 
pulmonary route. Since this delivery route allows the avoidance of first-pass 
metabolism and drug is administered at the target site, lower doses can be 
considered compared with oral route. Such a formulation approach may be 
beneficial for NSCLC patients, improving their survival rate and quality of life, 
and this can be a platform for other drugs used in the treatment of respiratory 
diseases.  
The findings indicate that an abbreviated impactor using the Fast Screening 
Impactor (FSI) may be a useful alternative tool compared to a full-cascade 
impactor (Next Generation Impactor, NGI) for simple aerosol characterisation of 
nebulised formulations for routine quality control of large-scale production, or in 
pharmaceutical development studies. The concept of abbreviated impactor 
measurement (AIM) using Efficient Data Analysis (EDA) is receiving with 
attention from medicine regulators and world pharmacopoeias for routine quality 
control of inhaled products. This study presents key data informing the 
development of this new methodology.  
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 Lung cancer 
 Background 
Lung cancer causes the most cancer-related deaths (more than 1.69 million deaths, 
19.20%) in both men and women worldwide (Zarogoulidis et al., 2013; Siegel et 
al., 2014). Lung cancer is divided into two types: 85% of all lung cancer cases are 
classified as non-small cell lung cancer (NSCLC), whereas small-cell lung cancer 
(SCLC) accounts for 15% of total cases (Babu et al., 2013; Goel et al., 2013). 
NSCLC is classified into three main types: squamous-cell carcinoma (25-30% of 
all cases), adrenocarcinoma (40% of the cases) and large-cell carcinoma (5-10% 
of lung cancers) (Zarogoulidis et al., 2013; Zappa and Mousa, 2016). The 
common signs and symptoms of NSCLC are cough, wheezing, breathlessness, 
loss of appetite and chest pain. However, most patients are asymptomatic. When 
the cancer spreads to other organs, it may affect bones, liver and nervous systems, 
causing bone pain, jaundice and fatigue. Patients who experience the common 
symptoms of NSCLC are generally referred for a chest x-ray and/or CT scan to 
determine whether the cancer has spreads beyond the lungs (Kayser et al., 2017; 
Grapatsas et al., 2017). More than 70% of patients with NSCLC are diagnosed 
with metastatic and locally advanced disease, while those having a localised 
cancer account for only about 20% of NSCLC cases at the initial diagnosis 
(Grapatsas et al., 2017; Rudokas et al., 2016). There are a number of risk factors 
associated with lung cancers, such as smoking, alcohol, air pollution, occupational 
exposure and genes. More than 80% of lung cancer deaths are attributed to 
cigarette smoking (Molina et al., 2008; Zappa and Mousa, 2016). 
 Current treatment options 
The treatment options for NSCLC are primarily based on the stage of the lung 
cancer. Surgery is the most successful and consistent therapy to remove the 
tumour for patients with early stages (stage I and stage II NSCLC), whereas those 
who are diagnosed with locally advanced (stage III NSCLCL) or metastatic (stage 
IV NSCLC) (approximately 70%) benefit better from cisplatin-based 
chemotherapy or targeted therapy (personalised medicine) (Molina et al., 2008; 
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Reck et al., 2013; Zarogoulidis et al., 2013). Radiation treatment is beneficial for 
those who do not respond to surgery or chemotherapy (Molina et al., 2008; Zappa 
and Mousa, 2016). The combination of chemotherapy, surgery and/or radiation 
therapy or adjuvant therapy is used as the standard treatment to reduce the risk of 
lung cancer relapse and to increase overall survival. However, this regimen is 
suitable only for certain patients with early-stage NSCLC (Schettino et al., 2008; 
Sangha et al., 2010; Zarogoulidis et al., 2013).  
 Targeted therapy 
Targeted therapy for NSCLC has been developed to treat specific molecular 
targets by altering major cell-signaling and regulatory pathways (Molina et al., 
2008). The epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, 
plays an important role in the development and progression of NSCLC 
(Zarogoulidis et al., 2013; Zappa and Mousa, 2016) and overexpresses in various 
epithelial tumours including NSCLC (40- 80%) (Schettino et al., 2008). Inhibitors 
of EGFR including tyrosine kinase inhibitors (TKIs) such as erlotinib and 
gefitinib as well as anti-EGFR antibodies such as cetuximab and panitumumab 
have shown clinical benefit in patients with NSCLC. However, TKIs are the most 
promising therapy for NSCLC due to a significant response for patients with lung 
adenocarcinoma (Riely and Ladanyi, 2008; Zappa and Mousa, 2016). EGFR gene 
mutations, which account for 10-15% of European and Asian patients with 
adrenoma carcinoma, can cause uncontrolled cell division (Zappa and Mousa, 
2016; Liao et al., 2017). These mutations are sensitive to EGFR tyrosine kinase 
inhibitors (EGFR-TKIs) which exhibited a good response rate of 70%, with 
significantly improved overall survival for patients who received erlotinib 
compared with a placebo (Zappa and Mousa, 2016). However, there was no 
difference in overall survival between gefitinib and placebo groups (Nurwidya et 
al., 2016; Chang et al., 2017).  
The first-generation EGFR-TKIs such as erlotinib (Tarveca®, 150 mg orally 
daily) and gefitinib (Iressa®, 250 mg orally daily) and the second-generation 
EGFR-TKIs such as afatinib (Gilotrif®, 40 mg orally daily) have all been 
approved by the US FDA as standard first-line treatment for advanced EGFR 
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mutant NSCLC (Liao et al., 2017). Among the three approved drugs, gefitinib is 
limited to use in a subgroup of patients with NSCLC, while afatinib has not 
improved the overall survival as compared to gefitinib and erlotinib treatment 
(Nurwidya et al., 2016; Yang et al., 2017a). The next section will further discuss 
erlotinib, EGFR –TKI, used in this study. The third-generation EGFR-TKIs such 
as osimertinib, olmutinib and rociletinib have been developed with activity 
against EGFR mutations, but with less skin rash and diarrhea adverse effect than 
first and second-generation EGFR-TKIs agents. However, these drugs are still in 
the trial phase (Liao et al., 2017; Yang et al., 2017a). 
According to the UK National Institute for Health and Care Excellence (NICE) 
and the US Food and Drug Administration (USFDA), erlotinib is approved as a 
first-line treatment for initial treatment of patients with NSCLC whose cancer has 
spread to other parts of the body and who have certain types of EGFR mutations, 
and as second or third line treatment for maintenance treatment of advanced-stage 
NSCLC (Zarogoulidis et al., 2013). However, erlotinib is associated with 
dermatological toxicities through the mechanism of EGFR-associated cutaneous 
toxicity, which is not completely understand since there are several steps involved 
in the inhibition of EGFR-mediated signaling pathways, including premature 
differentiation and stimulation of inflammation (Thatcher et al., 2009).  
Erlotinib is currently marketed for the treatment of locally advanced or metastatic 
NSCLC in film-coated oral tablet under the trade names of Erlocip® (Cipla), 
Tarceva® (Roche) and Erloshil® (Raichem). The usual clinical oral dose of 
erlotinib is 150 mg/day, which is its maximum tolerated dose (MTD) (Yeo et al., 
2010b, BNF, 2018). The mechanism of action, chemical structure as well as 
formulation approaches for erlotinib will be further described in Section 1.8.1. 
 Pulmonary drug delivery 
Approximately 70% of patients with NSCLC suffer from advanced local invasion 
and/or distant metastasis stage at the time of diagnosis, meaning that surgery is 
not sufficiently curative treatment for these patients (Reck et al., 2013; Rudokas et 
al., 2016). Moreover, current oral drug delivery of cytotoxic drugs may cause 
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systemic side effects and sub-therapeutic doses at the target sites (Hu et al., 2013; 
Rudokas et al., 2016). Pulmonary delivery may reduce the side effects of systemic 
administration and enhance therapeutic efficacy by delivering a chemotherapeutic 
agent directly to its site of action in order to achieve the most effective localised 
treatment (Patil and Sarasija, 2012). Therefore, strategies for targeting lung cancer 
locally (pulmonary drug delivery) have been considered not only for possible 
remission of cancer but also for the control of lung cancer metastases. Such local 
delivery can possibly enhance the effectiveness of surgery and/or radiotherapy 
(Hu et al., 2013; Rudokas et al., 2016).  
Pulmonary drug delivery is an attractive delivery approach as it can produce a 
rapid onset of drug action, is non-invasive and is an effective route of 
administration for drugs having local and systemic effects (Pilcer and Amighi, 
2010). Furthermore, lower dosages can be delivered since this delivery system 
allows the avoidance of first-pass metabolism and drug degradation compared 
with oral route. Further, unwanted side effects and drug interactions when more 
than one medication is administered concurrently can be minimised (Timsina et 
al., 1994). The physiology of lung ensures it is an attractive target for drug 
delivery. It provides a large absorptive surface area (approximately 70-140 m2) 
and a highly permeable membrane (0.2-0.7 µm thickness) especially in the 
alveolar region, the absorption site for most drugs and various macromolecules. 
Furthermore, the lung has a rich blood supply and low enzymatic activity 
compared to the gastrointestinal tract (GI) and liver. The pulmonary route thus 
offers efficient drug absorption to the systemic circulation (Labiris and Dolovich, 
2003; Patil and Sarasija, 2012). However, deposition of inhaled drugs within the 
airways and the effectiveness of the inhalation route are still challenging for 
multifunctional reasons including the physicochemical properties of drugs, the 
characteristic properties of formulations and the types of inhaled devices available 
(Rudokas et al., 2016). Adrenocarcinoma cells (40% of NSCLC cases) are found 
in small peripheral airways (bronchioles and alveoli) and type II aveolar cell, 
these regions are therefore major targets for NSCLC treatment (Zappa and Mousa, 
2016; Gazdar et al., 1990), with delivery approaches targeting these lung regions 
being be particularly appropriate. 
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 Lung physiology 
The respiratory tract is predominantly involved in the oxygenation of blood and 
the elimination of carbon dioxide. The respiratory tract starts from the nose and 
extends to the alveolar sacs. There are several ways of classifying the different 
regions of the respiratory airway; upper and lower respiratory tract is one of the 
most common ways. The upper respiratory tract comprises nose, nasal cavity, 
throat, pharynx and larynx, whereas the lower respiratory airway includes trachea, 
bronchi, terminal bronchioles, respiratory bronchioles, alveolar ducts and alveolar 
sacs.  
Another classification divides the airways into two main regions: the conducting 
region (the first 16 generations of the respiratory tract; from trachea to terminal 
bronchioles) and the respiratory region (including generations 17 to 23, between 
respiratory bronchioles and alveolar sacs), where gases are exchanged between 
blood and inhaled air (Kleinstreuer and Zhang, 2010). Aerosol flow and 
deposition differ in different regions of the respiratory tree (Figure 1-1), such that 
this model is commonly used in considerations of particle deposition in the human 
airways. 
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Figure 1-1 The human airways (Kleinstreuer and Zhang, 2010) 
 Inhalation aerosols and aerodynamic diameter 
In order to deliver medication to the deep lung region, certain parameters should 
be considered. The most critical parameter determining the site of aerosol 
deposition and distribution within the airways is particle size and this term is 
normally standardised to aerodynamic diameter (da, Eq.1-1). The aerodynamic 
diameter (da) is the diameter of a sphere of unit density that reaches the same 
terminal settling velocity in an air stream as the particle in question. This 
parameter depends on the particulate properties such as geometric size, shape and 
density and can be calculated using Eq. 1-1 (Chow et al., 2007).  
𝑑𝑎 =  𝑑𝑔𝑒𝑜 ∗  √
𝜌
𝜒  𝜌 𝜊 
                                                                                    Eq. 1-1 
where 𝑑𝑔𝑒𝑜 is the physical diameter of particle, ρ is the density of particle, χ is the 
dynamic shape factor and ρ0 is unit density. Since shape can influence the motion 
of the particles in the airsteam for non-spherical particles, the relationship 
between da and 𝑑𝑔𝑒𝑜  can be complexed in these cases. The dynamic shape factor 
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is expressed as the ratio of the drag force on a non-sphere particle to the drag 
force of a sphere with the same volume at the same velocity (Chow et al., 2007). 
Most inhalation systems are polydispersed, containing a range of particle sizes. 
Mass median aerodynamic diameter (MMAD), which refers to the particle 
diameter that has 50% of cumulative mass above and below it, is generally 
presented. The distribution of sizes or the variability of the particle diameters 
within the aerosol is expressed as the geometric standard deviation (GSD) for log 
normal distributions. This parameter is calculated from the ratio of the particle 
diameter at 84.13% and 15.87% on the cumulative distribution curve. A GSD 
equivalent to 1 indicates a monodisperse system, whilst, a GSD of > 1.2 indicates 
a polydispersed system (Colombo, 2013). 
 Mechanisms of aerosol deposition in the airways 
The particle size of an aerosol is a major factor determining the efficacy of a 
therapeutic aerosol, determining airways penetration, deposition, dissolution and 
clearance. More specifically, an aerosol size below approximately 5 μm is 
required to penetrate to the respiratory region. In order to reach alveolar regions, 
an aerosol size smaller than 2 μm is preferable. Particles with diameter less than 1 
μm may be exhaled during normal tidal breathing. On the other hand, larger 
droplets are deposited in the upper respiratory airways and quickly eliminated by 
mucociliary clearance mechanism (Chow et al., 2007) Thus, most inhalation 
products are formulated in the aerodynamic diameter range between 1 and 5 μm 
(Colombo, 2013).  
Three mechanisms, namely inertial impaction, gravitational sedimentation and 
Brownian diffusion, are predominantly responsible for particle deposition in the 
lung. All of these depend on particle diameter. Particle deposition can also occur 
by other mechanisms including interception and electrostatic precipitation (Figure 
1-2). 
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Figure 1-2 Particle deposition in the respiratory tract (Mossman et al., 2011) 
 
In the upper respiratory tract and at the conducting airway bifurcations, inertial 
impaction is the most important deposition mechanism for particles greater than 5 
μm and particular larger than 10 μm. The change in airflow direction causes 
particles having a large momentum to impact on the airway’s walls since their 
momentum tends to keep them on their original trajectories instead of following 
the air streamline. Hence, impaction normally occurs in the first 10 airways 
generations or near the sharp-angled bifurcations, where the velocity of airflow is 
high and airstream is turbulent. Particles in the size range 0.5 to 5 µm, which 
escape impaction, are largely deposited by gravitational sedimentation. This 
mechanism, resulting from the gravitational force, occurs in the last 5 or 6 
generation of airways (bronchioles and alveolar region), where the air velocity is 
low. Brownian diffusion is the most prevalent deposition mechanism for particles 
with diameter smaller than approximately 0.5 µm, where airstream velocity is 
near zero or absent (alveolar region). Deposition by this mechanism is caused by 
the random bombardment of gas molecules against the particles. This effect can 
result in an irregular motion of the particles from high to low concentrations, 
causing them to diffuse from the aerosol cloud to the airways’ walls and thus to 
deposit.  
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 Challenges in pulmonary delivery 
According to Eq.1-1, particles with smaller size, lower particle density and/or 
higher dynamic shape factor will have smaller aerodynamic diameter. One 
approach to enhance alveolar deposition is to create large porous hollow particles 
(LPHPs). This design is to lower the density of particles to achieve a small 
aerodynamic diameter. Previous studies have shown that larger porous particles 
have higher dispersibility from a delivery device and improved fine particle 
fraction as compared to smaller non-porous particles. This possibly due to their 
smaller surface-to-volume ratio, resulting in easier deagglomeration upon 
inhalation (Gharse and Fiegel, 2016). Larger particles with low density can lower 
the probability of inhaled drug losses before particles enter the airways, leading to 
a better systemic bioavailability as seen in the case of insulin in vivo (Edwards et 
al., 1997). 
Particle interactions including particle-particle and particle-surface interactions 
are another crucial factor for deep lung deposition. This is associated with van der 
Waals forces, which are related to particle shape, surface properties, size, 
hygroscopicity and electrostatic properties. For example, particles having lower 
van der Waals force (attractive force) and lower contact surface show less 
aggregation during aerosolisation, resulting in better flowability, aerosolisation 
and deposition (emitted dose and fine particle fraction) properties. This can be 
seen in a comparison of pollen-shaped particles and other particle shapes such as 
needles, cubes and plates (Hassan and Lau, 2009).  
When the aerodynamic diameter of the particles is very small compared with the 
dimensions of the airways, the centre of mass remains in a mainstream flow, 
while the distal ends of the particles may come into contact with an airway or 
alveolar wall, giving high interception deposition due to their large attractive 
forces. This can be seen in the case of elongated or needled-like particles such as 
fibres (Hassan and Lau, 2009; Cheng, 2014).  
Nanocarriers smaller than 200 nm have been demonstrated to escape macrophage 
phagocytosis. Hence, nanomaterials may remain longer in the lung fluid compared 
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to those in micrometre size range (Pardeike et al., 2011). As compared to 
microparticulate suspensions, nanoparticulate formulations have shown a smaller 
and more uniform droplet size, resulting in a better dose uniformity (Pardeike et 
al., 2011). In aspects of regional deposition in the lungs, particle size with the 
most efficient deposition in deep lung regions should be ideally in the range 0.5- 5 
µm (Pilcer and Amighi, 2010). However, the relationship between particle size 
and regional lung deposition of nanometre aerosol size has not been widely 
investigated.  
Conventionally, particles smaller than 1 µm considered to be easily exhaled. 
However, nanoparticles may have higher deep lung deposition in accordance with 
Brownian diffusion (Jabbal et al., 2017). Previously, Stahlhofen and his 
colleagues have investigated the influence of particle size on lung deposition 
(Stahlhofen et al., 1989). The findings have shown that the total lung deposition 
decreased with reducing particle size until 0.5 µm, where the total lung deposition 
troughed. Further decrease in particle size resulted in increasing total lung 
deposition, with equivalent or higher level as shown in Figure 1-3 (Carvalho et al., 
2011). Recently, the relationship between MMAD, total lung deposition and 
exhaled fraction was evaluated and the findings demonstrated that extra-fine 
particles (< 2 µm) were not related to a noticeably higher exhaled fraction (Jabbal 
et al., 2017). These observations possibly due to the different mechanisms of 
deposition predominantly for particles of different size with particle ≈ 0.5 µm not 
depositing well by diffusion, impaction or sedimentation. 
Few in vivo studies of nanoparticles administered by the pulmonary route have 
been assessed. Nebulisation of poly (DL-lactideco-glycolide) nanoparticles 
containing the anti-tuberculosis drug (rifampicin or isoniazid or pyrazinamide) 
improved drug bioavailability and decreased drug dosing in guinea pigs (Pandey 
et al., 2003; Lu et al., 2014). For lung cancer treatment, inhaled doxorubicin-
loaded nanoparticles resulted in significantly reduced tumours as compared to the 
control groups as in vivo study in mice (Roa et al., 2011; Lu et al., 2014). These 
findings support the potential of nanoparticles in pulmonary delivery. 
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Figure 1-3 The relationship of particle size and respiratory deposition fraction of 
inhaled product (Carvalho et al., 2011) 
 Inhalation devices for pulmonary delivery 
Currently, there are four main types of delivery devices for inhalation 
commercially available, which are pressurised metered-dose inhalers (pMDIs), 
dry powder inhalers (DPIs), soft-mist inhalers and nebulisers.  
 Pressurised metered- dose inhalers (pMDIs) 
Pressurised metered- dose inhalers (pMDIs) are the most common multi-dose 
devices used for pulmonary delivery (Dolovich and Dhand, 2011; Lavorini et al., 
2017). Their portability, disposability, relatively low cost, multidose convenience, 
and reproducible dose delivery has led to their popularity for the treatment of 
COPD and asthma (Newman, 2005; Stein et al., 2014; Taylor, 2018). 
Formulations for pMDIs can be as solutions or suspensions in liquefied propellant 
together with other excipients such as surfactants, co-solvents, and solubilising 
agents to solubilise and stabilise drug in the formulations (Newman, 2005; 
Ibrahim et al., 2015). Traditional chlorofluorocarbon (CFC) propellants are no 
longer used and have been replaced by non-ozone-depleting propellants, 
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hydrofluoroalkanes (HFAs) namely heptafluoropropane (HFA-227) and 
tetrafluoroethane (HFA-134a) (Ibrahim et al., 2015; Taylor, 2018).  
A major drawback of pMDIs is the low fraction of drug delivered (not more than 
20% of the stated emitted dose) to the lung attributed to high particle exit velocity 
and poor actuation and inhalation coordination by patients (Newman, 2005; Pilcer 
and Amighi, 2010; Lavorini et al., 2017). Spacer attachments (AeroChamber 
Plus®), valve holding chambers (Autohaler®) and breath-actuated pMDIs 
(Syncroner®, Easi-breathe®) have been developed in order to overcome problems 
with inhalation-actuation coordination since the devices can fire the dose 
automatically through a spring mechanism when the patients inhale. Also, these 
inhalation aids may slow down the velocity of the emitted aerosol cloud and allow 
efficient propellant evaporation, causing a relatively smaller size slowly moving, 
with improved potential for deep lung deposition and lower throat impaction 
(Ibrahim et al., 2015). However, spacer devices are not convenient to use. In 
addition, the static charge on the internal walls can occur with some models of 
plastic spacers, thereby decreasing the emitted dose to the patients (Newman, 
2014). 
 Dry powder inhalers (DPIs) 
Dry powder inhalers (DPIs) are convenient and simple-to use devices, with 
various advantages over pMDIs (Atkins, 2005; Pilcer and Amighi, 2010; 
Dolovich and Dhand, 2011). DPI formulations are propellant-free and do not 
require any excipients except sometimes a carrier (e.g. lactose). Moreover, DPI 
dosage forms generally have better chemical and physical stability than liquid 
formulations (Pilcer and Amighi, 2010). These inhaler devices can deliver larger 
drug doses than pMDIs, which are limited by the volume of the metering valve 
and the highest concentration of suspension that can be employed without valve 
clogging. DPIs require less coordination of breathing and actuation as compared 
to pMDIs since they are generally breath-actuated devices (Ibrahim et al., 2015; 
Taylor, 2018).  
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Based on the mechanism for powder aerosolisation, DPIs can be divided into two 
types; passively- (relying on the patient inspiration’s effort) and actively- DPIs 
(containing energy source) (Ibrahim et al., 2015). Active DPIs seem simpler to 
operate than the passive devices, though none of such advanced inhalers are 
currently available in the market. DPIs can also be classified into three types by 
the number of doses; single-unit dose, multi-unit dose and multi-dose reservoirs 
(Figure 1-4). In unit dose inhalers such as Aerolizer®, Cyclohaler® and 
Handihaler® (Figure 1-4a and 1-4b), drug dose is pre-metered in a single hard 
gelatin capsule which is discarded after use. This device requires the patients to 
insert a new capsule before each use. Multi-unit dose inhalers (Figure 1-4c) 
contain multiple pre-metered individual doses in replaceable foil blisters (Ellipta® 
and Diskhaler®). Multi-dose devices (Figure 1-4d) comprise a reservoir of drug 
powder (Easyhaler® and Turbuhaler®), from which the device-metered dose will 
be delivered upon each inhalation (Pilcer and Amighi, 2010; Ibrahim et al., 2015; 
Lavorini et al., 2017).  
However, the multitude of DPIs having unit-dose and multi-dose design, which 
may be complex and confusing for patients resulting in inhalation errors, and 
errors in device preparation, handling with a negative effect on adherence 
(Newman, 2014).  
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Figure 1-4 Dry powder inhaler devices; a) single-unit capsule dose, b) multiple-unit 
dose and c) multiple dose inhalers (Lavorini et al., 2017) 
 Soft-mist inhalers (SMIs) 
The soft-mist inhalers (Spiriva Respimat® and AERx®) also called metered-dose 
liquid inhalers and non-pressurised metered-dose inhalers are a new novel type of 
multiple-dose, propellant-free, hand-held liquid inhaler device (Hira et al., 2018).  
These are designed to produce a fine mist in a single breath from a solution within 
a pocket size device using a patient-independent and environmentally friendly 
energy source. As compared to pMDIs and DPIs, these devices generate a slow-
moving aerosol cloud with longer time for aerosol generation, leading to a higher 
fraction of emitted dose being deposited in the deep lungs. Thus, these innovative 
devices are superior to the pMDIs and the DPIs with respect to the ease of use, 
environmentally friendly, higher dose of drug deposition in the lungs, lower 
oropharyngeal deposition and no requirement for spacer devices (Dalby et al., 
2011).  
For the mechanism of aerosol generation, these devices contain a spring to force a 
metered-dose of solution through two-channel nozzles, generating two fine jets of 
liquid and the soft mist (Dalby et al., 2004; Bohr and Beck-Broichsitter, 2015). 
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Drug solutions can be formulated in either water or ethanol. Ethanol can be used 
as a solvent and preservative. Soft-mist inhalers are beneficial for patients who 
have difficulty in coordinating inhalation and actuation may represent in the 
future direction of novel delivery devices (Watts et al., 2008; Dalby et al., 2011; 
De Pablo et al., 2017).  
Until now, all the aforementioned devices (pMDIs, DPIs and SMIs) can deliver 
only small doses of the therapeutic agent (i.e. asthma) and thus may not be 
appropriate for the treatment of many diseases which large doses are needed 
including cancer and infectious diseases (Rudokas et al., 2016).  
 Nebulisers 
Nebulisers are devices which are used for converting liquid formulations (an 
aqueous solution or suspension) into an aerosol where most of the drug released is 
in droplets having an aerodynamic diameter of 1-5 µm (O'Callaghan and Barry, 
1997). Nebulisers have several advantages over pMDIs, DPIs and SMIs in that 
larger doses/volumes can be delivered over an extended period, requiring minimal 
processing of formulations (e.g. lack of organic solvents and drying stages) 
(Rudokas et al., 2016). Patients can inhale medication fluid through a facemask or 
mouthpiece during a normal tidal breathing, and thus these devices can be used 
for any patient groups and/or clinical conditions. They are alternative devices for 
patients who cannot coordinate actuation and inhalation for pMDIs and/or those 
who experience difficulties with the inspiration flow required by DPIs (Ibrahim et 
al., 2015). Nebulisers are useful for drugs that cannot be readily formulated for 
pMDIs and DPIs or where the therapeutic dose is too high for delivery by those 
devices. Moreover, different compatible solutions can be concurrently nebulised 
(Taylor and McCallion, 1997; Ari, 2014). 
There are some disadvantages of nebulisers; for example, a longer administration 
time is required, they have reduced portability, and there is a requirement for an 
external power source such as battery or main electric supply and compressed air 
for air-jet devices (Cipolla et al., 2013). 
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Commercially available nebulisers are divided into three categories depending on 
their operating principle: ultrasonic, air-jet, and vibrating-mesh nebulisers. 
 Ultrasonic nebulisers 
Ultrasonic nebulisers produce aerosol droplets at high frequency (1-3 MHz) using 
a vibrating piezoelectric crystal at the base of the device. The vibrations are 
transmitted directly to the surface of a drug solution, resulting in a fountain of 
liquid on the surface in a nebuliser chamber. The size distribution of aerosols is 
determined by baffles, which recycle large droplets and allow the smaller ones to 
be delivered for inhalation (Elhissi et al., 2012).  
During operation, heat is generated in the fluid being aerosolised which can 
denature heat-sensitive materials such as proteins (Ari, 2014). These devices are 
not suitable for delivering viscous liquids and suspensions, probably due to a 
reduced force used to atomise the fluid (Hess, 2008; Ibrahim et al., 2015). Also, 
increasing temperatures during operation may impact delicate formulations 
particularly liposomes, resulting in fusion and drug loss (Elhissi et al., 2012). 
Consequently, the popularity of this type of device has decreased in recent years 
particular with the advent of vibrating-mesh devices (Le Brun et al., 2000; Yeo et 
al., 2010a; Ari, 2014). 
 Air-jet nebulisers 
Air-jet nebulisers are the most commonly used nebulisers due to ease of use, 
convenience and relatively low cost (Hess, 2008). The driving gas passes through 
a narrow aperture (Venturi nozzle) from the compressor. At the aperture, the 
pressure decreases and the gas velocity increases, leading to a production of a 
cone shape. Due to a negative pressure, fluid is drawn up the feeding tube system 
into fine ligaments. The fine ligaments collapse into droplets due to the liquid’s 
surface tension (O'Callaghan and Barry, 1997; Lavorini, 2013; Taylor, 2018).  
During atomisation of liquid, coarse aerosol droplets that are the majority of 
liquid mass impact on baffles and the nebuliser works depending on the design of 
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air-jet devices. The large droplets will return to the fluid reservoir, while small 
droplets are emitted from the nebulisers. The design of the nebuliser device is 
critical, affecting droplet size and particle deposition (Hess, 2008). Other 
parameters including the characteristics of the fluid (density, viscosity, surface 
tension), the velocity and the flow rate of gas and fluid also determine the droplet 
size produced by nebulisers (Hess, 2000). For example, an increase in gas velocity 
can reduce droplet size (Hess, 2008; Lavorini, 2013; Ibrahim et al., 2015).  
Another crucial consideration relating particularly to the nebuliser design, in the 
use of air-jet nebulisers is the dead or residual volume. This parameter represents 
the volume that is trapped within the nebuliser and thus will not be successfully 
delivered from the device. The medication loss due to dead volumes can be 
minimised by optimising the internal design of the nebulisers and/or the operation 
by the patients during the treatment. Using a conical shaped reservoir can reduce 
the residual volume since this design decreases the surface area of the internal 
surface of the nebulisers. In addition, patients and clinicians may tap the devices 
to increase the aerosol and/or drug output (Hess, 2000; Lavorini, 2013). Also, 
adding diluent or more medical fluid may increase the amount of therapeutic 
agents delivered. However, this will prolong the administration time, potentially 
causing difficulties in maintaining good inhalation technique and a reduction of 
patient adherence during therapy (Rubin and Williams, 2014). 
There are many designs of jet nebulisers. This may cause variations in clinical 
outcomes between air-jet nebulisers combined with different flow rates, 
compressors and fill volumes (Abdelrahim et al., 2010; Saeed et al., 2017). Other 
drawbacks with the use of air-jet nebulisers are the noise from the compressor, a 
drop in the temperature of nebuliser fluid during use, limited portability and the 
requirement for a compressor (Waldrep and Dhand, 2008; Ibrahim et al., 2015). 
Consequently, nebuliser design has been developed to overcome some of the 
aforementioned problems. Air-jet nebulisers can be divided into three classes: 
constant output jet nebulisers, breath-enhanced jet nebulisers and breath-actuated 
jet nebulisers as described below. 
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1.4.4.2.1 Constant output jet nebulisers 
Constant output jet nebulisers such as Misty-Neb® and SideStream® are 
conventional constant-output devices producing aerosol during a patient’s 
inspiration, expiration and breath- holding (L Rau et al., 2004). They are easy to 
handle and use, with good patient compliance (Ari, 2014). However, aerosol 
and/or drug loss during the expiration phase and a large dead volume in the 
reservoir are serious problems, leading to relatively poor patient dosing and the 
variability of drug dose (Chatburn and McPeck, 2007).  
These problems have led to developments in air-jet nebuliser design in order to 
minimise the drug wastage and enhance drug output.  
1.4.4.2.2 Breath-enhanced jet nebulisers 
Breath-enhanced jet nebulisers such as the PARI LC® Sprint, PARI LCD® and 
NebuTech® generate aerosol droplets using a negative pressure from the patient’s 
inspiratory effort. Such devices are modified conventional air-jet devices, using 
two one-way valves. Figure 1-5 shows that the inspiratory valve opens and allows 
additional ambient air to be entrained into the nebuliser when the patient’s inhaled 
airflow is greater than the driving flow of the device. This results in higher aerosol 
output compared with conventional designs. By contrast, exhaled gas passes 
through an expiratory valve in the mouthpiece and the aerosol returns to the 
chamber for renebulisation. This can cause less aerosol/drug wastage to the 
surroundings (Ho et al., 2001; Lavorini, 2013; Ari, 2014).  
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Figure 1-5 Operating principle of breath-enhanced jet nebulisers (Coates and Ho, 1998) 
1.4.4.2.3 Breath-actuated jet nebulisers 
Breath-actuated jet devices are designed to generate aerosol only on inspiration, 
thereby decreasing drug waste to the atmosphere (Muchão and Silva Filho, 2010). 
These delivery systems can also adapt aerosol delivery in accordance with an 
individual patient’s breathing pattern. For instance, the HaloLite® analyzes the 
patient’s breathing pattern and then determines the precise dose delivered to each 
patient (Leung et al., 2004; Van Dyke and Nikander, 2007; Muchao and Filho, 
2010; Lavorini, 2013). Consequently, this type of nebuliser can reduce the 
variability in the delivered dose and drug waste, and enhance the amount of 
inspired aerosol as well as patient compliance (Lavorini, 2013; Ari, 2014). 
However, the drawbacks of this technology are loud noise in operation and high 
price (Muchao and Filho, 2010). 
 Vibrating-mesh nebulisers 
Vibrating-mesh nebulisers have shown numerous advantages over other nebuliser 
systems; in particular they are small and portable nebulisers, with quiet operation, 
short administration times, improved drug/aerosol output efficiency, precise and 
consistent drug delivery, low residual volume and the capability to deliver small 
drug volumes. Additionally, these devices efficiently deliver a wide range of heat-
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sensitive substances including insulin, nucleic acids and other proteins and 
peptides since they do not significantly heat up the fluid during nebulisation as the 
case of ultrasonic devices (Ghazanfari et al., 2007; Lavorini, 2013; Ari, 2014; 
Choi et al., 2018).  
However, there are several disadvantages with these devices. For example, they 
are not suitable for delivering viscous liquids or those that can crystallise on 
drying. Furthermore, some models are only available for specific drugs (drug-
device combinations) (Pritchard et al., 2018). Vibrating-mesh nebulisers are a 
relatively recent development in nebuliser technology, therefore they are 
expensive compared to ultrasonic and air-jet nebulisers (Lavorini, 2013; Ari, 
2014). It has been suggested that the biological safety and durability of these 
devices should be taken into considerations since the mesh metal can possibly be 
broken into small pieces after repeated use (Choi et al., 2018). 
Vibrating-mesh nebulisers can be divided into two main types according to their 
designs: actively vibrating and passively vibrating devices. However, aerosol 
production of both types is based on the same mechanism. Overall, fluid is forced 
through multiple micrometre-sized apertures in a mesh or aperture plate to 
generate the aerosol (Elhissi et al., 2012).  
Passively vibrating-mesh devices 
Passively vibrating-mesh nebulisers; for example, the Omron MicroAir NEU22®, 
consist of three main parts: 1) a piezoelectric crystal 2) a transducer horn and 3) a 
mesh plate containing 6000 tapered holes (3 µm in diameter). The piezoelectric 
crystal transmits high frequency vibrations via a transducer horn, which induces 
‘passive’ vibrations in the perforated plate, resulting in upwards and downwards 
movements of the plate to extrude the fluid through the mesh apertures and 
generate aerosol droplets (as Figure 1-6; Ghazanfari et al., 2007; Elhissi et al., 
2012; Lavorini, 2013).  
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Figure 1-6 Operating principle of passively vibrating-mesh nebulisers (Ghazanfari et al., 
2007) 
Actively vibrating-mesh devices 
Aeroneb®, eFlow® and Velox® are examples of actively vibrating-mesh nebulisers. 
These contain an aerosol generator comprising 1000 electroformed dome-shaped 
apertures in a plate and a vibrational element. The vibrating element creates 
micropump effect by contracting and expanding on application of an electrical 
current, this leads to vibration of the plate, consequently producing a slowly 
moving aerosol as liquids is drawn through the mesh apertures (Figure 1-7) 
(Ghazanfari et al., 2007; Elhissi et al., 2011a; Elhissi et al., 2012; Ari, 2014). 
 
Figure 1-7 Operating principle of actively vibrating-mesh nebulisers (Ghazanfari et al., 
2007) 
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Although vibrating-mesh nebulisers improve the efficiency of aerosol delivery 
due to their lower residual volume, drug waste on exhalation is still major issue 
due to continuous drug delivery without any adaptation of output to the patient’s 
breathing pattern (Denyer and Dyche, 2010). Adaptive aerosol delivery (AAD) 
technology such as the I-neb AAD System nebuliser determines the pattern of 
patient’s breathing so as to tailor the duration of aerosol production and improve 
the precision and reproducibility of drug dosing. These devices have been 
designed to pulse aerosol only during inhalation using one of two different 
breathing patterns (the Tidal Breathing Mode and the Target Inhalation Mode), 
thereby reducing drug waste on exhalation, and are thus particularly suitable for 
the delivery of expensive or potent drugs (Dhand, 2010; Nikander et al., 2010; Ari, 
2014; Pritchard et al., 2018). Furthermore, patients are guided to inhale slowly 
and deeply for 8 s, while aerosol is pulsed for up to 7 s when using the current 
version of the Target Inhalation Mode. This allows 1 s to enhance deposition in 
the deep lung, and decreases particle impaction in the upper airways by promoting 
slow and deep inhalation (Denyer and Dyche, 2010; Geller et al., 2010; Nikander 
et al., 2010).  
The I-neb AAD shows better performance in terms of outcomes, patient 
acceptance and adherence. However the high cost is a major drawback with the I-
neb AAD system. Also, healthcare staff, carers and patients need to be trained 
properly about how to clean and use these devices (Dhand, 2010).  
 Effect of fluid physicochemical properties on nebuliser performance 
In general, the vehicle in nebuliser formulations is water, often with the inclusion 
of other excipients such as a co-solvent, surfactant and stabiliser. Since both 
hypotonic and hypertonic solutions may produce bronchoconstriction, isotonic 
solutions with a pH in the range 3-10 are usually recommended (Beasley et al., 
1988; Kwong et al., 1990; Taylor, 2018). Studies have shown that isotonic 
solutions may become hypertonic during nebulisation in the case of air-jet 
nebuliser, though this osmolality change does not cause any adverse reactions in 
the airways. Preparations may be diluted with water or more usually normal saline 
before administration (Beasley et al., 1988).  
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Nebulisation is the process of converting bulk liquid into an aerosol. The 
relationship between the properties of liquid formulations and the operating 
principle of the device plays an important role in determining nebuliser 
performance (Carvalho and McConville, 2016). In order to assess the 
effectiveness of aerosol delivery, characteristic properties of disperse phase for 
formulations such as viscosity, surface tension, and ion concentration should be 
evaluated to determine whether these factors have an impact on aerosol size and 
output characteristics; for instance, on the proportion of aerosol droplets smaller 
than 5 µm and the total output (McCallion et al., 1995; Ghazanfari et al., 2007; 
Bohr and Beck-Broichsitter, 2015).  
It has been previously reported that droplet size is inversely proportional to fluid 
viscosity for air-jet nebulisers and vibrating-mesh nebulisers (Najlah et al., 2013). 
By contrast, a direct relationship between droplet size and fluid viscosity has been 
reported for ultrasonic devices (McCallion et al., 1995; Najlah et al., 2013). The 
viscosity and surface tension of nebuliser fluid also affect total drug/aerosol 
output of nebulisers since both parameters require energy to generate a new 
surface. For example, higher viscosity fluids result in aerosols having a smaller 
droplet size and a subsequent increase in FPF and FPD in the case of air-jet and 
vibrating-mesh nebulisers, but require a longer nebulisation time and are 
associated with lower output and output rate (Ghazanfari et al., 2007). Ultrasonic 
devices are not suitable to nebulise high viscosity (McCallion et al., 1995), whilst 
for both passively and actively vibrating-mesh nebulisers, aerosol generation 
ceases or becomes intermittent at higher viscosities (> 1.92cP). Consequently, air-
jet nebulisers are the most effective devices for generating aerosols from highly 
viscous preparations (Ghazanfari et al., 2007; Chan et al., 2011; Najlah et al., 
2013). 
The correlation between surface tension and aerosol size and/or aerosol output is 
complex. However, studies have demonstrated that an increased total drug output 
results for lower surface tension delivered by air-jet and ultrasonic devices for 
salbutamol sulfate solutions when surface-active agent is included (Arzhavitina 
and Steckel, 2010; Carvalho and McConville, 2016). 
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For vibrating-mesh nebuliser, the presence of ions at increasing concentration has 
been shown to cause a reduction in droplet VMD, thereby increasing FPF and 
FPD in vibrating-mesh nebulisers. It is proposed that the inclusion of ions in 
solutions can reduce water adhesion to the internal wall and mesh pores of the 
devices, leading to an earlier detachment of droplets from bulk solutions, a 
decrease in the variability of aerosol size, aerosol output rate, nebulisation time 
and increasing aerosol output. Therefore, the effective performance of vibrating-
mesh nebulisers may require the inclusion of electrolyte particularly halide ions 
(Ghazanfari et al., 2007).  
A recent study has reported that there was an inverse relationship between aerosol 
output and halide concentration for fluoride, bromide and chloride, while aerosol 
output was proportional to iodide concentration (Najlah et al., 2013). This may be 
because iodide ions have the greatest polarizing ability at the air-water interface 
compared to the other three ions, thereby modulating electrostatic repulsion 
within the aerosol cloud. This effect may lead to the finest aerosol, resulting in the 
highest aerosol output and FPF. On the other hand, other three ions are likely to 
be present in bulk fluid due to their less polarizing properties at the interface. All 
observations indicated that different types of halide ions affected the performance 
of vibrating-mesh nebuliser (Najlah et al., 2013; Bohr and Beck-Broichsitter, 
2015). Thus, the effect of various types of ion (cations and anions) requires 
further work for the better understanding of the correlation between ion presence 
in solutions and nebulisation performance. 
 Delivery of advanced formulations 
In nebulisers, the main operating principle of nebulisation is based on the 
atomisation of liquid into fine droplets; however, there are significant differences 
in the mechanism of aerosol generation, which impacts the formulation. 
Ultrasonic devices are generally considered not suitable for delivering high 
viscosity fluids (greater than 6cP), microparticulate dispersions, suspension, 
liposomes and thermolabile peptides or DNA (Hess, 2008; Ibrahim et al., 2015). 
However, these devices seem to have applications for aerosol delivery when the 
disperse phase is very small since it can be entrained into droplets, with examples 
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of radiolabelled solid lipid nanoparticles (200 nm) and itraconazole-loaded 
nanostructured lipid carriers (≈100 nm) being successfully delivered (Videira et 
al., 2002; Pardeike et al., 2011). 
Various formulations such as protein solutions (rhDNase I), suspensions 
(Pulmicort Respules®, budesonide suspensions), nanoemulsions, nanoparticles, 
polymeric micelles in the nanosize range and liposomal formulations can be 
effectively aerosolised using air-jet nebulisers (Moazeni et al., 2012; Carvalho and 
McConville, 2016). Aerosol generation of suspensions using this type of devices 
is dependent on the characteristic properties of formulation including particle size 
distribution of the dispersed phase in the presence of different excipients (Tadros, 
2008; Amani et al., 2010). The aggregation of nanoparticles may be observed 
during aerosolisation from these devices (Dailey et al., 2003; Carvalho and 
McConville, 2016). Several studies have shown partial protein degradation and 
some large aggregation with and without excipients at the air-water interface, 
attributed to the shear force during jet-nebulisation (Niven et al., 1996; Respaud et 
al., 2014; Hertel et al., 2015). 
Vibrating-mesh nebulisers have been demonstrated to be the most effective device 
for delivering a number of liquid formulations with better stability during 
aerosolisation (Respaud et al., 2014; Bohr and Beck-Broichsitter, 2015; Carvalho 
and McConville, 2016). Vibrating-mesh nebulisers are considered preferable to 
deliver protein than air-jet and ultrasonic devices since they do not significantly 
generate changes in temperature and minimise recycling processes, resulting in 
small changes to protein integrity (Bohr and Beck-Broichsitter, 2015).  
Among a large number of drug-carriers, liposomes (bilayered phospholipid 
vesicles) have shown potential to improve inhalation treatment regimens (Bohr 
and Beck-Broichsitter, 2015). Several studies of liposomal formulations delivered 
by these devices have shown that different device designs, lipid concentrations 
and types of lipid affect the properties of nebulised liposomes and the efficiency 
of delivery (Carvalho and McConville, 2016). For example, unilamellar 
liposomes smaller than 200 nm are suggested as an optimal system since they can 
be easily incorporated into aerosol droplets with minimal drug losses (Lehofer et 
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al., 2014). Moreover, incorporating cholesterol to make fluid state bilayers more 
rigid can reduce drug leakage during nebulisation (Lehofer et al., 2014; Cipolla et 
al., 2016). Delivery of liposomes using air-jet and vibrating-mesh nebulisers is 
more successful than with ultrasonic devices, as these less damage to liposome 
bilayers during aerosolisation (Elhissi et al., 2013). Recently, two liposomal 
formulations; Arikace® and Pulmaquin® have been studied in phase II/III clinical 
trials for the treatment of pulmonary infections (Paranjpe and Müller-Goymann, 
2014; Bohr and Beck-Broichsitter, 2015). 
In conclusion, critical formulation parameters including particle size, surface 
alteration, morphology, rigidity of nanocarriers as well as type of nebuliser need 
to be considered to achieve the most effective nanoparticle-based approach for 
pulmonary delivery. 
 Methods of aerosol particle size analysis 
Nebulised formulations need to be assessed for aerodynamic particle size, fine 
particle dose (mass), fine particle fraction and the emitted dose in order to 
compare nebulised systems and possibly to predict the clinical responses 
(Abdelrahim et al., 2010). It should be noted that the properties of the aerosol are 
a function of both the formulation and the particular device used for aerosolisation. 
The fundamental approaches that have been used for aerosol size analysis are 
microscopy, laser diffraction, particle time of flight (TOF), phase-Doppler particle 
size analysis (PDA) and cascade impaction.  
For routine measurements, laser diffraction has been commonly used for particle 
size distribution (PSD) of aerosols to estimate the deposition characteristic in the 
lung particularly in the case of nebulised aerosols (Clark, 1995). However, laser 
diffraction measures geometrical particle dimensions instead of aerodynamic 
particle size distribution based on volume, surface and number basis (Pilcer et al., 
2008). Volume median diameter (VMD) with the span value (distribution width) 
are commonly reported for particle size analysis (De Boer et al., 2002). Since the 
nebulised cloud can be sized when it emits from the mouthpiece before 
evaporation occurs, this technique is recommended by Ph. Eur. to use for rapid 
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size-distribution measurement of nebulised aerosol (Ziegler and Wachtel, 2005; 
Martin et al., 2006). Among all techniques, cascade impactors are the most widely 
method used for measurement of the particle size distribution by mass of 
inhalation products based on impaction. 
 Cascade impactors and impingers 
The inertial size-separation of particles in a cascade impactor depends on the 
aerodynamic diameter, a key parameter determining particle deposition in the 
lung during inhalation (Section 1.2.2). Cascade impactors allow calculation of 
FPF and other size fractions of the active pharmaceutical ingredient (API) as well 
as non-active ingredients in the formulations following chemical analysis (usually 
high performance liquid chromatography). Other methods cannot readily 
differentiate between active and non-active components in the formulation as they 
measure overall particle size distribution in the absence of chemical assay (Martin 
et al., 2006). Moreover, a fine particle mass corresponding to a particle size 
distribution of less than 5 µm is the key quality parameters for inhaled aerosol 
drug product specifications in accordance with European Medicines Agency 
guidelines (EMA, 2006). Cascade impactors provide the greatest information 
concerning aerodynamic particle size distribution (APSD) for aerosolised 
products with particles in the range of 0.5 to 5 µm and are therefore well suited 
for inhalation aerosol characterisation. For these reasons, cascade impaction is the 
standard method for characterisation of inhalation aerosols, including nebulisers 
and is included in United States Pharmacopoeia, European Pharmacopeia and 
British Pharmacopeia (Marple et al., 2003; Majoral et al., 2006; Taylor, 2018; 
Fishler and Sznitman, 2017). 
There are a number of impactors available; the two most widely employed are 1) 
the Andersen Cascade Impactor (ACI; Ph. Eur. Apparatus D) and 2) the Next 
Generation Impactor (NGI; Ph. Eur. Apparatus E). Both the ACI and NGI 
comprise a series of stages each made up of a plate, with specific nozzle size. 
Aerosolised particles are fractionated on the basis of inertial impaction according 
to their aerodynamic size distribution, when the aerosol is drawn into the device at 
a fixed flow rate. It should be noted that the cascade impactor is not a lung 
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simulator due to a numerous factors including the geometry at the point of impact, 
the hardness of the collection surface, coatings and a constant flow rate. Moreover, 
each collection stage throughout the impactor does not represent any specific 
deposition sites in the lung (Marple et al., 2003). However, the data obtained from 
the impactors allows prediction of the probability of an aerosol cloud’s deposition 
to the lower lung according to the airborne particle’s behavior in turbulent 
airsteams and they are rounetinely used in the pharmaceutical development and 
quality control of inhalation products. 
When aerosol droplets pass through the nozzles, large/dense particles will deposit 
on the collecting plate by impaction. Smaller/less-dense particles will follow the 
airstream, which is directed at a right angle to the exit of the nozzle, and they will 
impact on the subsequent collecting plate if they have been given sufficient 
momentum under high jet velocities (Figure 1-8).   
 
Figure 1-8 Airflow and particle in a cascade impactor (adapted from Copley, 2008) 
 
Deposited aerosol on each stage of the impactor is usually collected and assayed 
by high performance liquid chromatography (HPLC). Mass Median Aerodynamic 
Diameter (MMAD) and Geometric Standard Deviation (GSD), are calculated 
from a plot of cumulative fraction of active substance on each stage versus the 
cut-off diameter for that stage plotted on a log scale (Figure 1-9).  MMAD is 
determined as the particle size at 50% of cumulative fraction by mass for the 
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Vacuum 
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deposited particles or droplets. GSD is calculated from the same plot as for 
MMAD determination as mentioned using the equation below: 
GSD = √
𝑆𝑖𝑧𝑒 𝑋(𝐷84.13%)
𝑆𝑖𝑧𝑒 𝑌(𝐷15.87%)
 
 
Figure 1-9 The cumulative percentage of mass less than the stated aerodynamic diameters 
versus the cut-off diameter; log-probability plot (USP29 NF40) 
The ACI (Figure 1-10) and NGI (Figure 1-11) have been used for the 
determination of the fine particle dose and the aerodynamic particle size 
distribution of aerosols delivered by pMDIs and DPIs. The multistage liquid 
impinger (Ph. Eur. Apparatus C) also works on the principle of cascade impaction, 
and consists of five stages, with wet sintered glass collection plates followed by a 
terminal filter. The European Pharmacopoeia indicates the NGI is also appropriate 
for the evaluation of nebuliser performance by measuring the mass of active 
ingredient as a function of aerodynamic diameter.  
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Figure 1-10 Andersen cascade impactor (USP29 NF40) 
 
The NGI (Figure 1-11) used in this study is used with a 90º bend ‘induction port’ 
to mimic the human throat, followed by seven compaction stages and the micro-
orifice collector (MOC). A back-up filter after the MOC is used to ensure 
quantitative recovery of the extra-fine particles from small aerosol droplets (Berg 
et al., 2007b; Abdelrahim et al., 2010). This impactor has been calibrated at 15 
L/min for characterising the aerosol particle size distribution of nebulised aerosols 
between 0.5 and 5 µm with five stages having cut-off diameter in the appropriate 
range. This flow rate represents a good approximation to the midpoint flow rate 
achieved by a tidally breathing healthy adult (Abdelrahim and Chrystyn, 2009).  
 
Figure 1-11 Next Generation Impactor (Ph. Eur., 2017) 
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The Ph. Eur. requires cooling of the NGI at 5 ºC for at least 90 min before use in 
order to minimise evaporation effects and limit changes in droplet size during the 
assessment process. Some studies have reported that the MMAD of aerosol 
droplets determined with the impactor at lower temperature was larger than that 
determined using a non-cooled impactor (Finlay and Stapleton, 1999; Zhou et al., 
2005). This may be explained by differences in temperature between the aerosol 
exiting the nebuliser and the body of the impactor, resulting in significant droplet 
shrinkage by evaporation (Finlay and Stapleton, 1999).  
At 15 L/min, the cut-off diameters for each stage of the NGI are shown in Table 
1-1. 
Table 1-1 Cut-off diameters for the NGI stages when operated at a flow rate of 15 
L/min 
Stage Cut-off diameter (µm) 
1 14.1 
2 8.61 
3 5.39 
4  3.30 
5 2.08 
6 1.36 
7 0.98 
 
The United States and European pharmacopoeias recommend that collecting 
plates of the NGI are coated with silicone oil or high viscosity coatings to reduce 
particle bounce-off, particle re-entrainment and inter-stage loss of particles during 
aerosolisation for DPI-based formulations, since these effects can lead to a 
reduction of the collection efficiency of impactor stages, causing unreliable and 
distorted APSDs data. The collecting plates do not require coating with such 
materials for aerosol characterisation of nebulised products as these are no shifts 
in measured size distributions when uncoated and coated collecting plates were 
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investigated (Berg et al., 2007a; Berg et al., 2008; Abdelrahim and Chrystyn, 
2009). 
 Abbreviated Impactor Measurement (AIM) 
The aerodynamic particle size distribution (ASPD) of inhaled medicinal products 
is a critical quality attribute obtained with a full-cascade impactor. This parameter 
is closely linked with the location of drug deposition in the human lung (Nichols 
et al., 2016). Despites their advantages, cascade impactors are labour intensive 
and time-consuming to use. Consequently, a traditional cascade impactor-based 
analysis is not well suited for high throughput applications such as routine product 
quality testing, product development and comprehensive stability studies 
(Mitchell et al., 2010; Fishler and Sznitman, 2017; Mohan et al., 2017). 
Furthermore, drug deposited across the eight stages of the extended impactors 
may cause analytical quantification problems for formulations with low drug 
concentration such as potent drugs or low dose medications (Mitchell et al., 
2009a). Therefore, the development of simpler, rapid, accurate and precise 
technique has gained in the importance for product development and quality 
control of orally inhaled products. 
The glass/two-stage impinger (TSI; Ph. Eur.; Apparatus A; Figure 1-12) can be 
employed as an alternative to a full-stage impactor. Aerosol droplets are nebulised 
in the two stages of the impinger representing coarse aerosol (stage 1) and fine 
particle dose (stage 2), suggesting therapeutically useful aerosol (Hallworth and 
Westmoreland, 1987). The TSI has a number of drawbacks, particularly, the cut-
off diameter for the lower stage (stage 2) is 6.4 µm (Miller et al., 1992; Holzner 
and Müller, 1995), rather than 5 µm, as required for determining the fine particle 
dose (FPD) and fine particle fraction (FPF) (EMA, 2006). In addition, the high 
flow rate of 60 L/min employed may cause solvent/water evaporation, resulting in 
inaccurate measurement of aerosol size. Thus, the TSI provides less information 
about aerodynamic particle size distribution than a full cascade impactor/impinger, 
plus presents concerns regarding the suitability of the cut-off diameter for routine 
analysis. 
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Figure 1-12 Two-stage impinger (Miller et al., 1992) 
 
Whilst the two-stage impinger has been available for many years, it has largely 
fallen into disuse. Abbreviated Impactor Measurement (AIM), has not yet been 
included in international pharmacopoeias nor is it considered suitable by 
regulatory agencies. It is currently being researched as a relatively simple and 
quick method for aerosol analysis with improved productivity for the quality 
control of inhalation products. The AIM concept has commonly employed an 
abbreviated version of a full-stage NGI or ACI with two-size-fractionating stages 
of the cascade impactor and a final filter for assessing aerodynamic particle size 
distribution and fine particle dose of pMDIs and DPIs (Mitchell et al., 2009b; 
Nichols et al., 2016; Mohan et al., 2017). Currently, three abbreviated cascade 
impactors are available; Fast Screening Andersen (C- FSA; Copley Scientific Ltd., 
and T-FSA; Trudell Medical International), Reduced Next Generation Impactor 
(rNGI; Copley Scientific Ltd.) and Fast Screening Impactor (FSI; Copley 
Scientific Ltd. and MSP Corporation). All have been used to obtain APSD 
measurements and other quality attributes for marketed pMDIs and DPIs.  
The stainless steel Fast Screening Andersen impactor (FSA, Figure 1-13) is an 
abbreviated version of the standard full-resolution Andersen Cascade Impactor 
(ACI) used for quality control and product development for pMDI and DPI 
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formulations. The FSA consists of two inertial size-fractionation stages (with or 
without internal dead space), followed by a final filter. These stages represent 
coarse, fine and extra-fine particle fractions. The FPD collected from the FSA is 
the summation of drug mass on the surface of the size-fractionation stage and 
those deposited on the back-up filter (Mitchell et al., 2009a; Nichols et al., 2016).  
 
Figure 1-13 The Fast Andersen impactor a) C-FSA (without dead space) b) T-FSA (with 
dead space) (Nichols et al., 2016) 
The reduced Next Generation Impactor (rNGI), which is an abbreviated 
configuration of the NGI, can be divided into two types; the-filter-only 
configuration (rNGI-f; Figure 1-14a) and the modified-cup configuration (rNGI-
mc; Figure 1-14b). The rNGI-f employs the total internal volume of the 
conventional NGI, with all collecting plates in place connected to the vacuum 
pump. The rNGI-mc, employs a modified cup with an outlet tube attached directly 
to the vacuum pump, thus reducing the entire NGI internal volume. A filter is 
placed with a special rNGI filter holder on the top of the chosen stage for both 
configurations. The mass of drug deposited on all collecting plates above the 
chosen stage is defined as the coarse particle mass, while the mass of drug 
collected from the filter (i.e. on stage 3 or 4) is considered as the fine particle 
mass (Mohan et al., 2017).  
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Figure 1-14 The Reduced Next Generation Impactor a) rNGI-f b) rNGI-mc (Mohan et al., 
2017) 
The Fast Screening Impactor (FSI, Figure 1-15), a two-stage abbreviated impactor 
with a cut-off diameter of 5 µm between stages and equipped with the USP 
induction port and a pre-separator, collects coarse particle mass or non-inhalable 
mass (in a pre-separator chamber) and the fine particle mass (filter). A range of 
inserts (Figure 1-15b) allows a 5µm cut-off diameter with flow rates between 30 
and 100 L/min, allowing characterisation of DPIs and pMDIs (El-Gendy et al., 
2012). It should be noted that abbreviated impactors usually use the same 
components as their parent-full resolution impactors. The FSI does not have a 
parent-full cascade apparatus; however the NGI has been previously used as the 
reference impactor for comparisons based on the pre-separator (Mitchell et al., 
2012b). 
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Figure 1-15 Fast Screening Impactor (FSI), a) components of the FSI, b) additional insert 
and c) assembled FSI (Nichols et al., 2016) 
The AIM concept which employs impactors with 2 or 3 stages may improve 
overall method precision by eliminating impaction stages on which small amounts 
of active pharmaceutical ingredient (API) which are hard to assay or on which no 
drug is deposited (Mitchell et al., 2009a; Mitchell et al., 2010; Guo et al., 2013). 
Sampling errors may be decreased by summing data from several collecting plates, 
particularly where the mass of active substance recovered on some stages is near 
to the lower limit of quantification. However, the removal of some stages from a 
full-cascade impactor may produce changes in APSD metrics, resulting from 
particle bounce, internal losses and differences in evaporation behaviour in the 
abbreviated impactor as demonstrated for pMDIs and DPIs (Mitchell et al., 2008). 
Moreover, key parameters of aerosolisation such as MMAD and GSD cannot be 
calculated using an abbreviated impactor (Guo et al., 2013). However, it is 
possible to use the relatively limited data; coarse, fine and/or extra-fine particle 
mass obtained using AIM apparatus (Mitchell et al., 2009a).  
In terms of critical quality attributes for aerosolisation, the coarse particle mass 
(particle > 5µm) represents particle deposition in the throat and upper airways. 
The fine particle mass (particle <5 µm) represents drug particles that potentially 
penetrate into deep lung region, while particles smaller than 1 µm (extra-fine 
particle dose) have the possibility to reach the alveoli or be exhaled (Guo et al., 
2013). Two metrics: the ratio of coarse particle mass and fine particle mass and 
the total amount of particles sized within the impactor (impactor-sized mass; ISM) 
a) b) c) 
Chapter 1 Introduction 
 61 
are employed in what is termed ‘Efficient Data Analysis (EDA)’. The concept of 
EDA has been proposed as beneficial for routine quality control, allowing better 
decisions with respect to APSD determinations of inhaled products for quality 
control and batch release (Tougas et al., 2011a; Mitchell et al., 2012b; Mohan et 
al., 2017). However, this abbreviated apparatus should be validated on a product-
by-product basis to demonstrate an equivalent performance before applying an 
AIM approach for routinely characterisation of inhaler product (Tougas et al., 
2011a; Guo et al., 2013). 
The AIM-based systems have received attention from the pharmaceutical industry 
and instrument manufacturers in aspects of the design of AIM-based apparatus for 
evaluating specific type/drug product of DPIs, pMDIs and nebulisers (Tougas et 
al., 2011b). For example, the stage ‘0’ was included for T-FSA to mimic the 
internal dead volume of the ACI, when pMDIs containing low volatile solvents 
(ethanol) were characterised (Mitchell et al., 2009a; Tougas et al., 2011b). 
Moreover, there are few studies comparing the performance of abbreviated and 
their full-resolution cascade impactors for characterising inhalation products 
particularly pMDIs and DPIs. For example, the ability of two abbreviated CIs (C-
FSA and T-FSA) was investigated for characterising pMDIs. The findings show 
equivalent values of coarse particle fraction (CPF), fine particle fraction (FPF) 
and extra-fine particle fraction (EPF) compared to a full-resolution ACI when 
collecting stages were coated (Mitchell et al., 2009a; Mitchell et al., 2009b). 
When looking at the performance of the rNGI (rNGI-mc and rNGI-f) and the full-
resolution NGI for evaluating DPIs, significant differences in FPD, FPF and EDA 
metrics were observed for Foradil® and Relenza®. Whilst, Spiriva® yielded 
statistically similar data of those key parameters of aerosolisation for all three 
NGI configurations. Moreover, there were statistically differences in FPD for 
Foradil® and Relenza® obtained using the FSI and the NGI. However, FPF 
values for the three DPIs collected from both impactors were similar (Mohan et al., 
2017). These observations were possibly due to different products and/or device 
resistance. Further studies are required for a better understanding of these 
differences. 
Chapter 1 Introduction 
 62 
Among three available AIM-based apparatus, FSI with the cut-off diameter of 5 
µm between coarse and fine particle fractions can be used to demonstrate 
compliance with the EMA guideline for quality of orally inhaled products, 
reflecting directly to FPD and FPF calculations (5 µm). It should be noted that the 
use of the FSI for characterising the properties of nebulised formulations has 
received very little attention. Consequently, the FSI was the focus in this thesis. 
 Therapeutic agents used in this study and their formulation approaches 
 Erlotinib 
Erlotinib, an EGFR-TKI, inhibits tyrosine kinase activity on EGFR by completing 
with ATP at the ATP binding site. There are three pathways downstream of 
EGFR involving cell regulations (Schettino et al., 2008). Thus, the blockage of 
EGFR signaling pathways promotes cell cycle arrest and apoptosis, and leads to 
the inhibition of angiogenesis and cell invasion as shown in Figure 1-16.  
 
Figure 1-16 The mechanism of action of erlotinib (Hammerman et al., 2009) 
Erlotinib or N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, 
has low aqueous solubility and high permeability and therefore it is classified as 
class II in the Biopharmaceutics Classification System (BCS). Previous reports 
have shown that erlotinib has a pH-dependent solubility and its solubility 
increases with decreasing pH. The drug molecule is completely non-ionised and 
ionised at the pH values of 11 and 2, respectively (Tóth et al., 2016). Other 
physicochemical properties of erlotinib including molecular structure, molecular 
weight, molecular formula and log P are shown in Table 1-2. 
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Table 1-2 Physicochemical properties of erlotinib 
Molecular structure 
 
Molecular weight 393.43572 g/mol 
Molecular formula C22H23N3O4 
Log P (octanol/water) 2.75 (Tóth et al., 2016) 
pKa 5.18 (benzylimine) 
Aqueous solubility 
(µg/mL) at pH 6.8 
3-6  (Tóth et al., 2016; Truong et al., 2016) 
 
Erlotinib has been approved by the FDA and is available as a film-coated tablet 
(Tarceva®), with 60% bioavailability (Vrignaud et al., 2012). The oral absorption 
of erlotinib may increase when administered with food. However, food has an 
impact on the variability in absorption and potential side effects and thus, erlotinib 
is recommended to be taken on an empty stomach (Yang et al., 2017b). 
Erlotinib’s poor solubility limits bioavailability and hence, pharmaceutical 
technology has been employed to improve the solubility delivery of erlotinib 
using various formulation strategies as shown in Table 1-3. 
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Table 1-3 Formulation studies for erlotinib 
Delivery System Description Treatment Route Study 
Lipid-based 
nanocarriers 
Reverse micelle-loaded lipid nanocarriers containing 
erlotinib hydrochloride 
Pancreatic cancer - (Vrignaud et al., 2012) 
Liposomes co-loaded with erlotinib and doxorubicin Lung and breast 
cancer 
Intravenous (Morton et al., 2014) 
Erlotinib-loaded core-shell type lipid-polymer hybrid 
nanoparticles 
NSCLC - (Mandal et al., 2016) 
Microparticles containing erlotinib-loaded solid lipid 
nanoparticles 
NSCLC Pulmonary (Bakhtiary et al., 2017) 
Co-delivery of erlotinib and IL36 siRNA in amphiphilic 
lipid nanocarriers 
Psoriasis Topical (Boakye et al., 2017) 
Erlotinib-loaded solid lipid nanoparticles Lung cancer Pulmonary (Naseri et al., 2017) 
Erlotinib-loaded liposomes modified with galactosylated 
lipid 
 
Lung cancer Intravenous (Xu et al., 2017) 
Erlotinib-loaded nanoliposomal formulation NSCLC Intravenous (Zhou et al., 2018) 
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Table 1-3 (Cont) Formulation studies for erlotinib 
 
Non-lipid based 
nanocarriers 
Erlotinib-loaded poly caprolactone-polyethylene glycol-
polycaprolactone PCEC) nanoparticles 
NSCLC - (Barghi et al., 2014) 
Inclusion of erlotinib in cyclodextrin nanosponge 
complex 
Pancreatic cancer Oral (Dora et al., 2016) 
Solid self-emulsifying system containing erlotinib - Oral (Truong et al., 2016) 
Erlotinib-conjugated dextran-coated monocrystalline 
iron oxide nanoparticles 
Cancer Intravenous (Ali et al., 2016) 
Poly (D,L-lactic-co-glycolic acid)(PLGA) nanoparticles 
co-loaded with erlotinib and paclitaxel 
Breast Cancer Oral (Khuroo et al., 2018) 
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 Genistein 
Phytochemicals present in fruits and vegetables have been studied for their role in 
the prevention and cancer treatment in various lung cancer cell lines. In-vitro and 
in-vivo studies have demonstrated that the bioactive compounds present in the 
diet, including genistein (soybean), curcumin (turmeric) and fisetin (fruit and 
vegetables) produce alterations of cell cycle control, induce apoptosis, and inhibit 
angiogenesis and metastasis (Russo et al., 2010; Khan and Mukhtar, 2015). 
Consequently, the use of these dietary agents in monotherapy or in combination 
with chemotherapy has been gaining in interest. In the next section, the 
physicochemical properties of phytochemicals used in this study namely genistein 
and curcumin as well as their pharmaceutical formulations will be discussed. 
Flavonoids, chemically classified as compounds containing a phenylchromanone 
structure (C6-C3-C6) with at least one hydroxyl substituent, are especially 
promising candidates for cancer prevention (Yao et al., 2011). Genistein, the 
major flavonoid isolated from soybeans, has attracted a great deal attentions as an 
anticancer, antioxidant, antiinflammatory and antiproliferative agent (Danciu et al., 
2012; Andrade et al., 2014). Genistein can modify cancer progression by 
increasing apoptosis through the inactivation of the Akt signaling pathway. As 
seen from Figure 1-17, this pathway activates NF-kB, which transcribes genes 
important for cell survival, invasion and metastasis. The inhibition of NF-kB also 
partially explains the effects of genistein on cell cycle progression and apoptosis 
(Kumi-Diaka et al., 2010; Shukla et al., 2015; Cai et al., 2017).  
Genistein, through inhibition of the Akt pathway, has been shown to potentiate 
the activity of EGFR-TKIs; for example, erlotinib and gefitinib in NSCLCs. 
Consequently, down-regulation of Akt and NF-kB appears to correlate with the 
antitumour activity of EGFR-TKIs (Gadgeel et al., 2009; Li et al., 2012a; Li et al., 
2012b). Genistein has therefore been used to concomitantly decrease the toxicity 
of chemotherapeutic agents since a lower dose of cytotoxic drug is required when 
used in combination.  
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Figure 1-17 Schematic representation of the action of genistein on inhibition of EGFR 
signaling (Niero et al., 2014; Shukla et al., 2015) 
Genistein or 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one is a hydrophobic 
BCS class II molecule (Chen et al., 2013), having low aqueous solubility and high 
permeability as shown in Table 1-4. 
Table 1-4 Physicochemical properties of genistein 
Molecular structure 
 
Molecular weight 270.24 g/mol 
Molecular formula C15H10O5 
Log P (octanol/ water) 2.84 (Aditya et al., 2013) 
pKa 
 
 
7.63, 9.67 and 10.83 
Aqueous solubility (µg/mL) at pH ≈7 0.9-1.4 (Phan et al., 2013; Cai et al., 
2017) 
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Despite its attractive therapeutic properties, the low aqueous solubility of 
genistein limits its potential applications (Kim et al., 2017). Pharmaceutical 
technology has thus been employed for the delivery of genistein, using diverse 
pharmaceutical formulations to improve its dissolution profile and bioavailability 
as shown in Table 1-5. 
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Table 1-5 Formulation studies for genistein 
Delivery System Description Treatment Route Study 
Lipid-based 
nanocarriers 
Nanostructured lipid 
carriers co-loaded 
with genistein and 
curcumin 
Prostate cancer Oral (Aditya et 
al., 2013) 
Genistein-loaded 
nanoliposomal 
formulation 
Breast, ovarian 
and prostate 
cancers 
Oral (Phan et 
al., 2013) 
Genistein-loaded 
lipid nanocarriers 
Skin cancer Dermal (Andrade 
et al., 
2014) 
Genistein 
incorporated into 
nanostructured lipid 
carriers coated with 
a cationic Eudragit 
Precorneal 
retention 
Ocular (Zhang et 
al., 2014b) 
Genistein-loaded 
solid lipid 
nanoparticles 
- Oral (Kim et al., 
2017) 
Non-lipid based 
nanocarriers 
Genistein-loaded 
pluronic micelles 
- Oral (Kwon et 
al., 2007) 
Folic acid-
conjugated 
genistein-loaded 
chitosan 
nanoparticles 
Cervical cancer - (Cai et al., 
2017) 
Genistein-conjugated 
gold nanoparticles 
Lung cancer - (Stolarczyk 
et al., 
2017) 
Genistein 
incorporated into 
beta-cyclodextrin 
derivatives 
Anti-
inflammatory 
Topical (Danciu et 
al., 2012) 
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 Curcumin 
Curcumin (diferuloylmethane), a natural compound extracted from the rhizome of 
turmeric (Curcuma longa), has been used in a wide range of therapeutic 
applications; for example, it has been shown to have antimicrobial, antioxidant, 
antiparasitic, antimutagenic and anticancer activity (Anand et al., 2010; Khan and 
Mukhtar, 2015; Tsai et al., 2015). In this research, the anticancer activity on non-
small cell lung cancer was the interest. Although the mechanism of action in 
NSCLC is still not completely clear (Chen et al., 2016a; Shindikar et al., 2016), 
studies have shown that curcumin inhibits cell proliferation and induces cell 
apoptosis of human NSCLC through the suppression of the PI3K/Akt pathway 
(Jin et al., 2015; Tsai et al., 2015). Curcumin has been reported to significantly 
increase the cytotoxicity of erlotinib, thereby enhancing erlotinib-induced 
apoptosis, decreasing the expression of EGFR and inhibiting NF-kB signaling 
pathway in NSCLC cells (Khan and Mukhtar, 2015). In addition, this molecule 
has demonstrated synergistic antitumour activity in NSCLC when used with other 
chemotherapeutic agents such as cisplatin and adiponectin. Consequently, 
curcumin is one of the plant-based medicines used as an adjuvant agent in the 
lung cancer treatment and was chosen for investigation in this study. 
Curcumin or (1E, 6E)-1,7-bis (4-hydroxy-3-methoxyphenyl)- 1,6-heptadiene-3,5-
dione is considered a hydrophobic BCS class II drug (Hu et al., 2015), 
characterised by low solubility and high permeability (Table 1-6).  
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Table 1-6 Physicochemical properties of curcumin 
Molecular structure 
 
Molecular weight 368.39 
Molecular formula C21H20O6 
Log P 3.29 (Aditya et al., 2013) 
pKa 
 
 
8.5, 10 and 10.5 (Lee et al., 2013) 
Aqueous solubility (µg/mL) at 
pH 7.4 
0.6 (Shin et al., 2016) 
 
Nanotechnology has been employed to produce curcumin delivery systems to 
improve the water solubility, absorption rate and oral bioavailability of curcumin 
(Table 1-7). 
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Table 1-7 Formulation studies for curcumin 
Delivery 
System 
Description Treatment Route Study 
Lipid-based 
nanocarriers 
Curcumin-loaded 
nanoemulsions 
Malignant 
glioma 
Oral (Kumar 
et al., 
2016) 
Curcumin-loaded 
nanostructured lipid 
carriers 
Anti-
inflammatory 
Dermal (Chen et 
al., 
2016b) 
Curcumin-loaded 
solid lipid 
nanoparticles 
NSCLC - (Jiang et 
al., 2017) 
Curcumin-loaded 
liposomes 
Anti-
inflammatory 
- (Ng et 
al., 2018) 
Curcumin-loaded 
liposomes in liquid 
and dry powder 
form 
NSCLC Pulmonary (Zhang et 
al., 2018) 
Non-lipid 
based 
nanocarriers 
Curcumin-
cyclodextrin 
complexes 
Lung cancer Oral, 
intraperitoneal 
(Rocks et 
al., 2012) 
Poly(amidoamine) 
dendrimer 
containing 
curcumin 
NSCLC - (Wang et 
al., 2013) 
Curcumin-loaded 
methoxy 
polyethylene 
glycol-polylactide 
(mPEG/PLA) 
micelles 
NSCLC - (Zhu et 
al., 2017) 
Co-encapsulation of 
curcumin and 
doxorubicin in pH-
sensitive 
nanoparticles 
Breast cancer Intravenous (Cui et 
al., 2017) 
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 Thesis overview 
Erlotinib, genistein and curcumin, all classified as BCS class II drugs, were used 
as therapeutic agents in this study. The therapeutic application of the three active 
compounds, which may be used in the treatment of non-small cell lung cancer 
(NSCLC), is limited due to their poor aqueous solubility. In order to overcome 
this, nanocarriers may be employed to improve the water solubility. No study has 
previously investigated the nanocarriers co-loaded with erlotinib and genistein for 
potential synergistic antitumour activity. Although the co-delivery of curcumin 
and genistein has been previously reported, the route of administration and 
formulation approach is different from this study. Hence, this research describes 
studies to explore a strategy for delivering hydrophobic anticancer drugs using 
polymeric micelles, by synthesizing a novel micelle-forming genistein-mPEG 
conjugate for the delivery of either erlotinib or curcumin. Liposomes were also 
investigated for the co-delivery of erlotinib and genistein by pulmonary route as 
an alternative formulation approach. Lipid-based nanocarriers were chosen in this 
study since lipid-based nanocarriers administered by pulmonary route have 
previously shown high accumulation and long retention time in the lungs 
(Garbuzenko et al., 2014). 
Nebulised drug delivery has some advantages over pressurised metered-dose 
inhalers (pMDIs) and dry powder inhalers (DPIs), in terms of delivering large 
doses of drugs in an aqueous vehicle. The nebulised aerosols generated from the 
novel lipid-based aerosols were characterised using cascade impactor. An 
advantage of Abbreviated Impactor Measurement (AIM), which has been 
proposed for the routine quality control of inhaler products as an alternative to full 
impactors, is that it employs only 2 or 3 stages, representing coarse and fine 
particle fractions. This permits rapid, accurate quantification for low dose 
formulations. In this study, the Fast Screening Impactor (FSI), a two-stage 
abbreviated impactor with a cut-off diameter of 5 µm between stages was 
investigated as an alternative to the Next Generation Impactor (NGI) for in-vitro 
studies of nebulised liposomes. This investigation was anticipated to overcome 
the analytical quantification problem of drug-loaded liposomes. The properties of 
aerosols generated from micelles and liposomes by air-jet and vibrating-mesh 
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nebulisers were studied and compared using the same operating conditions using 
the NGI and FSI.  
Ultimately, formulation strategies explored in this thesis for co-delivery of 
therapeutic agents may overcome some of the problems associated with 
hydrophobicity of drug molecules while reducing the use of excipients, and be 
suitable for local treatment of NSCLC via nebulisation with potential for 
synergistic therapeutic activity. Moreover, the use of an abbreviated apparatus 
will hopefully contribute to a simpler and more rapid, accurate and precise 
technique for aerosol characterisation of both formulations during product 
development, whilst the data will help inform current databases about the 
usefulness of AIM for characterisation of inhaler products. 
 Aims and Objectives 
The aim of this study is to investigate new formulation approaches for the co-
delivery of genistein and curcumin, and genistein and erlotinib. Determining the 
aerosol properties of the final formulations delivered by air-jet and vibrating-mesh 
nebulisers is important for demonstrating future potential therapeutic applications. 
To achieve these aims, the study was conducted with the following objectives: 
1) To synthesise and characterise a novel genistein-methoxy poly(ethylene 
glycol) conjugate 
2) To develop and optimise formulations of curcumin and/or erlotinib-loaded 
genistein-methoxy poly (ethylene glycol) micelles with potential for 
pulmonary delivery 
3) To produce, characterise and optimise liposomes co-loaded with erlotinib 
and genistein with potential for pulmonary delivery 
4) To investigate the FSI as an alternative impactor to the NGI for aerosol 
characterisation of nebulised co-loaded liposomes using the same 
operating conditions. 
5) To investigate the effects of operating parameters on aerosol properties 
demonstrated using the FSI:   
I. Type of nebulisers (air-jet and vibrating-mesh nebulisers) 
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II. Impactor operating conditions  
 Impactor temperature (cooled and non-cooled FSI) 
 Flow rates (15 and 30 L/min) 
III. Liposome size reduction methods (probe-sonication and 
membrane-extrusion) 
Figure 1-18 outlines the flow of the research described in this PhD thesis. The 
project started with the synthesis and characterisation of genistein-methoxy poly 
(ethylene glycol) conjugate (Chapter 2). This was followed by the preparation of 
micellar formulations using this conjugate containing curcumin and/or erlotinib. 
The aerosol characteristics of these micellar systems following delivery using air-
jet and vibrating-mesh nebulisers were determined using the NGI (Chapter 3). 
Novel erlotinib and genistein co-loaded liposomes were prepared, characterised 
and optimised (Chapter 4). The drug-drug and drug-lipid interaction in these 
systems were studied using thermal analysis (Chapter 4). The FSI as an alternative 
impactor to the NGI was investigated and the aerosol properties of the optimised 
co-loaded liposomes size reduced by probe-sonication or extrusion delivered 
using air-jet and vibrating-mesh nebulisers were subsequently characterised using 
the FSI (Chapter 5). 
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Figure 1-18 Thesis overview describing preparation, characterisation and in vitro 
studies of optimised micelles and liposomes prepared for pulmonary delivery of 
genistein, erlotinib and curcumin 
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 Introduction 
Previous reports have demonstrated that the conjugation of chemotherapeutic 
agents; for example, paclitaxel, methotrexate, doxorubicin, camptothecin and 
small hydrophobic drug molecules, to water-soluble polymers to form drug–
polymer conjugates, provides a useful method for formulating these hydrophobic 
drugs (Qiu et al., 2010). Drug-polymer conjugates provide a potential strategy for 
improving the aqueous solubility of hydrophobic drugs, protecting the activity of 
drugs from metabolism or deactivation during systemic circulation, reducing the 
systemic side effects of potent drugs, and also enhancing passive or active 
targeting to the site of a drug’s pharmacological action (Hans et al., 2005; 
Khandare and Minko, 2006). The chemical and physical properties of polymers 
used in conjugation should be taken into consideration in order to modify and 
enhance the pharmacokinetic and bio-distribution profiles compared with 
traditional small molecular or macromolecular drugs (Larson and Ghandehari, 
2012).  
A number of polymers have been studied as hydrophilic drug carriers. Methoxy 
poly(ethylene) glycol (mPEG) is one of the most common candidates because it is 
hydrophilic, non-immunogenic, biodegradable, biocompatible and non-toxic. 
mPEG-drug conjugates have been reported to enhance the aqueous solubility of 
water-insoluble drugs, improve the efficacy of therapeutic agents through the 
enhanced permeability and retention effect and minimise the systemic side effects 
by reducing non-specific cell uptake (Hans et al., 2005; Xie et al., 2009; Banerjee 
et al., 2012).  
There are a numerous factors; for example, chemical structure, molecular weight, 
reactive functional group and steric hindrance that influence the outcome of 
conjugation of mPEG with bioactive molecules (Banerjee et al., 2012; Zhang et 
al., 2014d). mPEG, with molecular weight 5kDa, has been widely used for 
conjugation (Danafar et al., 2017) and consequently was chosen in this study. 
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In order to synthesize genistein-mPEG conjugate, the terminal hydroxyl group    
(-OH) of mPEG was converted to a carboxyl group (-COOH) via oxidation and 
was then attached to the –OH group of genistein through esterification. 
 Aims  
To synthesize and characterise a novel amphiphilic polymer that might be 
considered as a promising compound for producing carriers for hydrophobic 
drugs in further studies, by conjugation of a small hydrophobic drug to a 
hydrophilic polymer (genistein-mPEG conjugate) through an ester linkage. 
 Materials 
Genistein (4’,5,7-trihydroxyisoflavone) (GEN, LC Laboratories, USA) and poly 
(ethylene glycol) methyl ether with molecular weight 5 kDa, (mPEG, Sigma- 
Aldrich, UK) were used as the main materials for the synthesis of the amphiphilic 
polymer conjugate. The following reagents and solvents were obtained from 
Sigma-Aldrich (UK): erbium (III) trifluoromethanesulfonate 98%, 4-
dimethylaminopyridine (DMAP, 99%), N, N-dicyclohexylcarbodiimide (DCC, 
99%), N, N-dimethylformamide anhydrous (DMF, 99.8%), dimethyl sulfoxide 
(DMSO, >99.7%, gradient grade for HPLC), anhydrous dichloromethane (DCM, 
99.8%), magnesium sulphate (MgSO4, >99 %), triethylamine (TEA, >99.5%), 
chloroform (99.8%, analytical grade), methanol (99.9%, HPLC gradient grade) 
and ethyl acetate (99.8%). Acetronitrile (HPLC gradient grade) acquired from 
Fisher Scientific (UK) and succinic anhydride (SA) supplied by Merck (Germany) 
were used as the solvent and the reagent in polymer synthesis. Deionised water 
was produced by Purelab® Ultrapure Water Purification Systems (Thermo Fisher 
Scientific, UK). 
Silica gel 60 (0.040-0.063 mm, 99.5%) purchased from Alfa Aesar (USA) and a 
column with Rotaflo™ stopcock (40 mm diameter x 400 mm length) obtained 
from Fisher Scientific (UK) were used for the synthesized compound separation.  
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Deuterated chloroform (CDCl3) and dimethyl sulfoxide-d6 99.9% for 
1H NMR 
and 13C NMR structural analysis were obtained from Cambridge Isotope 
Laboratories (USA).  
 Methods 
 Synthesis of methoxypoly (ethylene glycol)-carboxyl (mPEG-COOH) 
Carboxylic acid end-group methoxypoly (ethylene glycol) (mPEG-COOH) was 
synthesized according to the method previously described (Jeon et al., 2003; 
Wang and Hsiue, 2005; Jeong et al., 2008; Xie et al., 2009; Xiang et al., 2011; 
Zhang et al., 2014a) with slight modification. Firstly, mPEG 5KDa (10 g, 2 
mmol) was dissolved in acetronitrile (20 mL) with magnetic stirring at room 
temperature. Meanwhile, succinic anhydride (0.1480 g, 1.4790 mmol) and erbium 
trifluoromethanesulfonate (0.0909 g, 0.1479 mmol) as shown in Table 2-1 were 
dissolved separately in acetronitrile (10 mL) and added dropwise in the flask of 
mPEG solution. Then, the mixture solution was refluxed for 2 h at 85C and the 
progress of the chemical reaction monitored by thin layer chromatography (TLC) 
eluted with a mixture of mobile phase as described in Section 2.4.3.1. 
After the reaction was complete, the solvent was removed by rotary evaporation 
(RC 900, Knf Neuberger GmbH, Germany) under vacuum at 60C for 10 min. 
The product, by-product, and unreacted reagents in the flask were rinsed with 
deionised water and transferred to a separating funnel to extract the product. After 
separation, the desired product was washed 3 times with a mixture of ethyl acetate 
and deionised water (50:50 %v/v). The separated product in an ethyl acetate layer 
was collected into a round-bottomed flask and all traces of water were then 
eliminated using magnesium sulphate (MgSO4). The ethyl acetate solution was 
afterwards passed through filter paper (110 mm diameter, Whatman®) to remove 
all MgSO4 clumps, and the filtrate was subsequently evaporated once by rotary 
evaporation at 60C for 5 min. The mPEG-COOH product was then obtained and 
dried in a desiccator overnight. 
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Table 2-1 Components used in mPEG-COOH synthesis 
Material Molecular 
weight (g/mole) 
Molar ratio 
mPEG 5K Da 5000 1 
Succinic anhydride 100.07 0.7395 
Erbium triflouromethanesulfonate 
10% mole 
614.47 0.07395 
 
 Synthesis of genistein-mPEG conjugate 
For the mechanism of esterification in the presence of DCC and DMAP, DCC 
(dicyclohexylcarbodiimide) initially reacted with mPEG-COOH. This resulted in 
an O-acylisourea intermediate. Genistein, which contains 3 –OH groups, was then 
added to activate –COOH group to form an ester linkage and yielded the 
genistein-mPEG product together with the stable dicyclohexylurea (DCU). 
However, DMAP, which is a comparatively stronger nucleophile than genistein, 
also reacted with O-acylisourea and yielded a reactive amide or active ester. This 
intermediate side product rapidly reacted with genistein and also produced 
genistein-mPEG conjugate (Gilles et al., 2015) as shown in Figure 2-1. 
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Figure 2-1 The reaction scheme for esterification in the presence of DCC and 
DMAP to produce the genistein-mPEG conjugate 
 Development of the genistein-mPEG conjugate synthesis 
Genistein-mPEG synthesis was undertaken according to the method previously 
described (Jiang and Kuang, 2009; Qiu et al., 2010; Soto-Castro et al., 2010; Yeap 
et al., 2012; Cholkar et al., 2014) with slight modification. The synthesis of 
genistein-mPEG conjugate was developed by varying two main factors such as 
the type of solvent and the composition of genistein and mPEG-COOH in terms 
of mole ratio. Anhydrous dichloromethane (DCM), anhydrous dimethylsulfoxide 
(DMSO) and anhydrous dimethylformamide (DMF) normally used for 
esterification reactions in the presence of DCC and DMAP were investigated 
using 1:1 mole ratio of genistein and mPEG-COOH, to obtain the suitable solvent 
for this reaction (Jiang and Kuang, 2009; Soto-Castro et al., 2010; Yeap et al., 
2012; Cholkar et al., 2014). Based on the preliminary data (Section 2.5.2.5), 
anhydrous DMF was the most suitable solvent and was then required for further 
optimisation. The mole ratio of genistein and mPEG-COOH was compared 
between 1:1 and 1:3 and the final ratio of 1:3 was chosen for the revised 
methodology of the genistein-mPEG conjugate synthesis as described in Section 
2.4.2.2. 
Genistein mPEG-COOH Genistein-mPEG conjugate 
O-acylisourea intermediate DCC 
mPEG-COOH 
DMAP 
Reactive amide Ester product O-acylisourea 
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 Optimised methodology of the genistein-mPEG conjugate synthesis 
Briefly, mPEG-COOH (5 g, 1.0 mmol), DMAP (12.2 mg, 0.1 mmol) and DCC 
(247.6 mg, 1.2 mmol) were dissolved in anhydrous DMF (40 mL) with magnetic 
stirring for 1 h. Genistein (90 mg, 0.33 mmol) was dissolved in anhydrous DMF 
(10 mL) and then added to the previous solution under nitrogen with stirring for 
48 h and the progress of the chemical reaction monitored by thin layer 
chromatography (TLC) as explained in Section 2.4.3.1. After the reaction was 
complete, the solvent was removed under vacuum by rotary evaporation at 60 °C 
in a water bath for 20 min and the product was further purified by column 
chromatography on a silica gel-packed column (40 mm diameter x 400 mm 
length) eluted with chloroform and methanol starting from 100% v/v chloroform 
to 80:20 % v/v chloroform: methanol. 
 Characterisation of the synthesized compound 
 Thin layer chromatography (TLC) 
For mPEG-COOH synthesis, the solvent system for TLC using TLC plates (5x10 
cm, coated with silica gel, Merck, USA) was chloroform/ methanol (70:30, %v/v) 
and the spray reagent consisted of sulfuric acid (Sigma-Aldrich, UK)/ethanol 
(VWR International Ltd., UK) (80:20, % v/v) and succinic vanillin (0.05% w/v, 
Sigma-Aldrich, UK). 
For genistein-mPEG synthesis, the solvent system for TLC was chloroform/ 
methanol (90:10, % v/v) using TLC plates explained above. 
 Fourier transform infrared (FT-IR) spectroscopy  
2 mg of mPEG, succinic acid, mPEG-COOH, genistein and genistein-mPEG were 
each analysed by a Perkin-Elmer Spectrum 100 FT-IR Spectrometer (Perkin-
Elmer, USA) using a KBr disk for preparation of samples. Data in the 
wavenumber range of 400-4,000 cm-1
 
were collected at a resolution of 4 cm-1
 
with 
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the number of scans at 4, and presented using the Perkin-Elmer Express software 
(Perkin Elmer, USA).  
 Nuclear magnetic resonance (NMR) spectroscopy 
10 mg samples of mPEG and mPEG-COOH were dissolved in 0.6 mL CDCl3, and 
10 mg samples of succinic acid, genistein, and genistein-mPEG were dissolved in 
0.6 mL of DMSO-d6. The spectra were obtained using an 500 MHz NMR 
spectrometer and data were processed using TopSpinTM software 4.0 (Bruker Ltd., 
UK). 
 Matrix-Assisted Laser Desorption-Time of Flight (MALDI-TOF) 
mass spectrometry 
MALDI-TOF mass analysis was performed using a Voyager-DE Pro mass 
spectrometer (Applied Biosystem, UK) equipped with a nitrogen laser (337nm, 3-
ns pulse width) and time-delayed extraction ion source. 5mg samples of mPEG-
COOH and genistein-mPEG were dissolved in alpha-cyno-4-hydroxycinnamic 
acid. The analysis was measured in positive linear mode using an accelerating 
voltage of 25 kV. 
 Results and discussion 
 Synthesis of methoxypoly(ethylene glycol)-carboxyl   (mPEG-COOH)  
 TLC  
Thin-layer chromatography (TLC) is a rapid analytical technique and commonly 
used in synthetic chemistry and pharmaceutical analysis, e.g. for isolating the 
impurities of samples, identifying individual components in a given sample, and 
monitoring the progress of a reaction (Khale, 2010). Different compounds in the 
sample move up a TLC plate by capillary action from its original spot at different 
rates due to two main considerations, the differences in their attraction to the 
stationary phase normally silica gel and differences in solubility in the mixture of 
eluting solvents. The mobile phase, which is a mixture of co-solvents, has less 
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polarity than silicon oxide (silica) due to the Si-O-H bond at the surface of the 
silica gel on the TLC plate. Hence, different compounds are separated due to these 
two main factors and reported as the total distance travelled by a component 
divided by the distance travelled by solvent from the original point (Rf value) 
(Meyers and Meyers, 2001). In general, more polar substances have stronger 
interaction with the silica and are adsorbed tightly on to the TLC plate, and this 
thus contributes to a lower Rf value compared with less polar components.  
The compounds separated using TLC can be identified by several techniques; for 
example, physical (individual colour of compound or fluorescence of substance in 
short or long wavelength UV light), chemical (visualising agent needed) and 
biological (biodetector needed) methods (Pyka, 2014). As mPEG-COOH does not 
have any aromatic rings, it would not be directly detected on a TLC plate in UV 
light. Therefore, the spray reagent, vanillin in hot sulfuric acid, was prepared to 
detect the structure of hydroxyl or carbonyl or polyester compounds. The 
mechanism of visualisation can be explained by the electrophilic aromatic 
substitution of a phenol group of vanillin in the presence of sulfuric acid, resulting 
in the formation of a coloured compound (Johnson et al., 1977). As seen from 
Figure 2-2, the spot of the product, mPEG-COOH appeared at a lower position (Rf 
value = 0.24) compared with the starting material, mPEG (Rf value = 0.60). This 
suggests mPEG-COOH was more polar than mPEG due to the attachment of 
carboxylic group, resulting in greater retention at the silica binding sites. TLC 
technique was used in this study as a screening tool, the reaction was further 
confirmed using FT-IR and NMR (Zhang et al., 2007b).  
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Figure 2-2 TLC plate of starting materials and product of mPEG-COOH synthesis 
 FT-IR 
mPEG-COOH synthesis was confirmed using FT-IR analysis (Figure 2-3a -2-3c). 
The absorption bands of methylene units (-CH2-) and ether links (C-O-C) with 
stretching and asymmetrical stretching vibration, which appeared at 
approximately 2,880 cm-1 and 1,100 cm-1, respectively, could be observed in 
spectra of both mPEG and mPEG-COOH (Zhang et al., 2007b; Castillo et al., 
2014; Gao et al., 2016). Furthermore, the sharp peaks at approximately 1,470, 960 
and 840 cm-1 also demonstrated the essential polyethylene oxide backbone of 
mPEG and mPEG-COOH as expected (Zhang et al., 2007b; Jeong et al., 2008; 
Castillo et al., 2014; Danafar et al., 2017). The FT-IR data for the mPEG-COOH 
product exhibited all mPEG bands, whereas the FT-IR spectrum of mPEG did not 
show any absorption peaks in the range of 1,750-1,700 cm-1. This indicated the 
absence of carbonyl group (C=O) in mPEG (Sant and Nagarsenker, 2011). 
The FT-IR spectrum for succinic acid (Figure 2-3b) showed distinctive bands with 
scissoring vibration at 1,410 cm-1 and stretching vibration at 1,685 cm-1, 
corresponding to the skeleton carbon (-CH2-) and carbonyl group of carboxylic 
acid, respectively (Castillo et al., 2014). The characteristic carbonyl peak of 
succinic acid disappeared; meanwhile, a new absorption peak was detected at 
1,737 cm-1 in mPEG-COOH. This new band, which appeared in three batches of 
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mPEG-COOH product, indicated the presence of the carbonyl group (C=O) of 
carboxylic acid with stretching vibration. Furthermore, a significant shift of 52 
cm-1 (from 1,685 to 1,737 cm-1) implied the effect of the carboxylic acid 
functional group being introduced to the end-hydroxyl group of mPEG due to 
ring-opening of succinic anhydride. The IR data were in agreement with 
previously reported values, supporting successful synthesis of the mPEG-COOH 
(Zhang et al., 2007b; Zhang et al., 2009; Zhang et al., 2014a).  
Two broad peaks for the –OH groups of alcohol and carboxylic acid molecule 
were also expected to be present, ranging from 3,550 to 3,200 cm-1 (mPEG) and 
3,000 to 2,500 cm-1 (mPEG-COOH), respectively. However, these were not 
detected using FT-IR. This might be because the intensity of vibrational 
frequencies of the 1 terminal –OH group was comparatively weaker than that of 
over 100 repeating units of ethylene oxide in the same IR spectrum for both 
polymers. Moreover, a KBr disk might not be translucent, possibly due to water in 
the disk and/or poorly dispersed sample. Therefore, the structure of this 
synthesized polymer was then further confirmed by 1H- and 13C-NMR. 
 
Figure 2-3 FT-IR of spectra of a) mPEG, b) succinic acid and c) mPEG-COOH 
a) mPEG 
c) mPEG-COOH 
b) succinic acid 
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 NMR 
H-NMR 
From Figure 2-4a - 2-4b, 1H NMR spectra of mPEG and mPEG-COOH in CDCl3 
showed multiple peaks in the range of 3.60-3.67 ppm, corresponding to the 
protons of repeating units (–OCH2-CH2O-)n. A single peak at 3.37 ppm was 
ascribed to the protons of the terminal methyl group (O-CH3). The characteristic 
mPEG-COOH peak at 4.26 ppm was assigned to the methylene protons in mPEG 
adjacent to the succinyl group (CH2C(=O)OCH2CH2 ) and the multiple peaks at 
2.64 ppm came from the methylene proton of the succinyl group (CH2-CH2-
COOH). A signal at 12.14 ppm in the 1H-NMR spectrum of succinic acid (Figure 
2-4c), which represented the protons of –COOH, disappeared in mPEG-COOH. 
All these results confirmed the existence of a carboxyl group in mPEG-COOH 
due to ring-opening of succinic anhydride upon reaction, and this was in 
agreement with the IR data (Section 2.5.1.2). 
In order to determine the degree of conversion of hydroxyl group to carboxyl 
group, the hydroxyl moiety peak area was measured and directly compared with 
the areas of other peaks in the same 1H-NMR spectrum (Dust et al., 1990). In this 
study, the integration ratio of peak area of the protons from the terminal mPEG 
methyl group (3.37 ppm) to the methylene protons adjacent to succinyl group 
(4.26 ppm) was 3:2, indicating the complete conversion of the end-hydroxyl 
group of mPEG into carboxyl group with the mole ratio of 1:1 (Zhang et al., 
2007b; Zhang et al., 2009). This result was also in agreement with previously 
reported values (Ishii et al., 2005; Zhang et al., 2007b; Jeong et al., 2008; Zhang 
et al., 2009; Qiu et al., 2010; Wu et al., 2010; Sant and Nagarsenker, 2011; Du et 
al., 2012; Liu et al., 2014a; Zhang et al., 2014a; Gao et al., 2016). 
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Figure 2-4 H-NMR spectra of a) mPEG, b) mPEG-COOH and c) succinic acid 
b) 
a) 
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Figure 2-4 (Cont.) H-NMR spectra of a) mPEG, b) mPEG-COOH and c) succinic acid 
 
 
C-NMR  
As shown in Figure 2-5a, the 13C-NMR spectrum of mPEG exhibited a peak at 
59.21 ppm corresponding to the –O-CH3 group, and a distinctive sharp peak 
around 70.73 ppm due to repeating units (–OCH2-CH2O-)n. The 13C-NMR 
spectrum of mPEG-COOH (Figure 2-5b) had a peak at 28.52 ppm ascribed to -
COOCH2CH2COOH-. A peak, which implied the existence of the carboxyl group 
(-COOH), appeared at 170.71 ppm in mPEG-COOH. Furthermore, there was an 
obvious shift in the terminal C in mPEG adjacent to –OH group (-CH2OH) from 
61.89 to 63.97 after succinic acid was introduced to its molecule. These values 
were in agreement with previous reports (Jeong et al., 2008; Zhang et al., 2009). 
All these combined results confirmed that a new functional group (-COOH) was 
successfully attached to the terminal part of mPEG. 
 
c) 
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Figure 2-5 C-NMR spectra of a) mPEG and b) mPEG-COOH 
a) 
b) 
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 Development of the mPEG-COOH synthesis 
According to the procedure previously described (Jeon et al., 2003; Wang and 
Hsiue, 2005; Jeong et al., 2008; Xie et al., 2009; Xiang et al., 2011; Zhang et al., 
2014a), mPEG-COOH can be synthesized using different methods based on the 
same chemical reaction, shown in Figure 2-6. The ring of succinic anhydride is 
opened and then introduced into the end- hydroxyl group of mPEG by a 
substitution and elimination reaction. The combined results of the NMR analysis 
demonstrated the existence of –COOH at the end of the mPEG molecule. 
 
Figure 2-6 Scheme of mPEG-COOH synthesis 
In general, acylation of the mPEG with excess succinic anhydride results from the 
presence of 4-(dimethylamino)pyridine (DMAP) and triethylamine (TEA) in an 
anhydrous non-polar solvent (Jeon et al., 2003; Xie et al., 2009; Chen et al., 2011; 
Zhang et al., 2014a; Karolina et al 2016).  
1,4 dioxane and pyridine are normally used as anhydrous non-polar solvents. 
These are not environmental friendly and are harmful for operators. Therefore, 
other solvents, which are more environmental friendly, should be used as 
alternatives where possible. Additionally, humidity has to be strictly controlled 
during reactions because moisture can interfere with the reaction progress. 
Moreover, mPEG-COOH, which is the intermediate product for a further 
synthesis step, takes at least 24 h to produce by the conventional synthesis process. 
Hence, it would be useful to find other procedures that take a shorter time to 
obtain this intermediate product. 
Erbium trifluromethanesulfonate (Er(OTf)3 has been reported to be an efficient, 
non-toxic, and recyclable catalyst in several organic reactions. This effective, 
rapid, and waste-free method yields good results and can be done in a short 
+ 
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reaction time with minimal amounts of waste under almost neutral conditions, 
with no further requirement for a purification process (Antonio et al., 2004; 
Renato et al., 2009; Tran et al., 2015; Herrera Cano et al., 2016). In this study, 
Er(OTf)3 was chosen as the catalyst to investigate the transformation of the end-
hydroxyl group of mPEG to  carboxylic acid. The reaction mixture was heated at 
reflux for 2 h at 85°C in order to reduce the reaction time compared with other 
conventional methods (Antonio et al., 2004). Therefore, the use of TEA and 10% 
mole DMAP were replaced with 10% mole of erbium trifluoromethanesulfonate 
in the studied reaction. 
In this revised synthesis, mPEG-COOH was prepared with modifications by using 
mPEG, succinic anhydride and erbium trifluromethanesulfonate in the presence of 
acetronitrile with the lowest molar ratio (1:0.7350:0.0735) (Xie et al., 2009) to 
lessen the unreacted succinic anhydride which would affect the subsequent 
reaction step as illustrated in Figure 2-7. 
 
Figure 2-7 The scheme of mPEG synthesis in the presence of erbium 
trifluoromethanesulfonate and succinic anhydride 
Over all, all the results from TLC, FT-IR, 1H-NMR and 13C-NMR demonstrated 
that mPEG-COOH was synthesized successfully using this revised methodology. 
This product, then, had been transferred to the subsequent reaction step. 
 Synthesis of genistein-mPEG 
 TLC 
TLC was used to monitor and assess the completion of reactions. From the TLC 
plate (Figure 2-8), it can be seen that the spot produced by the product, genistein-
mPEG appeared in three positions compared with all starting materials, mPEG-
COOH, DCC and DMAP.  This means that the product of this reaction was a 
mixture and required purified to obtain the final product.  
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Figure 2-8 TLC of starting materials and product of genistein-mPEG synthesis 
 FT-IR 
The synthesis of genistein-mPEG (Figure 2-9) was confirmed using FT-IR. The 
IR spectrum of genistein (Figure 2-10a) exhibited two broad bands at 3,403 cm-1 
and 3,086 cm-1 due to the phenolic –OH and C-H stretching vibration, 
respectively. The presence of carbonyl (C=O), C-O and aromatic C=C stretching 
bands appeared in the range of 1,660-1,640 cm-1, 1,260-1,000 cm-1 and 1,600-
1,400 cm-1, respectively. IR data for genistein were in agreement with previous 
reports (Usha et al., 2005; Crupi et al., 2007; Almahy and Alhassan, 2011; Pandit 
and Patravale, 2011). The FT-IR spectrum of mPEG-COOH (Figure 2-10b) 
showed characteristic absorption peaks at approximately 1,780 cm-1 corresponding 
to C=O, and at 2,880, 1,470, 1,100, 950 and 840 cm-1 ascribed to the essential 
polyether backbone as outlined in Section 2.5.1.2. 
The absorption peaks of phenolic –OH at 3,403 cm-1 disappeared in the spectrum 
for genistein-mPEG conjugate (Figure 2-10c), implying the conjugation of the 
phenolic -OH group of genistein (Sojitra et al., 2010). However, the IR spectrum 
of mPEG-COOH also did not show any broad bands of –OH of free –COOH in 
that region. Thus, the attachment of –OH group of genistein to the –COOH group 
of mPEG-COOH could not be confirmed from this absorption peak.  
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Although most of the characteristic bands of genistein-mPEG conjugate (Figure 
2-10c) were almost the same as those of mPEG-COOH (Figure 2-10b), there were 
two new absorption bands at 1,654 cm-1 and in the region 1,600-1,400 cm-1. These 
two bands, which were characteristic of genistein, indicated the existence of a 
C=O group and the attachment of the C=C aromatic ring of genistein to mPEG-
COOH upon an esterification reaction. However, the intensity of the IR 
absorption of these two bands was weaker than those for genistein. This might be 
because there was less genistein in the drug-polymer conjugate compared with a 
raw material of genistein. Also, the stronger absorption of mPEG-COOH could 
comparatively decrease the signal of genistein in the conjugate due to numerous 
repeating units of ethylene oxide.  
Many peaks appeared in the range 1,500 – 800 cm-1 in the IR spectra of genistein 
(Figure 2-10a) and mPEG-COOH (Figure 2.10b). This would be likely to lead to 
either an overlap or an elimination of these functional vibrations merging into 
boarder bands and decreased signals for genistein-mPEG conjugate, as can be 
seen in the case of methotrexate in methotrexate-PEG-PAMAM conjugate 
(Noorzidah et al., 2012) and naproxen conjugated mPEG-PCL (Karami et al., 
2016). 
All these bands in FT-IR spectrum, which showed the characteristic mPEG-
COOH and genistein bands together with a new peak of C=O, provide evidence of 
the successful conjugation of genistein to mPEG-COOH polymer. However, 1H-
NMR was also employed further to confirm the structure of the final product of 
the synthesis. 
 
Figure 2-9 The structure of genistein-mPEG 
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Figure 2-10 FT-IR spectra of a) genistein, b) mPEG-COOH and c) genistein-mPEG 
 NMR 
H-NMR 
The 1H NMR spectrum of the genistein-mPEG conjugate in DMSOd6 showed a 
singlet peak at 3.24 ppm due to the –O-CH3 group and multiple peaks in the range 
of 3.41-3.43, 3.57-3.59 and 3.63-3.65 ppm attributed to the CH2O unit of the 
mPEG-COOH molecule (Figure 2.11a -2.11b). The poly (ethylene) oxide 
repeating units (–OCH2-CH2O-)n of mPEG-COOH produced multiple bands 
around 3.50 ppm. The peak in the region 4.09-4.11 ppm was attributed to 2H from 
the CH2C(=O)OCH2CH2 group of the mPEG-COOH molecule.  
Additionally, the characteristic peaks at 6.21, 6.37 and 8.31 ppm were due to 1H 
on the aromatic ring and the duplex peaks between 6.81-6.83 ppm and 7.36-7.38 
were due to 2H on the benzene ring of genistein (Figure 2-12a - 2.12b). There 
were 2 singlet peaks at 9.59 and 12.95 ppm presenting the –OH groups of the 
genistein molecule. 1H-NMR results were in agreement with previous reports for 
genistein molecule (Hassan and Nafisa, 2011; Pandit and Patravale, 2011; 
Stolarczyk et al., 2017).  
 a) genistein 
b) mPEG-COOH 
c) genistein-mPEG- 
conjugate 
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When the NMR signals of genistein and genistein conjugate were compared 
(Figure 2-12a- 2-12b), there were slight chemical shifts corresponding to 1H and 
2H on the benzene rings in the range of 6.21-8.32 ppm. Also, the characteristic –
OH peak on the phenol ring at 10.87 ppm was absent in the spectrum of the 
conjugate, confirming the formation of the chemical bond. In addition, the 
integration ratio of peak area of the protons from the terminal methyl group of 
mPEG-COOH (3.24 ppm) to the protons from the hydroxyl group of genistein 
(12.95 ppm) was 3:1, indicating the complete formation of an ester linkage 
between genistein and mPEG-COOH. These findings allow the conclusion that 
genistein was successfully conjugated with mPEG-COOH with a mole ratio of 1:1 
using 1H-NMR analysis. 
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Figure 2-11 H-NMR of a) genistein-mPEG synthesis and b) mPEG-COOH component 
of genistein-mPEG conjugate 
a)  
b) 
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Figure 2-12 H-NMR of a) genistein component of genistein-mPEG conjugate and b) 
genistein  
a) 
b) 
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 Mass spectroscopy 
MALDI TOF analysis is one of the most useful techniques to identify molecules 
which have molecular weights lower than 10 KDa and for polymer analysis, 
allowing determination of chemical structure by analyzing the mass and the 
charge of ions (Riebeseel et al., 2002; Qiu et al., 2010). In this research, based on 
the molecular weight of the starting materials, the average molecular weight of 
genistein-mPEG conjugate was expected to be in the range 5,200-5,400 Da. 
MALDI TOF analysis showed a shift in the average mass distribution of the drug-
polymer to the higher masses compared with mPEG-COOH, from 5,004.25 to 
5,276.30 Da (Figure 2-13a- 2-13b). The mass distribution shift of 272.05 Da, 
which was very close to the reported molecular weight of genistein (270.24 Da), 
indicated that one mPEG-COOH molecule carried exactly one genistein molecule. 
Thus, MALDI TOF analysis can reflect the degree of ligand loading as report 
previously (Ajazuddin et al., 2013; Heath et al., 2016). All the combined results 
from TLC, FT-IR, NMR and mass spectrometry have demonstrated that the 
conjugation of genistein and mPEG-COOH was successful with a mole ratio of 
1:1. 
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Figure 2-13 Mass spectra of a) mPEG-COOH and b) genistein-mPEG- 
b.) genistein-mPEG-COOH 
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 Development of the genistein-mPEG conjugate synthesis 
For anhydrous DCM, mPEG-COOH, DCC and DMAP could be dissolved freely. 
However, genistein is sparingly soluble in this solvent, suggesting that anhydrous 
DCM might not be a suitable solvent in this case. 
Anhydrous DMSO, all reagents were freely soluble, and the solution was clear 
before purifying the product. The boiling point of DMSO is 180°C. It, thus, 
cannot be removed by rotary evaporation, even when using very low pressure, 
indicating that this solvent was not suitable and practical for the synthesis of this 
conjugate. Therefore, anhydrous DMF was the next solvent investigated. 
Anhydrous DMF was chosen for this reaction for two main reasons. First, all 
reagents dissolved freely, except mPEG-COOH, which needed heat to facilitate 
dissolution. Second, the boiling point of DMF is lower than DMSO and therefore, 
it was easier and more convenient to remove DMF by rotary evaporation. 
Therefore, DMF was used for the further step to obtain the optimal mole ratio of 
genistein and mPEG-COOH. 
In terms of the molar ratio between genistein and mPEG-COOH, a ratio of 1:1 for 
acidic and hydroxyl compound is usually employed (Liu et al., 2014a). Initially, 
genistein and mPEG-COOH in the ratio of 1:1 was investigated, with TLC used to 
monitor the progress of the reaction. Genistein attached to at least one mPEG-
COOH molecule was aimed in this study. However, there was a spot for genistein, 
indicating that not all of genistein molecules were incorporated into mPEG-
COOH and the amount of drug used was excessive at this ratio. Due to the fact 
that genistein contains three hydroxyl groups (–OH) and each group can possibly 
carry one mPEG-COOH molecule through an ester bond, this factor may result in 
an insufficient quantity of mPEG-COOH in the reaction. These observations 
consequently led to a decrease in molar ratio of genistein and mPEG-COOH and 
1:3 mole ratio of drug and polymer was subsequently further investigated. 
1:1 and 1:3 ratios of genistein and mPEG-COOH were compared by the size of 
the genistein spot on the TLC plate. The larger the spot, the more incomplete the 
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reaction was. From the TLC plate, both ratios showed the spot of genistein, 
indicating there was still genistein residue and the reaction was incomplete. 
Increasing amount of mPEG-COOH was consequently suggested for further 
optimisation. This could be because mPEG-COOH in the first step had not yet 
been purified and possibly still contained a mixture of unreacted mPEG. 
Therefore, adding a higher amount of mPEG-COOH or reducing the mole ratio of 
genistein and mPEG-COOH in further studies was expected to be one of the 
solutions to compensate for the actual required amount of mPEG-COOH, 
minimise an excessive of genistein in this reaction and improve a yield of 43.7%. 
 Conclusion 
A novel amphiphilic genistein-mPEG conjugate was synthesized via two main 
reaction steps: (1) the terminal hydroxyl group of mPEG was converted into a 
carboxylic group by reacting with succinic anhydride in the presence of erbium 
trifluoromethanesulfonate; (2) the end-carboxyl group of mPEG-COOH was 
reacted with hydroxyl group of genistein by esterification condensation with 1:3 
mole ratio of genistein and mPEG-COOH through an ester linkage in the presence 
of DCC and DMAP.  
The production of this drug-polymer conjugate obtained as a light yellow powder, 
was confirmed using TLC, FT-IR, 1H-NMR and mass spectrometry. 
Consequently, this compound was then studied further for erlotinib, curcumin and 
other hydrophobic drugs as new nanocarriers as outlined in Chapter 3. 
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 Introduction 
The bioavailability of hydrophobic drugs used in the treatment of non-small-cell 
lung cancer (NSCLC) is limited by their aqueous solubility. Erlotinib has been 
extensively studied in patients with NSCLC, though problems with toxicity, 
stability and sub-therapeutic drug levels remain (Wang et al., 2012; Truong et al., 
2016). Curcumin, a hydrophobic polyphenol extracted from Curcuma longa, has 
several pharmacological applications including for the treatment of NSCLC 
(Aditya et al., 2013; Tsai et al., 2015).  Genistein, the major isoflavone isolated 
from soybeans, has attracted a great deal of attention as a chemo-preventive agent 
and has also shown synergistic activity with erlotinib in three separate NSCLC 
cell lines (Gadgeel et al., 2009; Tang et al., 2011). Genistein and curcumin, are 
both commonly used as major ingredients in Asian foods, and have been 
previously studied in combination for their potentiation effects including anti-
cancer activity (Aditya et al., 2013). Therefore, combinations of a herbal 
substance and a cytotoxic drug (genistein+ erlotinib) and of two herbal substances 
(genistein+curcumin) were investigated in this study.  
The therapeutic applications of these three compounds (all BCS class II; poorly 
water- soluble but highly permeable) are limited due to their low aqueous 
solubility (Chen et al., 2013; Hu et al., 2015; Yang et al., 2017b), consequently 
formulation approaches have been investigated to overcome these problems to 
enhance their therapeutic applications.  
The treatment of lung cancer is impeded due to systemic side effects associated 
with current oral and injected therapies and sub-therapeutic levels of drugs at the 
target site. Colloidal drug delivery systems; for example, liposomes, polymeric 
nanoparticles and micelles, have been used as drug carriers for pulmonary 
delivery to improve the solubility of hydrophobic drugs, prolong their circulation 
time and reduce drug toxicity (Yang et al., 2015). In this chapter, the amphiphilic 
drug-polymer conjugate (genistein-mPEG) described in Chapter 2 will be further 
assessed to determine whether it forms self-assembled polymeric micelles suitable 
for the delivery of erlotinib or curcumin by the pulmonary route. Polymeric 
micelles incorporating either erlotinib or curcumin were prepared and 
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characterised for drug entrapment to obtain the optimal drug/polymer mass ratio 
and to study the effect of physicochemical properties such as the partition 
coefficient (log P), water solubility, melting point, molecular structure and 
molecular weight on the properties of the polymeric micelles formed.  
Nebulised drug delivery has the advantages of delivering large doses of drugs and 
nano-sized delivery systems with minimal processing compared to pressurised 
metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs).  Therefore, the 
aerosol properties of optimised formulation delivered by two nebuliser types (air-
jet and vibrating-mesh nebulisers) were determined using the Next Generation 
Impactor (NGI). 
 Aims 
1. To measure the critical micelle concentration (CMC) of genistein-mPEG 
conjugate using dynamic light scattering (DLS) analysis  
2. To study the incorporation of the hydrophobic drugs, erlotinib and curcumin, 
into genistein-mPEG polymeric micelles 
3. To characterise and optimise curcumin-loaded genistein-mPEG polymeric 
micelles for potential delivery to the lung 
4. To assess the aerodynamic characteristics of nebulised micelles delivered by 
air-jet and vibrating-mesh nebulisers using the Next Generation Impactor (NGI)  
 Materials 
Erlotinib 99% (LC Laboratories, USA) and curcumin 95% (Alfa Aesar, USA) 
were used as hydrophobic drugs for solubilisation in genistein-mPEG polymeric 
micelles. Methanol (99.9%, HPLC gradient grade), absolute ethanol (99.8%, 
analytical grade) and HPLC grade water purchased from Sigma Aldrich (Poole, 
UK) were used as solvents in the preparation of formulations. 
Chapter 3 Hydrophobic drug-loaded genistein-mPEG micelles 
 107 
The following reagents and solvents obtained from Sigma Aldrich (Poole, UK): 
methanol (99.9%, HPLC gradient grade), dimethyl sulfoxide (DMSO, >99.7%, 
HPLC gradient grade), acetronitrile (ACN, 99.9%, HPLC gradient grade), HPLC 
grade water and trifluoroacetic acid (TFA, >99.0%) were used for the quantitative 
HPLC determination of curcumin and erlotinib. 
 Methods 
 High performance liquid chromatography (HPLC) methods for assay 
of erlotinib and curcumin 
 Chromatographic conditions for HPLC analysis of erlotinib  
The analysis was conducted using a high performance liquid chromatography 
(HPLC) system equipped with an auto sampler and UV/Vis detector (Agilent 
1100 Series, USA). A Synergi 4 µm Polar-RP 80 ºA HPLC column (250 x 4.6 
mm x 4 µm) was used as the stationary phase for drug separation.  
For erlotinib, isocratic elution was carried out with the mobile phase comprising a 
mixture of ACN and 0.1% v/v TFA in HPLC grade water (50:50 %v/v). The 
eluents were degassed before pumping through the column at a flow rate of 1 
mL/min. The column temperature was maintained at 25 °C and the sample 
injection volume was 10 µL, with a run time of 10 min. The UV wavelength was 
set at 246 nm throughout the entire experiment. To determine the quantity of 
erlotinib in the genistein-mPEG micelles, it was assayed using HPLC 
chromatographic parameters as present in Table 3-1. The validation of the high 
performance liquid chromatography (HPLC method) for erlotinib according to 
ICH Q2 (ICH Guideline, 2005) will be described in Section 3.4.1.5. 
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Table 3-1 HPLC chromatographic conditions for assay of erlotinib 
HPLC parameters  
Injection volume (µL) 10 
UV/Vis detector wavelength (nm) 246 
Mobile phase (ACN: 0.1% v/v TFA in HPLC grade water) 50:50 
Column temperature (°C) 25 
Flow rate (mL/min) 1 
Run time (min) 10 
 
 Chromatographic conditions for HPLC analysis of curcumin 
The HPLC method for assay of curcumin was developed and previously validated 
in our laboratory (Merchant, 2017). HPLC chromatographic parameters such as 
composition of the mobile phase, flow rate of the eluents and sample injection 
volume were the same as those used in the erlotinib HPLC assay. However, the 
column temperature was set at 40ºC and the UV wavelength was fixed at 420 nm, 
with the run time was 15 min period. 
To determine the content of curcumin in the genistein-mPEG polymeric micelles, 
the HPLC conditions shown in Table 3-2 were employed. 
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Table 3-2 HPLC chromatographic conditions for assay of curcumin 
HPLC parameters  
Injection volume (µL) 10 
UV/Vis detector wavelength (nm) 420 
Mobile phase (ACN: 0.1% v/v TFA in HPLC grade water) 50:50 
Column temperature (°C) 40 
Flow rate (mL/min) 1 
Run time (min) 15 
 
 Preparation of HPLC calibration curve for erlotinib  
A standard stock solution of erlotinib 1000 g/mL was prepared by dissolving 10 
mg of erlotinib in 5 mL of DMSO in a 10 mL volumetric flask. The sample was 
bath-sonicated for a few min and the volume was made up to the final volume of 
10 mL. To study the linearity, serial dilutions of the stock solution were made in 
the range of 1- 70 g/mL; 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60 and 70 g/mL.  
 Preparation of HPLC calibration curve for curcumin 
A standard stock solution of curcumin 1000 g/mL was prepared by dissolving 25 
mg of curcumin in 20 mL of methanol in a 25 mL volumetric flask. The sample 
was subjected to bath sonication and diluted with the same solvent to the final 
volume of 25 mL. Serial dilutions of stock solution were prepared in the range of 
3- 50 g/mL; 3, 4, 5, 10, 20, 30, 40 and 50 g/mL in order to study the linearity. 
Calibration curves for erlotinib and curcumin were obtained by plotting peak area 
on the Y-axis against concentration of assay solution on the X-axis. 
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 Analytical method validation of erlotinib 
The HPLC method for erlotinib was validated for linearity, precision, accuracy, 
limit of detection and limit of quantification following the International 
Conference on Harmonisation (ICH Q2) guidelines. 
3.4.1.5.1 Linearity 
Linearity in this study was performed by taking four samples of all serial dilutions 
of 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70 g/ mL from the stock solution and then 
injecting 10 L of each concentration into the HPLC chromatographic system and 
recording the response. The degree of linearity was then determined by 
calculating the correlation coefficient. The slope, intercept and correlation 
coefficient of erlotinib were determined from the equation describing the response.  
3.4.1.5.2 Precision 
Precision is an expression of the closeness of individual measurement to each 
other or the degree of scatter. In this study, two parameters; namely the inter-day 
and intraday precisions were assessed. Intraday precision was performed by 
injecting three concentrations (8, 35 and 55 g/mL) in triplicate per concentration 
onto the chromatographic system on the same day. Meanwhile, the inter-day 
precision was determined with those concentrations on three consecutive days. 
The repeatability study was undertaken by injecting the chosen concentration of 
35 µg/mL 9 times to obtain the relative standard deviation (%RSD) calculated 
using equation Eq.3-1.  
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (%𝑅𝑆𝐷) =  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 
𝑀𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒
 x 100                                           Eq. 3-1 
where;  %RSD- percent relative standard deviation 
3.4.1.5.3 Accuracy  
Accuracy measures the closeness of agreement between the actual value and the 
value found. The accuracy study was determined by the recovery method, using a 
series of concentrations between 3 and 70 μg/mL for erlotinib. This analysis was 
Chapter 3 Hydrophobic drug-loaded genistein-mPEG micelles 
 111 
performed in triplicate for the quantification of erlotinib. Then, the percentage 
recovery was calculated following equation Eq. 3-2. 
Accuracy (%RE) =100 –  
(𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑣𝑎𝑙𝑢𝑒−𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑣𝑎𝑙𝑢𝑒)
𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑣𝑎𝑙𝑢𝑒
 x100                  Eq. 3- 2 
where;  %RE- relative error 
3.4.1.5.4 Limit of detection 
The limit of detection (LOD) is defined as the lowest concentration of an analyte 
that can be detected under the prescribed conditions, but not quantified. It can be 
calculated using the following equation Eq. 3-3 according to ICH guidelines:  
𝐿𝑂𝐷 =  
3.3 𝜎
𝑆
                              Eq. 3- 3 
where;   σ = the standard deviation of the response   
   S = the slope of the calibration curve estimated from calibration curve 
3.4.1.5.5 Limit of quantification 
The limit of quantification (LOQ) is the lowest concentration of substance in a 
sample that can be determined with acceptable precision and accuracy under the 
stated operational conditions of the method. It can be calculated using the 
following equation Eq. 3-4 according to ICH guidelines: 
𝐿𝑂𝑄 =  
10 𝜎
𝑆
                                              Eq. 3- 4 
 Critical micelle concentration of genistein-mPEG conjugate 
A stock solution of polymeric micelles was prepared by the thin-film hydration 
method. 50 mg of genistein-mPEG was dissolved in 20 mL of methanol in a 250 
mL round-bottomed flask and then a rotary evaporator (RC 900, Knf Neuberger 
GmbH, Germany) was used to remove the solvent under low pressure at 150 bars 
for 20 min at 70 ºC, with a rotation speed of 150 rpm to produce a thin film of 
polymer. The resultant film was flushed with nitrogen gas to remove residual 
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solvent and then hydrated with 5 mL of HPLC grade water with vigorous hand-
shaking and rotated on the rotary evaporator at 250 rpm for 10 min at 60 ºC in a 
water bath to obtain a micellar solution of 10 mg/mL genistein-mPEG. To 
determine the critical micelle concentration (CMC) of the conjugate, serial 
dilutions of the stock solution were made in the range of 10-0.078 mg/mL; 10, 5, 
2.5, 1.25, 0.625, 0.3125, 0.156, 0.078 mg/mL.  
The CMC was determined from the linear relationship between the intensity of 
scattered light and concentration (Topel et al., 2013), using the Malvern Nano ZS 
Zetasizer (Malvern Instruments Ltd, UK) containing a 4mW He-Ne laser, 
operating at 633 nm. 1.0 mL of each diluted solution was placed without further 
dilution into the zeta potential DTS1070 folded capillary cell (Malvern, UK), and 
light scattering measured at 25°C by non-invasive back scatter (NIBS) optics, at 
an angle of 173º, for high sensitivity and good quality of signal.  
The data were plotted as scattered light intensity (the derived count rate in kilo 
counts per second, kcps) on the Y-axis against concentration of genistein-mPEG 
conjugate in HPLC grade water (in a logarithmic scale) on the X-axis. The 
intersection of two linearly extrapolated lines yielded the CMC value of genistein-
mPEG conjugate in mg/mL. 
 Preparation of drug-loaded genistein-mPEG polymeric micelles 
 Preparation of erlotinib-loaded genistein-mPEG polymeric micelles 
A stock solution of erlotinib (1.25 mg/mL) was prepared in a 28 mL glass vial by 
dissolving 25 mg of erlotinib in 20 mL of absolute ethanol. Erlotinib-loaded 
genistein-mPEG polymeric micelles were prepared by the thin-film hydration 
method as shown in Figure 3-1.  
2 mL of stock solution was added to 50 mg of genistein-mPEG dissolved in 20 
mL of absolute ethanol in a 250 mL round-bottomed flask. The mixture was 
subjected to bath sonication (Ultrawave U95 Ultrasonic Cleaner, Ultrawave 
Precision Ultrasonic Cleaning Equipment, UK) to ensure the complete dissolution 
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of drug and polymer, and solvent was subsequently removed by rotary 
evaporation using the conditions described in Section 3.4.2. The resultant film 
was flushed with nitrogen and then hydrated with 10 mL of HPLC grade water to 
form polymeric micelles having polymer concentration of 5 mg/mL. Freshly 
prepared micelles were bath-sonicated for a few minutes to aid dispersion. Then, 
non-incorporated drug was removed by passing once through a 0.45 μm cellulose 
acetate syringe filter membrane (Merck Millipore Ltd., UK), to give a filtrate of a 
drug-loaded micellar solution (Moazeni et al., 2012). 
Empty (drug-free) micelles were also prepared using the same method in the 
absence of drug for comparative purposes to study the effect of drug incorporation 
on the properties of the polymeric micelles. 
All formulations were characterised (Section 3.4.4) for mean hydrodynamic 
diameter, size distribution (polydispersity index, PDI), zeta potential and drug 
entrapment (entrapment efficiency and drug loading). The data are presented as 
mean values± standard deviation for triplicate experiments using three different 
batches. 
 
 
Figure 3-1 Preparation of erlotinib-loaded genistein-mPEG micelles 
OO
HO
O
OH
O
curcumin
1) Erlotinib solution + 50 mg of 
conjugate in absolute ethanol was 
evaporated using a rotary evaporator 
2) The thin film was hydrated 
with 10 mL of HPLC water with 
vigorous hand-shaking 
3) The solution was rotated 
on the rotary evaporator to 
yield a micellar solution 
4) Micellar dispersion was bath-
sonicated for few min to aid 
dispersion 
5) Non-incorporated erlotinib 
was removed by filtration to 
obtain drug-loaded micelles 
Chapter 3 Hydrophobic drug-loaded genistein-mPEG micelles 
 114 
 Preparation of curcumin-loaded genistein-mPEG polymeric micelles 
A stock solution of curcumin (1.25 mg/mL) was prepared in a 28 mL glass vial by 
dissolving 25 mg of curcumin in 20 mL of methanol. Curcumin-loaded genistein-
mPEG polymeric micelles were prepared by the thin-film hydration method under 
the operating conditions outlined in Section 3.4.3.1.  
 Characterisation of micellar formulations 
 Particle size distribution 
The hydrodynamic diameter (expressed as Z-average value) and the particle size 
distribution (polydispersity index, PDI) were measured using the Malvern Nano 
ZS Zetasizer (Malvern Instruments Ltd, UK) by dynamic light scattering (DLS). 
1.0 mL of drug-loaded micelles was placed undiluted into the zeta potential 
DTS1070 folded capillary cell (Malvern Instrument Ltd, UK), and then the 
hydrodynamic diameter and the size distribution of micelles undergoing Brownian 
motion within the aqueous dispersion were determined at 25°C in triplicate. 
A PDI value < 0.1 indicates a monodispersed sample, < 0.3 is typically considered 
a relatively monodispersed system, whereas > 0.7 is determined as a 
polydispersed system (ISO-22412, 2008). 
 Surface charge of empty and erlotinib or curcumin-loaded genistein-
mPEG polymeric micelles  
For zeta potential measurements, 1.0 mL of hydrophobic drug-loaded polymeric 
micelles and empty micelles was measured using the Malvern Nano ZS Zetasizer 
and zeta potential determined based on electrophoretic mobility using the 
Helmholtz- Smoluchowski equation.  
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 Drug -loading and entrapment efficiency 
The content of erlotinib in micelle formulations was determined using HPLC. 1 
mL of micelle solutions was diluted with DMSO to a final volume of 10 mL prior 
to quantification using the HPLC conditions shown in Table 3-1. 
For curcumin, 1 mL of formulations was diluted with methanol to a final volume 
of 10 mL prior to determination by the HPLC chromatographic parameters 
presented in Table 3-2. 
The entrapment efficiency (%EE) and drug loading (%DL) were calculated using 
the following equations: 
Encapsulation efficiency (%EE) = 
mass of  drug in micelles
mass of drug available for encapsulation
 × 100           Eq. 3-5 
Drug loading (%DL)                   = 
mass of drug in micelles
mass of polymer and drug
 × 100                              Eq. 3-6 
 Transmission electron microscopy 
The morphology and aggregation behaviour of empty and curcumin-loaded 
genistein-mPEG micelles were observed using a transmission electron microscope 
(TEM; Philips Electron Optics BV, Netherlands). To prepare the samples for 
TEM, a drop of micelle solution was placed on a copper grid and the excess fluid 
removed with filter paper. The sample was negatively stained with a drop of 
uranyl acetate (1%, w/v), and left in place 2 min. The sample was then dried under 
ambient conditions prior to loading into the TEM. 
 Optimisation of curcumin-loaded genistein-mPEG micelles 
The incorporation of curcumin into genistein-mPEG polymeric micelles was 
varied to identify the optimal drug/polymer concentration (as % w/w). To prepare 
different initial concentrations of curcumin-loaded micelles (2.5%, 5%, 10% and 
20% w/w drug in polymer); 1, 2, 4 and 8 mL of stock solution of curcumin (1.25 
mg/mL) were directly pipetted into 50 mg of genistein-mPEG dissolved in 20 mL 
of methanol. The method for preparing polymeric micelles having polymer 
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concentration of 5 mg/mL was as described in Sections 3.4.2 and 3.4.3. The final 
preparations were characterised for mean hydrodynamic diameter and 
polydispersity index (Section 3.4.4.1), zeta potential (Section 3.4.4.2) and drug 
entrapment (Section 3.4.4.3) in each experiment making three independent 
measurements.  
 Mass output and time to dryness for various fill volumes delivered 
from air-jet and vibrating-mesh nebulisers 
2, 4 and 8 mL of HPLC grade water were directly pipetted into a pre-weighed air-
jet nebuliser (Pari LC® Sprint Reusable nebuliser, PARI Medical Ltd, UK). The 
compressor (Pari TurboBoy, PARI Medical Ltd, UK) produced a medium flow 
rate of 4.0-6.0 L/min through the air-jet nebuliser reservoir (Kendrick et al., 1997; 
Dennis et al., 2008). Fluid was nebulised to dryness, with hand tapping of the 
nebuliser to maximise the mass output.  
For the vibrating-mesh nebuliser (Pari Velox®, PARI Medical Ltd, UK), 2, 4 and 
6 mL of HPLC water were placed in the reservoir and nebulisation was 
commenced and continued to dryness. The differing fill volumes of water for 
these two devices were based on their minimum and maximum fill volumes. 
The nebulisation time to dryness (min) for both nebulisers was recorded after 
aerosol generation ceased completely. After that, the nebuliser was weighed to 
determine the weight or mass of residual volume. Aerosol mass output (%) was 
calculated for the different fill volumes using Equation 3-7. 
Aerosol mass output= 
Weight difference of nebuliser before and after nebulisation
Weight of fluid placed into the nebuliser reservoir
 x100%    Eq. 3-7 
 Comparison of aerosol properties of nebulised curcumin micelles 
using the Next Generation Impactor (NGI)  
The NGI (Copley Scientific, UK) was set up according to the requirements of 
European Pharmacopoeia (Ph. Eur. 9.0, 2017, Section 2.9.44 Preparations for 
nebulization characterization), after cooling the impactor at 2-8ºC for at least 90 
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min to prevent water evaporation during use. The air-jet and vibrating-mesh 
nebulisers with mouthpiece adapter were connected to the induction port, and the 
NGI was attached to the vacuum pump (Copley Scientific, UK). The air-flow rate 
generated by the Pari TurboBoy compressor was monitored using flow meter  
(Copley Scientific, UK) at 15 L/min which represents the midpoint flow of tidal 
breathing for adult (Abdelrahim and Chrystyn, 2009). The removable cups of the 
NGI did not require coating with silicone as for dry powder inhaler 
characterisation (Abdelrahim and Chrystyn, 2009). A microfibre back-up filter (7 
mm diameter Grade GF/D, Whatman®, UK), recommended by previous studies, 
was placed after the Micro Orifice Collector (MOC, which is the final stage in the 
NGI), to retain the smallest aerosol droplets when the NGI is operated at 15 L/min 
(Abdelrahim and Chrystyn, 2009). 4 mL of optimised curcumin-loaded micelles 
(containing curcumin at a concentration of 114.01 µg/mL, based on encapsulation 
efficiency of curcumin-loaded polymeric micelles at 5% w/w drug in total 
conjugate (45.60% EE; Table 3-5)) was placed in both nebuliser reservoirs and 
nebulisation continued for 10 min based on the results of time to dryness for 4 mL 
fill volume of water using an air-jet nebuliser. This was to compare the 
performance of these two devices for delivering curcumin-loaded micelles under 
the same operating conditions.  
Deposited material was collected by rinsing with methanol from the nebuliser 
reservoir, induction port, NGI collection cups and the back-up filter. All collected 
samples were made up to fixed volumes for HPLC assay. The curcumin deposited 
on the induction port, all NGI stages, internal filter and that still remaining in the 
nebuliser was quantified by HPLC analysis (Section 3.4.1.2). Mass balance, 
Emitted Dose (ED), Fine Particle Dose (FPD) and Fine Particle Fraction (FPF) 
were calculated as follows: 
Mass balance (%) = 
Mass of drug from nebuliser to filter
Mass of drug initially placed into the nebuliser
x 100               Eq. 3-8  
Emitted Dose (%ED) = 
Mass of drug from induction port to filter
Mass of drug from nebuliser to filter
x 100                 Eq. 3-9          
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Fine Particle Dose (FPD) = Drug mass less than 5 µm determined from the plot of 
cumulative mass of active substance versus cut-off diameter.                                                        
Fine Particle Fraction (FPF) = Percentage cumulative fraction of drug less than 5 
µm from the plot of cumulative fraction of active substance versus cut-off 
diameter.        
 Statistical analysis 
All measurements were carried out in triplicate and the data are presented as the 
mean  standard deviation. Comparison of the data from two groups or more was 
statistically analysed by Student’s t-test and analysis of variance (ANOVA) 
followed by Tukey’s post hoc test, using SPSS Statistic 22 Software. A p value of 
< 0.05 was considered significant.  
 Results and discussion 
 HPLC assay for the quantification of erlotinib and curcumin 
 HPLC chromatogram of erlotinib and erlotinib-loaded genistein-
mPEG polymeric micelles 
Figure 3-2 and 3-3, show the chromatograms of erlotinib and erlotinib-loaded 
genistein-mPEG micelles in DMSO using the erlotinib HPLC assay. The peak for 
DMSO (solvent font) occurred at a retention time of approximately 3 min for both 
chromatograms. For erlotinib, the symmetrical chromatogram appeared at the 
retention time of 4.57 min (Figure 3-2). Two peaks appeared at different retention 
times of approximately 4.57 and 5.79 min were due to erlotinib and genistein-
mPEG, respectively (Figure 3-3). This indicated that neither the drug-polymer 
conjugate nor DMSO would interfere with quantification of erlotinib. The run 
time for the HPLC analysis of erlotinib was set at 10 min based on these HPLC 
chromatograms. 
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Figure 3-2 HPLC chromatogram of erlotinib in DMSO 
 
 
Figure 3-3 HPLC chromatogram of erlotinib-loaded genistein-mPEG polymeric 
micelles dissolved in DMSO 
 HPLC chromatograms of curcumin and curcumin-loaded genistein-
mPEG polymeric micelles 
Commercial grade curcumin contains not only curcumin, but also approximately 
10-20% of desmethoxycurcumin and less than 5% of bisdesmethoxycurcumin as 
shown in Figure 3-4 (Sharma et al., 2005). The HPLC chromatogram of curcumin 
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(Figure 3-5) exhibited three peaks comprising curcumin and its derivatives with 
good peak resolutions. The major peak appeared at a retention time of 
approximately 10.54 min was ascribed to curcumin, whereas the two minor peaks 
corresponding to bisdemethoxycurcumin and demethoxycurcumin presented at 
retention times of approximately 8.99 and 9.73 min, respectively. A solvent peak 
of methanol was detected at approximately 2.95 min. This was in a good 
agreement with previous reports; using similar conditions for the HPLC analysis 
of curcumin (Mollaei et al., 2013; Fonseca-Santos et al., 2016). Genistein-mPEG 
was not detected under the same HPLC conditions (Figure 3-5 and 3-6), ensuring 
that genistein-mPEG conjugate will not interfere the quantitative result of 
curcumin throughout the further studies. 
 
Figure 3-4 The structure of curcumin and its derivatives 
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Figure 3-5 HPLC chromatogram of curcumin and its derivatives in methanol 
 
Figure 3-6 HPLC chromatogram of curcumin loaded genistein-mPEG micelles 
dissolved in methanol 
 Calibration curve for erlotinib  
To study the linearity of erlotinib, dilutions were made in the range of 1-70 µg/ 
mL. A plot of erlotinib concentration against peak area response was linear over 
this concentration range (Figure 3-7). 
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Figure 3-7 Calibration curve of erlotinib using HPLC analysis (n=3) 
 Calibration curve for curcumin 
A plot of curcumin concentration against peak area was found to be linear over 
the range of 3-50 µg/mL (Figure 3-8).   
 
Figure 3-8 Calibration curve of curcumin using HPLC analysis (n=3) 
 Analytical method validation 
The results of analytical method validation including linearity, precision, accuracy, 
limit of detection and limit of quantification were shown the acceptable values 
following ICH guidelines in Table 3-3. 
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The developed reverse phase high performance liquid chromatography (RP- 
HPLC) for the determination of erlotinib does not require any buffer solutions 
throughout the analysis compared with the reported methods (Latha et al. 2017; 
Faivre et al., 2011; Bolandnazar et al., 2013). However, erlotinib was still eluted 
in the short running time with the good result of precision, accuracy and linearity. 
These validation results were achieved using ICH guidelines in the term of 
validation of analytical procedures; therefore, this novel method can be used to 
determine the amount of erlotinib in laboratories through at the remaining studies. 
Table 3-3 Regression characteristics, validation and system suitability for the analysis of 
erlotinib (n=4) 
Parameters  
Retention time (min) 4.6 
Linearity range (µg/ mL) 3-70 
Number of samples per curve 10 
Limit of detection (µg/ mL) 0.78 
Limit of quantification (µg/ mL) 3.00 
Accuracy (%) 97.60 – 108.69 
Precision (%RSD, n=3) 1.89- 7.52 
Repeatability (%RSD) at 35 µg/mL (n=9) 2.70 
 
 Critical micelle concentration of genistein-mPEG conjugate 
The critical micelle concentration (CMC), which is the minimum concentration of 
surfactants and/or polymers required for micelle formation, is an important 
parameters to define the characteristics of surface active agents and micelles 
(Owen et al., 2012). A number of direct and indirect methodologies are available 
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for its measurement; for example, fluorescence intensity, electrical conductivity, 
surface tension, UV absorbance, and scattered light intensity have been used to 
determine the CMC value based on a sudden change in physical properties upon 
micelle formation. Fluorescence spectroscopy and light scattering are the two 
most commonly employed techniques due to their high precision and sensitivity to 
the thermodynamic properties of micelles (Torchilin, 2001; Topel et al., 2013; Fu 
et al., 2015).  
Compared to fluorescence spectroscopy, DLS has shown equivalent performance 
in terms of its sensitivity, but is more practical for routine use. Three main 
parameters: the intensity of scattered light, correlation function of scattering 
intensity and measured size changed were determined by DLS in this study, in 
order to confirm micelles were formed from the conjugate in an aqueous medium, 
and to measure the CMC of genisten-mPEG-COOH (Topel et al., 2013). 
Figure 3-9 shows that there were two distinct slopes from the plot of the average 
intensity of scattered light (Derived Count Rate, in kilo counts per second, kcps) 
against various concentrations of genistein-mPEG (mg/mL, on a logarithmic 
scale). The intensity of scattered light remained at the same level for the polymer 
concentrations between 0.08 and 0.83 mg/mL. This was due to the background 
scattering from either monomers of drug-polymer conjugate or HPLC grade water 
in the preparations (Davis et al., 2011; Topel et al., 2013). However, there was an 
increase in scattering intensity with increasing polymer concentration from 1.25 to 
10 mg/mL, resulting from the self-aggregation of monomer/surfactant molecules 
or micelles.  
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Figure 3-9 Effect of increasing concentration on scattered light intensity for 
genistein-mPEG solutions (n=3, mean± S.D.) 
In theory, at low concentrations (below CMC), there are single polymer chains/ 
monomers dispersed insufficiently in the bulk solution and at the interface of air-
water phase. As the polymer concentration reaches the CMC, both polymer chains 
and micellar aggregates are saturated in an aqueous environment and at the 
interface (Owen et al., 2012). To determine the CMC, best curve fitting was 
employed to obtain the intersection of two lines drawn through all data points. In 
this work, the intersection of two straight lines corresponding to the CMC of 
genistein-mPEG conjugate was 1.35 mg/mL (2.56 x 10-4 M). 
The correlation function curve indicates the formation of micelles. Figure 3-10 
shows that there were poor signal to noise ratios when very low concentrations 
were studied. This means that hydrodynamic diameter of very diluted micelles 
could not be detected since the time-dependent correlation function of the 
scattering intensity was not reproducible, being similar to water (Ogino et al., 
1988; Topel et al., 2013).  However, the intercepts of correlation functions 
increased markedly when the polymer concentrations were above the CMC, 
suggesting the presence of micelles (Topel et al., 2013). The measured size was 
determined and the results demonstrate that there was a rapid change in size 
around the CMC (Figure 3-11), in good agreement with a previous report using 
the DLS technique (Topel et al., 2013) 
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Thus, changes in the intensity of scattered light, measured size and correlation 
function depended on the concentration of amphiphilic polymer. This confirms 
that genistein was successfully attached to mPEG and that this conjugate self-
assembled into micelles. 
 
Figure 3-10 Effect of increasing concentration on correlation function (signal 
intensity to baseline noise ratio)  (n=3, mean± S.D.) 
 
 
Figure 3-11 Effect of increasing concentration on mean hydrodynamic diameter of 
genistein-mPEG solutions (n=3, mean± S.D.) 
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 Characterisation of drug-loaded genistein-mPEG micelles  
 Size distribution, surface charge and drug entrapment of erlotinib-
loaded micelles 
Erlotinib at 5%, 10% and 20% w/w drug in total conjugate was incorporated into 
polymeric micelles, prepared above the CMC of genistein-mPEG-COOH (1.35 
mg/mL). From preliminary studies, %EE could not be accurately determined 
because drug concentrations for all formulations were lower than the LOD (0.78 
µg/mL) and LOQ (3.00 µg/mL) of HPLC determination, being approximately 3%, 
1% and less than 1% for 5%, 10% and 20% w/w drug in polymer, respectively. 
Moreover, a turbid white suspension due to the colour of erlotinib powder was 
seen during preparation, suggesting that this polymer conjugate was not 
appropriate for a micelle formulation of erlotinib, in terms of the ability to 
accommodate erlotinib and the stability.  
 Size distribution, surface charge and drug entrapment of curcumin-
loaded micelles  
A transparent yellowish micellar solution of curcumin with no precipitation was 
formed in which curcumin could be accurately quantified by HPLC analysis in the 
desired concentration range. This indicates the successful incorporation of 
curcumin into genistein-mPEG polymeric micelles.  
Physical entrapment of drug is generally considered to dominate for micelles 
formed from drug-polymer conjugates, especially for hydrophobic drugs 
(Batrakova et al., 2006). Previous studies have shown that physical entrapment 
depends on a number of factors; for example, solubility of the drug in water 
(hydrophilicity/ hydrophobicity); the preparation method (dialysis, oil-in-water 
emulsification, solvent evaporation, etc.); and the interrelations of drug and the 
core-forming block of polymeric micelle including the steric properties, the block 
length of hydrophobic and hydrophilic segments of polymer and the physical 
properties of inner core segment (crystallinity, glass transition temperature, etc.) 
(Batrakova et al., 2006; Raval et al., 2012; Takahashi et al., 2014; Rao et al., 
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2015). It is noted that parameters such as the preparation method for loading 
drugs into polymeric micelles and the amount as well as the type of polymer used 
were constant for the two drugs studied here. Thus, the physicochemical 
properties of erlotinib and curcumin are likely to affect drug entrapment, and 
hence micellisation may not be suitable for incorporating all drugs as discussed 
below.  
The partition coefficient (log P value) or the octanol/water coefficient (Kow) 
expresses the ratio of concentrations of a compound in a mixture of organic and 
aqueous phases. The solubility of a solid compound depends on the energy 
required to break its crystal lattice. Curcumin has a higher log P value 
(respectively; 3.29 and 2.75 for curcumin and erlotinib) but lower water solubility 
(respectively; 0.6 and 3-6 µg/mL for curcumin and erlotinib) compared to 
erlotinib; these factors are likely to lead to the differences in drug incorporation. 
Curcumin molecules are more likely to reside within the hydrophobic core of the 
micelles than erlotinib based on their physicochemical properties, resulting in a 
significantly higher in drug entrapment (Table 3-4). 
Table 3-4 Properties of erlotinib and curcumin and their incorporations into 
genistein-mPEG polymeric micelles (n=3, mean± S.D.) 
Hydrophobic 
drugs 
Erlotinib Curcumin 
Molecular 
structure 
 
 
Entrapment 
efficiency 
(%EE) 
N/A 45.60± 6.19 
Drug loading 
(%DL) 
N/A 2.17± 0.29 
*5% w/w drug in polymer; drug and polymer concentrations were 0.25 and 5 
mg/mL in water, respectively 
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Considering the chemical structures of these two hydrophobic drugs, nitrogen 
atoms from the quinazolinamine ring and oxygen from methoxyethoxy chains of 
the erlotinib molecule may form weak electrostatic bonding with the carboxylic 
group (-COOH) of genistein-mPEG conjugates at the surface of micelles. 
Furthermore, the rigid structure and the steric hindrance of erlotinib comprising 
three benzene rings attached to alkyne (C  C; Triple bond) could limit the 
rotation of the erlotinib molecule to penetrate and align into the hydrocarbon 
region and inner core of micelles. These effects may result in weakening of van 
der Waals’ force, π-π stacking interaction and H-bonding with genistein within 
the hydrophobic core, such that, the entrapment efficiency was very low. 
For curcumin, the molecular structure is more flexible; there are fewer aromatic 
rings, and the molecule is smaller than erlotinib, with no bulky aliphatic side 
chains, so that it may pack more easily into the polymeric micelles. Hydrophobic 
interaction (van der Waals’s force) and/or π-π stacking interaction and H-bonding 
between curcumin and genistein within the hydrophobic core can enhance the 
encapsulation of curcumin, due to the two benzene rings of curcumin. 
Furthermore, the two hydroxyl groups (-OH group) on the benzene rings of 
curcumin are easier to protonate and have stronger ionic interaction and H-
bonding with the carboxylic group (-COOH) of genistein-mPEG. This can ensure 
higher entrapment efficiency as compared to erlotinib, being approximately 
45.6%. 
Overall, the results demonstrate that the amphiphilic drug-polymer conjugate can 
self-assemble to form micelles. This synthetic polymer seems unsuitable for 
erlotinib delivery possibly due to its molecular structure limiting micellar 
incorporation. However, it has shown that genistein-mPEG can be considered a 
promising compound for producing drug-carriers for curcumin, and may be the 
applicable for other hydrophobic drugs. Therefore, curcumin-loaded genistein-
mPEG polymeric micelles were studied further for potential pulmonary delivery. 
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 Characterisation and development of curcumin-loaded micelles 
The aim of this study was to investigate whether the synthesis of genistein-mPEG 
conjugate would improve the water solubility of curcumin by including the drug 
molecule in the hydrophobic core of micelles. As seen from Figure 3-12, 
curcumin-incorporated into genistein-mPEG-COOH micelles after passage 
through a 0.45µm membrane filter were transparent yellow, suggesting curcumin 
is well-dispersed in an aqueous solution (Yang et al., 2015). This can be attributed 
to the structure of amphiphilic micelles, allowing PEG segments to serve as 
hydrophilic shell in water. Meanwhile, the genistein components of the conjugate 
were packed in the hydrophobic core of the micelle, serving as a binding site for 
curcumin (Danafar et al., 2014). Figure 3-12 demonstrates that this amphiphilic 
drug-polymer conjugate could serve as a carrier for curcumin, and curcumin-
loaded genistein-mPEG micelles were consequently characterised for further 
studies. 
  
Figure 3-12 Appearance of curcumin dispersed in genistein-mPEG micelles (a) pre-
filtration (b) post-filtration  
 Effect of curcumin concentration on size distribution, surface charge, 
entrapment efficiency and drug loading of micellar formulations  
3.5.4.1.1 Effect of curcumin concentration on micelle size distribution 
Particle of size larger than about 200 nm can be easily recognised and 
phagocytosed by alveolar macrophage within the alveolar airspace, resulting in an 
(a) (b) 
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insufficient concentration of drug at the tumour site and the failure of treatment 
(Menon et al., 2014; Lee et al., 2015b; Nakamura et al., 2016).  
Considering delivery to the lungs, nanocarriers in the range 50 -200 nm, achieve 
alveolar deposition, as reported for nanosuspensions (Dandekar et al., 2010; 
Amini et al., 2014; Menon et al., 2014), and can be readily incorporated into the 
droplets during aerosol generation from nebulisers (Kamali et al., 2016). 
Polydispersity Index (PDI), which is a measure of the size distribution or the size 
uniformity in the sample, can be a measure of physical stability of nanoparticles, 
indicating particle aggregation (Masarudin et al., 2015; Clayton et al., 2016). 
Therefore, the mean size of the genistein-mPEG polymeric micelles produced in 
this study was considered ideally to be approximately 200 nm or smaller, with a 
PDI <0.3 representing a stable micelle formulation, suitable for nebulised delivery 
to the airways. 
The DLS results showed that mean diameter of curcumin-loaded micelles was 
approximately 200 nm with one peak of narrow size distribution (PDI<0.2) for all 
drug concentrations, representing as a relatively monodispersed system of 
appropriate size (Table 3-5, Figure 3-13). When curcumin concentration was 
increased from 2.5% to 20% w/w drug in conjugate, a significant increase in 
hydrodynamic diameter from 173.62 to 215.18 nm (p<0.05) was observed. These 
results were in agreement with previous reports, suggesting that physically-
encapsulated curcumin could expand the inner core and the space within the 
micelles, contributing to a larger measured size (Song et al., 2014; Gao et al., 
2015).  
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Table 3-5 Characterisation of curcumin-loaded genistein-mPEG micelles at different drug concentrations (n=3, mean ± S.D.) 
Curcumin 
concentration 
Hydrodynamic 
diameter (nm)  
Polydispersity Index  Zeta Potential 
(mV) 
Entrapment 
Efficiency (%) 
Drug Loading 
(%) 
2.5% 173.62± 2.16 0.08± 0.03 -14.52± 2.81 43.36± 3.67 1.06± 0.09 
5% 197.54± 2.27 0.07± 0.04 -15.88± 0.86 45.60± 6.19 2.17± 0.29 
10% 211.80± 1.65 0.06± 0.02 -16.70± 1.49 32.48± 9.67 2.95± 0.88 
20% 215.18± 5.12 0.18± 0.14 -16.72± 0.99 10.20± 3.85 1.69± 0.65 
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Figure 3-13 Size distribution of curcumin-loaded genistein-mPEG polymeric 
micelles at concentrations of a) 2.5%, b) 5%, c) 10% and d) 20% (w/w drug in 
polymer)  
3.5.4.1.2 Effect of curcumin concentration on the surface charge of micelles 
Surface charge is an important factor determining whether the nanocarriers will 
adhere to cells having opposite charge and also impacts the physical stability of 
colloids (Danafar et al., 2014); a high value of zeta potential either negative or 
positive is recommended for long-term stability (Mahajan and Mahajan, 2016).  
Nanocarriers with positive charge interact through electro-static forces with 
negatively-charged cell membranes, resulting in highly effective internalisation 
(Wang et al., 2011). On the other hand, nanoparticles with negative charge; for 
instance, PLGA and gold nanoparticles, have been described as penetrating cell 
membranes through caveolae-mediated pathways (Wang et al., 2011).    
The surface modification of nanocarriers using PEG has been demonstrated to 
enhance passive targeting through a stealth effect, due to a protective barrier 
against the adherence of serum proteins. This can contribute to a reduction of 
nanocarriers being taken by macrophages (Iyer et al., 2015; Hassanzadeh et al., 
2017).  In this study, all curcumin-loaded genistein-mPEG formulations were 
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negatively charged; between -14 and -16 mV as shown in Table 3-5. This value 
was in agreement with previous reports using mPEG 5kDa in conjugates (Yin et 
al., 2013; Danafar et al., 2014; Gao et al., 2015). The negative-charge may 
possibly be due to protonation of the carboxylic group (–COOH) from the 
presence of residual mPEG-COOH in genistein conjugate in deionised water (pH 
values between 5.5 and 6.5), resulting in the COO- ion.  
Overall, the conjugate of genistein and mPEG was likely to be suitable for 
forming polymeric micelles for cancer delivery, due to the small hydrodynamic 
diameter (< 200 nm), narrow size distribution, and high negative charge (ranging 
from -14 to -16 mV) of the micelles. However, in order to achieve optimal 
therapy, drug entrapment was further considered. 
3.5.4.1.3 Effect of curcumin concentration on drug entrapment in genistein-
mPEG micelles 
Drug entrapment of hydrophobic drugs in micelles may be attributed to chemical 
conjugation or physical entrapment. Physical entrapment was expected to be the 
main factor in this study (Mahajan and Mahajan, 2016). There was a marked 
increase in drug loading between 2.5% and 5% w/w curcumin-encapsulated 
genistein-mPEG micelles (p<0.05), being approximately 1.06 % and 2.17%, 
respectively (Table 3-5). However, entrapment efficiency for both formulations 
was similar (p>0.05). When 5% and 10% w/w curcumin-loaded micelles were 
compared, entrapment efficiency and drug loading for both preparations showed 
no significant differences (p>0.05), suggesting that 5% curcumin is the optimal 
content for efficient entrapment. Interestingly, there was a noticeable drop in 
entrapment efficiency and drug loading (p<0.05) for 20% w/w curcumin. This 
might be because micelles were saturated with curcumin at high concentration, 
with no available space to accommodate further molecules of curcumin. Therefore, 
higher amounts of curcumin in the initial formulation used to generate micelles 
resulted in the lower drug entrapments calculated according to Equations 3-1 and 
3-2.  
Higher concentrations of curcumin in curcumin-loaded polymeric micelles 
significantly increased the mean hydrodynamic diameter (Table 3-5; p<0.05). 
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However, changes in PDI and surface charge were not evident (p>0.05). The 
initial weight ratio between curcumin and the synthesized conjugate of 1:20 (5% 
w/w) was chosen for further characterisation as due to the maximum 
solubilisation of curcumin in the conjugate, with mean micelle size < 200nm. 
3.5.4.1.4 Effect of curcumin incorporation on the size distribution of 
genistein-mPEG micelles 
When empty micelles (drug-free) and the 5% w/w curcumin-loaded genistein-
mPEG micelles were compared, the mean diameter of blank micelles was 
considerably larger than those in the presence of drug (p<0.05; Table 3-6). This 
may be attributed to the intermolecular forces between curcumin and genistein in 
the conjugate. It is possible that encapsulated curcumin molecule caused stronger 
van der Waal’s interactions and/or electrostatic forces with genistein compared 
with empty micelles. Furthermore, the phenyl groups of curcumin could possibly 
also have hydrophobic-hydrophobic interaction with alkyl chain of mPEG-COOH 
as seen in the case of the incorporation of meso- tetraphenyl porphine into 
polyethylene glycol – distearoyl phosphatidyl ethanolamine and the incorporation 
of norcantharidin into poly (ethylene glycol) -poly (caprolactone) polymeric 
micelles (Ahmad et al., 2014). All of these factors result in a more tightly packed 
micelle core as in previously reported (Chen et al., 2012; Scarano et al., 2014; Li 
et al., 2016; Gong et al., 2017). 
The size distribution was also affected by the incorporation of curcumin. The 
value of PDI was significantly lower (p<0.05) and the size distribution curve 
showed only one peak for drug-loaded micelles, indicating a relatively uniformly 
dispersed or more homogeneous population compared to empty self-assembled 
micelles as shown in Figure 3-14. Whereas empty micelles show broader size 
distribution peak, possibly indicating aggregation. 
The data suggest that the strong physical interactions consisting of hydrophobic-
hydrophobic interactions, H-bonding and π-π stacking between curcumin and 
genistein-mPEG conjugate contributed to a reduced mean size of the carriers and 
relatively lower PDI for curcumin-encapsulated micelles compared with blank 
micelles (p<0.05).  
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Table 3-6 Size distribution of empty and curcumin-loaded genistein-mPEG micelles 
(n=3, mean ± S.D.) 
Formulationsa Hydrodynamic 
diameter (nm)a 
Polydispersity Index 
(PDI) 
Empty genistein-mPEG- 
micelles 
274.48± 27.41 0.38± 0.05 
5% curcumin-loaded 
genistein-mPEG micelles 
197.54± 2.27 0.07± 0.04 
a Polymer concentration = 5 mg/mL 
 
Figure 3-14 Size distribution of a) empty genistein-mPEG polymeric micelles and b) 
curcumin-loaded genistein-mPEG polymeric micelles 
 Transmission electron microscopy of empty and curcumin-loaded 
genistein-mPEG polymeric micelles 
TEM images of empty genistein-mPEG micelles (Figure 3-15a) and curcumin-
containing genistein-mPEG micelles (Figure 3-15b) demonstrate that micelles for 
both preparations were well-dispersed in aqueous medium as individual spherical 
micelles with narrow size distribution. The sizes of both formulations observed 
under TEM were smaller as compared to those measured by DLS, being 
approximately 140 nm and 190 nm for curcumin-loaded micelles, and 30 nm and 
250 nm for empty micelles, respectively. This is in agreement with previous 
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reports and may be explained by the different techniques and physical conditions 
of TEM and DLS for measuring particle size (Qiu et al., 2009; Gao et al., 2013).  
The combined results of the morphology, mean particle size and size distribution 
of blank and curcumin-loaded micelles determined by TEM and DLS confirm the 
molecular self-association of genistein-mPEG conjugate into polymeric micelles, 
into which curcumin can be incorporated. 
 
Figure 3-15 TEM images of a) empty micelles and b) curcumin-loaded genistein-
mPEG micelles after filtration 
 Effect of nebuliser fill volume on time to nebulise to dryness and 
aerosol output for air-jet and vibrating-mesh nebulisers 
In general, nebulisers do not release all of the fluid-loaded into the nebuliser 
chamber as an aerosol. The amount of liquid that remains in the device at the end 
of nebulisation is referred to as ‘the residual volume’ or ‘dead volume’ (Elhissi et 
al., 2013). The weight output or aerosol mass output, represents the weight of 
product successfully delivered by the nebuliser, and depends on a combination of 
factors; including the fill volume of fluid at the beginning of nebulisation, the 
efficiency of device, the nebulisation time, the design of the nebuliser reservoir, 
and the physicochemical properties of the formulation such as the viscosity, the 
surface tension, the concentration of drug solution and sometimes ion content 
(Kendrick et al., 1997; Ghazanfari et al., 2007). It is noted that drug output, which 
a.) b) 
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expresses the percentage of drug or active ingredient emitted from the nebuliser, 
considered a critical factor for clinical outcomes, is not necessarily the same as 
aerosol mass output (Kendrick et al., 1997; Elhissi et al., 2013). The aim of this 
study was to measure the time taken to nebulise 2, 4 and 8 mL of HPLC grade 
water to ‘dryness’ i.e. the point at which aerosol output ceased and to determine 
the percentage nebulised at a specific time, in order to establish the suitable 
nebuliser fill volume before micellar aerosols were characterised. 
From previous literature, the suitable fill volume should be at least twice the 
residual volume and sufficient to deliver a therapeutic dose of medicine with 
minimal drug loss (Kendrick et al., 1997). A large residual volume indicates that a 
large amount of drug remains in the nebuliser and cannot be inhaled, and thus in 
practice, adding a diluent to small fill volumes is recommended in order to 
maximise drug delivery over the nebulisation period (Rubin and Williams, 2014)). 
However, larger volumes of medical fluid increase administration time (Rubin 
and Williams, 2014). A period of nebulisation in the range of 5-10 min is 
recommended, as a prolonged nebulisation time may affect patience adherence 
(Kendrick et al., 1997; Jevon and Ewens, 2001; Chan et al., 2011).  
There are various types of air-jet nebuliser designs as mentioned in Chapter 1; for 
example, constant output, breath-actuated and breath-enhanced air-jet nebulisers 
which have different output rates due to the design of the device and the 
positioning of internal baffles (Lavorini, 2013; Ibrahim et al., 2015). For all 
designs, the driving pressure or driving gas flow is the major determinant of 
output (O'Callaghan and Barry, 1997). The Pari® LC Sprint jet nebuliser used in 
this study is a breath-enhanced jet nebuliser, that is modified from a conventional 
device to increase the output rate, and decrease the nebulisation time and aerosol 
waste (Lavorini, 2013).  
Increasing in fill volumes of water from the minimum of 2 mL to the maximum 
volume of 8 mL in the Pari air-jet nebuliser reservoir based on manufacturer’ s 
literature required a longer time for nebulisation to dryness, from approximately 3 
min to 20 min (Figure3-16a). A shorter time is usually preferable for patient 
Chapter 3 Hydrophobic drug-loaded genistein-mPEG micelles 
 139 
convenience; however, the percentage aerosolised in specific time should also be 
considered, so as to achieve the most effective localised treatment.  
Figure 3-16b shows that greater than 50 % of water in the reservoir was nebulised 
for all fill volumes. A fill volume of at least 2 mL in an air-jet nebuliser is usually 
recommended by manufacturers (Clay et al., 1983); however, only 56.19 % 
released as aerosol in this study. In order to increase the proportion of water 
emitted from an air-jet device, increasing the fill volume was required. Increasing 
the fill volume to 4 and 8 mL considerably enhanced the percentage nebulised, 
being 78.34% and 87.12%, respectively. The time taken to nebulise 8 mL was 
approximately double as that for a 4 mL fill (respectively; 20 min and 9 min) 
(Figure 3-16a).  
 
Figure 3-16 Effect of fill volumes of water on (a) time to nebulise to dryness and (b) 
percentage nebulised at dryness using an air-jet nebuliser (n=3, mean± S.D.) 
Vibrating-mesh nebulisers are more efficient and provides more consistent and 
higher doses of drug to patients with smaller residual volume than air-jet devices 
(Ari, 2014; Pritchard et al., 2018). However, these devices are more expensive 
due to the increased number of tolerance critical components that associated with 
the electronic control circuit as well as the material used in the mesh manufacture 
(i.e. platinum, palladium, nickel and stainless steel) and require thorough cleaning 
(Ghazanfari et al., 2007; Ari, 2014; Pritchard et al., 2018). A vibrating-mesh 
nebuliser was used as the alternative device in this study to improve output 
efficiency. In these devices, vibration of a perforated plate results in extrusion of 
liquid through the mesh pores, causing aerosol generation as described in Chapter 
1 (Figure 1-7). The times taken to nebulise defined volumes of water to ‘dryness’ 
for the vibrating-mesh nebuliser (Pari Velox®) was studied and compared with 
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the air-jet nebuliser (Figure 3-17). For 2 and 4 mL fill volumes, it took less time 
(p<0.05) for the vibrating-mesh nebuliser (respectively; 2.23 and 6.41 min) 
compared to the air-jet nebuliser (respectively; 3.39 and 9.15 min).  
 
Figure 3-17 Effect of fill volumes of water on time to nebulise to dryness for the 
vibrating-mesh nebuliser (n=3, mean± S.D.) 
All fill required less than 10 min to reach dryness state with the vibrating-mesh 
device. However, the percentage aerosolised could not be measured for the 
vibrating-mesh device due to the mechanism of aerosol generation, which leads to 
the deposition of most of the aerosol at the base of the device housing, resulting in 
high residual volume (Chan et al., 2011) unless the aerosol is drawn from the 
device by patient breaths. For air-jet nebulisers, the compressed air produces the 
aerosol droplets and directs them towards the patient for inhalation. By contrast, 
the direction of the aerosol stream is directed downwards for vibrating-mesh 
nebuliser as demonstrated in Figure 3-18 (Ghazanfari et al., 2007).  
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Figure 3-18 Schematic diagram of the mechanism of a) air-jet and b) vibrating-mesh 
nebulisers (Carvalho et al., 2016) 
Based on these results, 4 mL was considered an appropriate fill volume for further 
studies. This allows complete delivery of aerosol (to dryness) and would represent 
an acceptable time to nebulise a suitable volume of fluid for clinical applications. 
For further studies, the dispersant used in the optimised micelles was also HPLC 
grade water. It is noted that in practice, solutions should be isotonic to avoid 
bronchospasm. However, water was used in this study to keep formulations as 
simple as possible, so as to understand the impact of key formulation variables. 
Hence, 4 mL of curcumin-loaded genistein-mPEG micelles delivered by both 
nebulisers for 10 min was initially employed for the aerodynamic assessment of 
nebulised micellar aerosols using a cascade impactor. 
 Assessment of aerosol properties of curcumin-loaded genistein-mPEG 
micelles delivered from air-jet and vibrating-mesh nebulisers using 
the Next Generation Impactor (NGI)  
The Next Generation Impactor (NGI) was set up for aerosol characterisation of 
optimised curcumin-loaded genistein-mPEG micelles according to the 
requirements of the Ph. Eur. as described in Section 3.4.7. 4 mL of micellar 
solution was nebulised at a flow rate of 15L/min for 10 min using air-jet and 
vibrating-mesh nebulisers under the same operating conditions. Then, the 
aerosolisation parameters: Emitted Dose (ED), Fine Particle Mass or Fine particle 
a) b) 
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Dose (FPD), Fine Particle Fraction (FPF), Mass Median Aerodynamic Diameter 
(MMAD) and Geometric Standard Deviation (GSD) delivered for both nebulisers 
were determined and compared as shown in Table 3-7.  
Table 3-7 Aerosol parameters of curcumin-loaded genistein-mPEG micellar aerosols 
delivered from air-jet and vibrating-mesh nebulisers into the cooled NGI at a flow rate of 
15L/min (n=3, mean± S.D.) 
Type of nebulisers Air-jet (Pari LC® Sprint 
nebuliser) 
Vibrating-mesh (Pari 
Velox®) 
Mass balance (%) 88.16± 0.80 % 89.19± 2.11 % 
Emitted Dose (ED) 60.79± 0.19 % 50.83± 1.38 % 
Fine Particle Dose (µg) 123.00± 13.11 88.33± 15.28 
Fine Particle Fraction 
(%) 
47.00± 1.00 % 36.33± 2.89 % 
MMAD (µm) 5.24± 0.09 6.09± 0.21 
GSD 1.96± 0.02 1.65± 0.02 
 
The mass balances for both air-jet and vibrating-mesh devices were within 
European Pharmacopeia acceptance limits. Therefore, the NGI can be used to 
compare these two nebulisers in order to assess the suitable device for delivering 
curcumin-loaded micelles. Emitted Dose, which represents the dose of drug 
emitted from the nebuliser, was considerably higher for the air-jet nebuliser 
(p<0.05) compared with vibrating-mesh nebuliser. The MMAD for the air-jet 
device was smaller than vibrating-mesh device (p<0.05), whereas the GSD values 
were similar, being in the range of 1.65-1.96, indicating a polydispersed aerosol. 
Moreover, the air-jet nebuliser produced significantly higher FPD and FPF 
(p<0.05) compared to the vibrating-mesh nebuliser, as expected based on the 
MMAD values for both nebulisers. 
The lower efficiency of the vibrating-mesh device in this study was at variance 
with other reports. In previous studies, vibrating-mesh nebulisers were more 
efficient than air-jet nebulisers in terms of shorter time to complete nebulisation 
and/or yielding higher output rate (Ghazanfari et al., 2007; Elhissi et al., 2012; Ari, 
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2014). However, the performance of vibrating-mesh devices is highly affected by 
the physicochemical properties of the fluid being nebulised, particularly viscosity, 
surface tension, drug concentration and ion content (Zhang et al., 2007a; Chan et 
al., 2011; Elhissi et al., 2011a). The less efficient output of vibrating-mesh 
nebuliser could be due to the high negative surface charge of curcumin-loaded 
micelles (-18 mV), or drug crystallisation with particles adhering to and blocking 
the mesh apertures during aerosol generation. Furthermore, high electrostatic 
charge has been previously reported to inhibit the flow of fluid through mesh 
pores and/or the detachment of aerosol droplet, and also to increase the aerosol 
deposition on the wall of nebuliser (Manunta et al., 2011). These factors could 
possibly cause the lower energy input for atomisation and output rate as reported 
in the case of the delivery of receptor-targeted nanocomplexes with high surface 
charge by a vibrating-mesh nebuliser for gene therapy (Manunta et al., 2011).  
According to Poiseuille’s law (Equation 3-10), the performance of vibrating-mesh 
nebuliser depends on fluid properties. A higher density and lower viscosity of 
solution result in higher liquid flow through the mesh pores and greater aerosol 
output (Zhang et al., 2007a). Therefore, the inclusion of viscosity reducing agents 
may alter fluid output as seen in the reports for solutions and liposomes 
(Ghazanfari et al., 2007; Zhang et al., 2007a; Elhissi et al., 2011a; Elhissi et al., 
2012).  
𝑄 =  𝜋𝜌 △ Ρ𝑅2 4𝔶𝐿⁄                                                                     Eq. 3-10 
where  ρ= the density, R= the radius of aperture, △ Ρ= the pressure drop across 
aperture, L= the length of solution pumped through aperture, η= the fluid viscosity 
and Q= liquid flow 
Previous studies have also shown that the inclusion of electrolyte or surfactant can 
reduce water adhesion to the internal structure of reservoir surfaces and mesh 
pores of the mesh nebuliser by increasing the electrical conductivity and the 
repulsive force towards the bulk solution and decreasing the droplet surface 
charge (Ghazanfari et al., 2007). These effects lead to an earlier detachment of 
droplets from the bulk solution and consequently decrease the nebulised aerosol 
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size, resulting in an enhanced emitted dose and drug output (Deshpande et al., 
2002; Ghazanfari et al., 2007; Chan et al., 2011). Furthermore, the presence of ion 
in solution (especially halide ions; for example NaCl solution) can reduce the 
droplet size and cause an increase in output rate, FPF and FPD (Ghazanfari et al., 
2007).  
The lack of excipients in this study may result in non-ideal properties of fluid, 
reflected in the lower efficiency of vibrating-mesh nebuliser as compared to air-jet 
nebuliser (Beck-Broichsitter and Oesterheld, 2017). Further formulation 
development would be appropriate to enhance the delivery of a micelle solution 
from these devices. 
Overall, the curcumin-encapsulated genistein-mPEG micelles were effectively 
delivered by an air-jet nebuliser with satisfactory values for the key aerosol 
quality parameters (Kendrick et al., 1997). However, the characteristic properties 
of the formulation are likely to be the predominant reason for an unexpected 
performance of vibrating-mesh nebuliser. Thus, further investigations of nebuliser 
performance for micelle delivery should be conducted to determine the effect of 
physicochemical properties of medical fluids in the presence of suitable types and 
concentrations of surfactants, electrolytes and viscosity modifying agents during 
aerosol generation to achieve the specific requirements for lung delivery. 
 Conclusions 
The incorporation of curcumin into genistein-mPEG micelles was successfully 
achieved using the thin-film hydration method. This synthesized conjugate was 
not suitable for the delivery of erlotinib due to its molecular structure limited 
micellar incorporation. However, curcumin-encapsulated micelles with desired 
mean size and drug entrapment have shown the potential for pulmonary delivery, 
performed by air-jet and vibrating-mesh nebulisers as demonstrated using the NGI. 
The results showed that the performance of the air-jet device was superior to 
vibrating-mesh device in terms of higher %ED, FPD and FPF for this formulation 
(5% w/w curcumin-loaded genistein-mPEG micelles), which are the key 
parameters of aerosolisation. However, further studies on physicochemical 
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properties of micellar formulations in the presence of surfactants, electrolytes and 
viscosity agents during nebulisation are required for the better understanding of 
the differences in nebuliser performance. 
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 Introduction 
In Chapter 3, curcumin was successfully incorporated into genistein-mPEG 
polymeric micelles, though these nanocarriers could not adequately incorporate 
erlotinib. Liposomes are considered safe, biocompatible and biodegradable lipid-
based drug carriers, which have previously been proposed for pulmonary delivery, 
for various applications including cancer treatment (Elhissi et al., 2011a; 
Sercombe et al., 2015; Rudokas et al., 2016). Liposomes consist of one or more 
bilayers of amphiphilic molecules that have a hydrophilic head and two 
hydrophobic chains (Bozzuto and Molinari, 2015).  
The degree of drug loading into liposomes depends on various factors including 
the physicochemical properties of drugs, the nature of the lipid membrane, the 
composition of the formulations (type of lipid, lipid-to-cholesterol ratio, drug-to-
lipid ratio) as well as the method of preparation (Pattni et al., 2015; Chountoulesi 
et al., 2017). Liposomes can be classified on the basis of their lamellarity, namely 
uni-, oligo- and multilamellar vesicles, which depends on the method used for 
their preparation and post-formation processing (Bozzuto and Molinari, 2015; 
Pattni et al., 2015).  
Dipalmitoylphosphatidylcholine (DPPC) was chosen as the major component of 
the liposome formulation in this study as it is the predominant constituent of lung 
surfactant (Kaviratna and Banerjee, 2012; Joshi et al., 2014). DPPC liposomes 
containing erlotinib and genistein individually or together were prepared by thin-
film hydration to obtain multilamellar vesicles (MLVs). This classical 
manufacturing technique is suggested for hydrophobic drugs since those 
molecules become incorporated in the phospholipid bilayer upon the formation of 
self-assembled liposomes (Pattni et al., 2015). Multilamellar vesicles were then 
reduced in size by probe-sonication to yield unilamellar vesicles. Unilamellar 
liposomes are ideal since they can easily fit into smaller aerosol, with minimal 
drug leakage during nebulisation (Lehofer et al., 2014; Cipolla et al., 2016). 
Cholesterol and DOPE used as stabiliser and helper lipid respectively were also 
included to obtain the desired characteristics of liposomes co-loaded with 
erlotinib and genistein, in terms of vesicle size, surface charge, encapsulation 
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efficiency and the stability of liposomes. Furthermore, the incorporation of 
cholesterol into liposomes may improve stability during aerosolisation (Cipolla et 
al., 2016).  
Hydrophobic molecules are incorporated into liposomal bilayers (Figure 4-1). 
Cholesterol as well DOPE and hydrophobic drugs used in the formulation may 
complete for the same region within the DPPC bilayer. Therefore, an 
understanding of the effect of drugs and excipients on the properties of the lipid 
bilayer is important with respect to drug entrapment efficiency, drug release and 
in-vitro stability (Budai et al., 2003; Wu et al., 2012).  
 
Figure 4-1 The structure of liposomes containing hydrophobic drug, cholesterol and 
DOPE within lipid bilayer (Phan et al., 2013; Monteiro et al., 2014) 
The mobility of the molecules within and across the lipid bilayer is dependent on 
the temperature. The DPPC bilayer undergoes a pre-transition (transformations in 
the orientation of the polar head groups of DPPC) and a main phase transition 
(transformations in the orientation of acyl chains of hydrophobic region) when 
increasing the temperature. These thermotropic behaviours play an important role 
in bilayer fluidity, permeability and stability (Gardikis et al., 2006; Wu et al., 
2012; Monteiro et al., 2014). Specifically, the DPPC bilayer has low fluidity and 
permeability to encapsulated exogenous compounds at a temperature below the 
main gel phase to the liquid-crystalline phase transition (Tc = 41 °C). However, 
DPPC bilayers have high fluidity at a temperature above the Tc (Monteiro et al., 
2014).  
The Tc of phospholipids depends on a number of factors; for example, the degree 
of saturation of the acyl chains, the length of the hydrocarbon chains and the type 
Hydrophobic drug Cholesterol Unsaturated lipid 
i.e. DOPE 
Saturated phospholipid 
i.e. DPPC 
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of the polar head group (Monteiro et al., 2014). Figure 4-2 shows the effect of 
cholesterol incorporation into the bilayer of a saturated PC such as DPPC on the 
bilayer properties. As results of the addition of cholesterol, the fluidity and 
permeability of DPPC bilayer decrease in a fluid state as compared to DPPC 
bilayer at above the Tc. By contrast, the bilayer becomes less condensed but more 
fluidity and permeable when compared with the pure DPPC at below the Tc. The 
inclusion of unsaturated lipids (DOPE), cholesterol and biomolecules, which 
affect bilayer packing may have a significant impact on the thermal properties and 
permeability of DPPC-based bilayer. 
 
Figure 4-2 Influence of temperature and cholesterol on the DPPC phospholipid 
bilayer (Monteiro et al., 2014) 
Differential Scanning Calorimetry (DSC) has proved a valuable thermal analytical 
approach for investigating the thermodynamic lipid phase transition and the 
interaction of agents with saturated lipid such as DPPC by measuring thermal 
changes of the lipid bilayer. Multichannel Differential Scanning Calorimetry 
(MCDSC) was therefore used in this study to investigate drug interactions with 
the phospholipid bilayer membrane and to determine maximum drug 
incorporation (drug/lipid ratio) for a better understanding of the co-loaded 
liposomal formulation during pre-formulation studies. 
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 Aims 
4.2.1 To develop and validate a reversed-phase high-performance liquid 
chromatography (RP-HPLC) method for quantification and co-quantification of 
erlotinib and genistein in accordance with International Conference on 
Harmonisation (ICH) guidelines. 
4.2.2 To investigate the lipid composition of DPPC-based liposomes for the 
delivery of erlotinib and genistein as individual and co-loaded formulations and to 
characterise the properties of liposomes in terms of particle size distribution, 
surface charge and encapsulation efficiencies of both drugs.  
4.2.3 To characterise individual and co-loaded liposomal formulations using two 
methodologies (HPLC and MCDSC analysis) that may be useful to estimate the 
maximum incorporation and to understand bilayer interactions of erlotinib and 
genistein in DPPC-based liposomes. 
 Materials 
Erlotinib >99% (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-
amine) and genistein >99% (4’,5,7-trihydroxyisoflavone) (LC Laboratories, USA) 
were used as hydrophobic drugs in the liposomal formulations. The phospholipids, 
hydrogenated soy phosphatidylcholine (HSPC, L-α-phosphatidylcholine, 
hydrogenated (Soy)), DPPC (1,2- dipalmitoyl- sn- glycerol- 3- phosphocholine) 
and DOPE (1,2-dioleyl- sn- glycerol- 3- phosphoethanolemine), supplied by 
Lipoid (Ludwigshafen, Germany), were used without further purification as the 
major and helper lipids, respectively. Cholesterol (Sigma-Aldrich; Poole, UK) 
was used as the bilayer stabiliser in the liposomes. Absolute ethanol (99.8%, 
analytical grade), chloroform (99.8%, analytical grade) and HPLC grade water 
acquired from Sigma-Aldrich (Poole, UK) were used as solvents and a diluent in 
liposomes. The following reagents and solvents were obtained from Sigma-
Aldrich (Poole, UK): dimethyl sulfoxide (DMSO, >99.7%, HPLC gradient grade), 
acetonitrile (99.9%, HPLC gradient grade), trifluoroacetic acid (TFA, >99.0%) 
and HPLC grade water, and used for a validated HPLC method for the 
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quantitative determination of genistein and erlotinib, and simultaneous analysis of 
the drugs in combination. 
 Methods  
 Validation of HPLC analytical method for erlotinib and genistein  
 Chromatographic conditions for HPLC analysis of erlotinib and 
genistein  
A validated HPLC analysis was developed for the quantitative determination of 
erlotinib and genistein individually and for co-quantification of the two drugs in 
combination, to allow calculation of entrapment efficiency for individually load 
and co-loaded liposomes. Preliminary studies on the UV absorbance of erlotinib 
and genistein performed by UV-Vis Spectrophotometer (Agilent Cary 100, UK), 
gave the λmax values for erlotinib and genistein as 246 and 260 nm, respectively. 
Quantification was carried out using an HPLC system equipped with an auto 
sampler and UV/Vis detector (Agilent 1100 Series, USA) at a wavelength of 246 
nm for quantification of erlotinib and 260 nm for genistein. A Synergi Polar-RP 
80A HPLC Column (250 x 4.6 mm x 4 m) acquired from Phenomenex, 
Torrance, California, an ether-linked phenyl phase suitable for the separation of 
polar and aromatic components, was used as the stationary phase for separation in 
this study. As erlotinib and genistein have benzene rings in their main structures 
and different polarities, this column was considered appropriate for the separation 
of these two compounds, and also suitable for the isolation of these two drugs 
from other materials used in the formulations.  
Isocratic elution was carried out with a mobile phase comprising a mixture of 
acetonitrile and 0.1 % v/v TFA in HPLC grade water (50:50 % v/v). The eluents 
were degassed before being pumped through the column at a flow rate of 1 
mL/min. The column temperature was maintained at 25C and the sample 
injection volume was 10 L, with a run time of 10 min. The UV wavelength was 
set to shift from 246 nm to 260 nm after 5.2 min for simultaneous quantification 
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of the two drugs, while the wavelength for individual analyses remained fixed 
throughout the entire experiment.  
HPLC chromatographic conditions of erlotinib and genistein for individual and 
co-quantification analysis are summarised in Table 4-1. 
In order to ensure there was no interference between other components present in 
the liposomes preparation and the two drugs, empty liposomes (formulation 
without drug) comprising DPPC, cholesterol and DOPE (72:8:20 mol%) were 
studied using the same HPLC chromatographic systems. 
Table 4-1 HPLC chromatographic conditions for assay of erlotinib and genistein using 
individual and simultaneous methods 
Drug Erlotinib Genistein Simultaneous 
Injection volume (L) 10 10 10 
UV/Vis detector 
wavelength (nm) 
246 260 246 and 260 
Mobile phase (100% v/v 
acetronitrile : 0.1% TFA in 
HPLC grade water) 
50:50 50:50 50:50 
Column temperature (C) 25 25 25 
Flow rate (mL/min) 1 1 1 
Run time (min) 10 10 10 
Retention time (min) 4.6 5.8 4.6 (Erlo) 
5.8 (Gen) 
 
 Preparation of standard solutions and calibration curves for 
erlotinib and genistein  
Two standard stock solutions of erlotinib and genistein of 1000 g/mL were 
individually prepared by dissolving 25 mg of erlotinib in 20 mL of DMSO and 25 
mg of genistein in 20 mL of methanol in separate 25 mL volumetric flasks. The 
sample was bath-sonicated for a few minutes to ensure complete dissolution of 
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drug, and solutions made up to the final volume of 25 mL. After that, 0.35 mL of 
the stock solution was diluted to 5 mL in a 5 mL volumetric flask to obtain the 
highest concentration of 70 g/mL. For the linearity study, serial dilutions of 
standard solutions were made in the range of 1 - 70 g/mL; 1, 2, 3, 4, 5, 10, 20, 30, 
40, 50, 60 and 70 g/mL. Individual calibration curve for erlotinib and genistein 
were plotted, with taking peak area on the Y axis and analyte concentration on the 
X axis. 
For simultaneous quantification of erlotinib and genistein, both stock solutions 
were prepared individually in DMSO before mixing to avoid potential chemical 
reaction between these two drugs at high concentrations. Subsequently, equal 
volumes of each stock solution were diluted with DMSO in the same volumetric 
flask, in order to make an equivalent series of concentrations ranging from 1 to 70 
µg/mL for both drugs. 
 Analytical method validation 
4.4.1.3.1 Linearity 
Linearity in this study was performed by taking four samples of all serial dilutions 
of 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70 g/mL from the stock solution and then 
injecting 10 L of each concentration into the HPLC chromatographic system and 
recording the response. The degree of linearity was then determined by 
calculating the correlation coefficient. The slope, intercept and correlation 
coefficient of erlotinib, genistein and co-quantification were determined from the 
equation describing the response. It is noted that the ranges of tested 
concentrations for preparing individual and co-quantification HPLC analysis of 
erlotinib and genistein were the same. 
4.4.1.3.2 Precision 
Intraday precision was performed by injecting three concentrations (8, 35 and 55 
g/mL) in triplicate per concentration onto the chromatographic system on the 
same day. Inter-day precision was determined with those concentrations on three 
consecutive days. The repeatability study was undertaken by injecting the chosen 
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concentration of 35 µg/mL 9 times to obtain the relative standard deviation 
(%RSD) calculated as mentioned (Eq.3-1).  
4.4.1.3.3 Accuracy  
The accuracy was determined by the recovery method, using a series of 
concentrations between 3 and 70 μg/mL for erlotinib and between 2 and 70 μg/mL 
for genistein in triplicate for the quantification and co-quantification of erlotinib 
and genistein. The percentage recovery was calculated using as mentioned (Eq. 3-
2). 
4.4.1.3.4 Limit of detection 
As mentioned in Section 3.4.1.5.4 
4.4.1.3.5 Limit of quantification 
As mentioned in Section 3.4.1.5.5 
 Preparation method for liposomes containing erlotinib or genistein 
and liposomes co-loaded with erlotinib and genistein 
 Effect of drug concentrations on the properties of DPPC liposomes 
The aim of this study was to investigate the maximum drug loading into DPPC 
liposomes and to characterise the properties of co-loaded liposomes for mean size, 
particle size distribution, surface charge and encapsulation efficiency. Two stock 
solutions of erlotinib and genistein (each 1.25 mg/mL) were prepared individually 
by dissolving 25 mg of erlotinib and 25 mg of genistein in 20 mL of absolute 
ethanol in separate 28 mL glass vials. DPPC liposomes with incorporated drug 
were prepared by the thin-film hydration method. To prepare formulations of 
different initial drug/lipid concentrations (% w/w), 1 mL, 2 mL and 4 mL of drug 
solution was added to 50 mg of DPPC to obtain 2.5, 5 and 10% w/w drug in 
DPPC individually, respectively. The phospholipid (DPPC) and drug (erlotinib or 
genistein) were dissolved together in 30 mL of a mixture of absolute ethanol and 
chloroform (4:1 v/v) in a 250 mL round-bottomed flask. The mixture was then 
placed into a bath sonicator and sonicated to ensure the complete dissolution of 
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drug and lipid. Solvent was removed using a rotary vacuum evaporator (RC 900, 
Knf Neuberger GmbH, Germany) at 150 bars for 20 min at 60C to acquire a thin 
film of drug and lipid. The dry thin film was flushed with nitrogen gas at ambient 
temperature for 5 min to remove residual solvent and then hydrated with 20 mL of 
HPLC water with vigorous hand-shaking, followed by gentle rotation on the 
rotary evaporation equipment at 200 rpm for 30 min at 60°C in a water bath to 
produce MLVs of 2.5 mg/mL lipid content.   
For co-loaded formulations, erlotinib and genistein co-loaded liposomes were 
prepared using the thin-film hydration method as outlined above. 1 mL, 2 mL and 
4 mL of stock solution of each drug (1.25 mg/mL in absolute ethanol) was added 
to 50 mg of DPPC, yielding a series of drug concentrations in lipid of 
approximately 2.5, 5 and 10% for each drug w/w. 
Empty liposomes, without either drug, were also prepared using the same method. 
This was to compare and study the effect of drug incorporation on the properties 
of the liposomes.  
Upon successful production of the MLVs, their sizes were reduced by probe 
sonication to achieve the required mean size of 100- 200 nm (Dandekar et al., 
2010; Amini et al., 2014). Liposomes in this range can be readily into the droplets 
during nebulisation (Cipolla et al., 2016) with minimal drug waste as well as 
achieving greater avoidance of alveolar macrophage uptake within alveolar 
airspace compared with those larger than 200 nm (Kamali et al., 2016; Nakamura 
et al., 2016). 
Non-incorporated drug was removed by syringe filtration. Each 2 mL of 
formulations was filtered through a 0.45-μm cellulose acetate membrane filter 
(Merck Millipore Ltd., UK) once, yielding a filtrate of drug-loaded liposomes.  
 Effect of cholesterol content on the properties of DPPC liposomes 
Drug concentration was initially fixed at 5% w/w drug in total lipid, while the 
content of cholesterol in DPPC (mol%) for erlotinib or genistein liposomal 
formulations was varied as shown in Table 4-2. The range of these concentrations 
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was chosen based on values successfully employed in a previous study of 
genistein liposomes (Phan et al., 2013). 2mL of drug solutions (1.25 mg/mL from 
each stock solution in absolute ethanol) and lipid phase (50 mg in total, 
comprising DPPC and cholesterol) were dissolved in 30 mL of a mixture of 
absolute ethanol and chloroform (4:1 v/v). Liposomes were prepared, sonicated 
and characterised as described in Section 4.4.2.1. The results were reported as the 
mean and standard deviation (mean ± S.D.) of three separate experiments. 
Table 4-2 The content of DPPC and cholesterol in erlotinib or genistein liposomal 
formulations 
Composition 
Quantity (mg) 
F1 
0 mol% 
cholesterol 
F2 
8 mol% 
cholesterol 
F3 
15 mol% 
cholesterol 
F4 
30 mol%  
cholesterol 
DPPC 100 mol%  
= 50 mg 
92 mol%  
= 47.81 mg 
85 mol%  
= 45.75 mg 
70 mol%  
= 40.79 mg 
Cholesterol 0 mol%  
= 0 mg 
8 mol%  
= 2.19 mg 
15 mol%  
= 4.25 mg 
30 mol%  
= 9.21 mg 
 
 Effect of the addition of DOPE on the properties of liposomes 
The aim of this study was to investigate the effect of the inclusion of 20 mol% 
DOPE (as previously successfully employed in a genistein liposome preparation 
(Phan et al., 2013)) on the properties of liposomes by comparing the liposomal 
formulation with and without DOPE. Drug-loaded liposomes (5% w/w erlotinib 
or 5% w/w genistein in total phospholipid) comprising 8 mol% of cholesterol 
(2.18 mg), 20 mol% of DOPE (10.51 mg) and 72 mol% of DPPC (37.31 mg) were 
prepared individually as described in Section 4.4.2.1.  
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For co-loaded preparations, erlotinib (2.5% w/w) and genistein (2.5% w/w), 
cholesterol (8% w/w) in total lipid were fixed (based on the results of individual 
formulations), whereas the concentrations of DOPE in total phospholipid (0, 10, 
20, 30 and 40 mol% of lipid contents) and DPPC up to 100% w/w lipid were 
varied as shown in Table 4-3. All liposomal formulations were characterised as 
outlined in Section 4.4.3. 
Table 4-3 The composition of DPPC: cholesterol: DOPE in erlotinib and genistein co-
loaded liposomal formulations 
Composition 
Quantity (mg) 
F1 = 0% 
DOPE 
F2 = 10% 
DOPE 
F3 = 20% 
DOPE 
F4 = 30% 
DOPE 
F5 = 40% 
DOPE 
Erlotinib 1.25 mg 1.25 mg 1.25 mg 1.25 mg 1.25 mg 
Genistein 1.25 mg 1.25 mg 1.25 mg 1.25 mg 1.25 mg 
DPPC 47.81 mg 42.55 mg 37.31 mg 32.08 mg 26.87 mg 
Cholesterol 2.18 mg 2.18 mg 2.18 mg 2.18 mg 2.18 mg 
DOPE 0.00 mg 5.26 mg 10.51 mg 15.74 mg 20.95 mg 
 
 Effect of sonication time on liposome particle size distribution and 
drug entrapment 
The purpose of this experiment was to study the influence of duration of probe-
sonication on mean particle size, polydispersity index (PDI) and entrapment 
efficiency (%EE) of erlotinib and genistein individually. Optimised genistein or 
erlotinib-loaded MLVs liposomes, with lipid phase DPPC: cholesterol: DOPE 
(72:8:20 mol%), were prepared individually and their size reduced by 30 min 
probe-sonication. 20 mL of MLVs were placed in a 20 mL glass vial and kept in 
an ice bath throughout the size reduction. Probe sonication (MSE Soniprep 150, 
MSE, UK) was undertaken at a constant output of 12 watts (5 min/cycle and 1 
min cooling at 4 ºC, to avoid overheating). The titanium probe (9.5 mm diameter) 
was immersed to a depth of 15 mm above the bottom of the glass vial. The time 
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for sonication (15, 30, 45 and 60 min) was varied to obtain a mean diameter of 
100 to 200 nm. After that, optimal sonication time was fixed for the preparation of 
liposomes co-loaded with erlotinib and genistein. 
 Characterisation of liposomes 
 Particle size distribution measurement by dynamic light scattering 
The mean hydrodynamic diameter and the particle size distribution were 
measured using the Malvern Nano ZS Zetasizer (Malvern Instruments, UK). 1.0 
mL of liposomes was placed without further dilution into the zeta potential DTS 
1070 folded capillary cell (Malvern instrument, UK). Three measurements were 
determined at 25 ºC. The data are expressed as mean Z-average particle diameter 
and polydispersity index (PDI). 
 Surface charge determination 
For zeta potential measurements, the samples were prepared and assessed using 
the Malvern Nano ZS Zetasizer as described in Section 4.4.3.1. Three independent 
measurements based on electrophoretic mobility using the Helmholtz-
Smoluchowski equation were determined and reported as mean values± S.D. 
 Transmission electron microscopy 
The morphology and aggregation behaviour of co-loaded liposomes was studied 
following placement on a carbon grid and negative staining with one drop of 
uranyl acetate (1% w/v), and observation using a transmission electron 
microscope (Philips Electron Optics BV, Netherlands), as described in Section 
3.4.4.4. 
 Drug-loading and entrapment efficiency 
1 mL of each formulation was diluted with ethanol to a final volume of 5 mL 
prior to HPLC analysis. The entrapment efficiency (%EE) and drug loading 
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(%DL) of erlotinib and genistein were calculated using equations (Eq. 3-5 and Eq. 
3-6) as outlined in Section 3.4.4.3. 
 Thermal analysis  
Differential Scanning Calorimetry (DSC) has been extensively used as a highly 
sensitive technique for studying the interaction of biomolecules with phospholipid 
bilayers (Taylor and Morris, 1995; Elhissi et al., 2006b; Chiu and Prenner, 2011). 
In general, the incorporation of exogenous molecules into a lipid bilayer has more 
pronounced effect on the pre-transition than the main transition (Elhissi et al., 
2006b; Saunders et al., 2007). Changes in the thermotropic behaviour of the main 
transition phase are dependent on the localisation of drug, with more obvious 
change when drug is located between C1 and C10 of the hydrophobic hydrocarbon 
region (Saunders et al., 2007).  
In recent times, DSC instrumentation with increased sensitivity or High 
Sensitivity DSC (HSDSC) has been employed in a number of studies to provide 
more accurate and reliable data, especially for small thermal events such as the 
pre-transition which are difficult to accurately measure by conventional DSC 
(Saunders et al., 2007). HSDSC was used for studying the interaction of 
hydrophobic drugs (erlotinib and genistein), cholesterol and DOPE with DPPC 
bilayer that may affect drug incorporation during pre-formulation studies. 
 Determining suitable lipid concentrations and scan rate for DSC 
analysis  
DPPC liposomes were prepared by the lipid thin-film hydration method (Section 
4.2.2.1) and sonicated for 30 min. To identify suitable lipid concentrations, DPPC 
concentrations of 2.5, 20 and 40 mg/mL were studied with the aim of achieving 
good resolution in the DSC thermogram at the minimum lipid concentration. The 
pre (Tpre) and main phase transition temperatures (Tm) and enthalpy of transition 
for DPPC-based liposomes (kJ/mol) were compared with previous reports. 
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For scan rate, 0.5 and 1 °C/min were studied for DPPC liposomes using a High 
Sensitivity Differential Scanning Calorimeter (HSDSC), a Multi cell DSC (TA 
instruments, Newcastle, UK).  
 Investigation of effect of drugs and helper lipids of different 
concentrations on DSC thermograms 
1 mL of formulations having total lipid concentration 40 mg/mL were each placed 
into a DSC sample cell (TA Instruments, Newcastle, UK), which was sealed using 
a rubber O-ring and cell cap to ensure an airtight fit. The reference cell was empty. 
Nitrogen was supplied to prevent vapour condensation on the sample cells during 
cooling (Elhissi et al., 2006b; Saunders et al., 2007). Fifteen liposomal 
formulations characterised in this study were listed below: 
 DPPC 
 DPPC/Cholesterol 
 DPPC/DOPE 
 DPPC/Cholesterol/DOPE 
 DPPC containing erlotinib at concentrations of 2.5, 5% and 10% 
 DPPC containing genistein at concentrations of 2.5%, 5% and 10% 
 DPPC containing both drugs at concentrations of 2.5% and 5%  
 DPPC/Cholesterol/DOPE containing erlotinib at concentration of 2.5% 
 DPPC/Cholesterol/DOPE containing genistein at concentration of 2.5% 
 DPPC/Cholesterol/DOPE containing erlotinib and genistein at 
concentrations of 2.5% 
 
All scans were undertaken at a rate of 0.5 °C/min from 15 to 70°C. The thermal 
behaviour of liposomes was evaluated based on the temperature of the pre-
transition (Tpre), main phase transition temperature (Tm), enthalpy (∆H) and half-
height width (HHW) of the main endothermic peak using the instrument software. 
Three independent DSC measurements were determined and values are reported 
as mean ± SD. 
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 Statistical analysis 
All experiments were carried out in triplicate and results are present as the mean ± 
S.D. Data were statistically analysed using either Student’s t-test or analysis of 
variance (ANOVA) and Tukey’s post hoc test, using IBM SPSS Statistic 22 
software. A p value < 0.05 was considered significant. 
 Results and discussion 
 Validation of HPLC analysis 
 HPLC chromatograms of erlotinib and genistein 
The retention times for erlotinib and genistein were approximately 4.6 (Figure 4-
3) and 5.8 min (Figure 4-4), respectively. In order to ensure there was no chemical 
reaction between two drugs prior to the pre-formulation studies of this 
combination, the retention times and the peak responses of HPLC methods for 
individual and simultaneous determination of erlotinib and genistein were 
assessed. Based on the comparison of chromatograms (Figure 4-3, Figure 4-4 and 
Figure 4-5), no difference in the retention times and the peak areas of both drugs 
individually and in combination was evident. This suggests no interaction 
between these two active ingredients impacting the HPLC analysis at the 
concentrations investigated.  
Blank liposomes (formulation without any drugs) containing DPPC, cholesterol 
and DOPE were injected into the HPLC system, with only one chromatographic 
peak at 2.7 min as seen in Figure 4-6, Figure 4-7, Figure 4-8 and Figure 4-9. This 
observation indicates that the three components used in the formulation will not 
interfere in the quantitative of both drugs in the remaining studies. 
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Figure 4-3 HPLC chromatogram of erlotinib (10 µg/mL) 
  
 
Figure 4-4 HPLC chromatogram of genistein (10 µg/mL) 
 
=====================================================================
Acq. Operator   : NATTIKA                        Seq. Line :  11
Acq. Instrument : Instrument 1                    Location : Vial 31
Injection Date  : 6/20/2016 1:30:42 PM                 Inj :   1
                                                Inj Volume : 10.000 µl
Acq. Method     : C:\CHEM32\1\DATA\NATTIKA\200616 2ND GENISTEIN CALIBRATION CURVE 2016-06-20
                  11-30-15\NATTIKA 50 50M AT 260NM.M
Last changed    : 1/23/2016 3:19:31 PM by NATTIKA
Analysis Method : C:\CHEM32\1\METHODS\PARACETAMOL.M
Last changed    : 9/4/2013 3:23:30 PM by NAIB
min0 1 2 3 4 5 6 7 8 9
mAU
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 VWD1 A, Wavelength=260 nm (C:\CHEM32\...6 2ND GENISTEIN CALIBRATION CURVE 2016-06-20 11-30-15\031-1101.D)
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=====================================================================
                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: VWD1 A, Wavelength=260 nm
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.038 BB    0.5136  208.78206    6.57083   4.9320
   2   5.837 BB    0.1155 4024.39063  534.99316  95.0680
 
Totals :                  4233.17268  541.56399
 
 
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\...0616 2ND GENISTEIN CALIBRATION CURVE 2016-06-20 11-30-15\031-1101.D
Sample Name: 50MCG/ML
Instrument 1 10/3/2017 10:40:39 AM PLERNTA Page 1 of 1
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Figure 4-5 HPLC chromatogram of erlotinib (10 µg/mL) and genistein (10 µg/mL) 
 
    
 
Figure 4-6 HPLC chromatogram of blank liposomes consisting of DPPC, cholesterol 
and DOPE 
  
 
=====================================================================
Acq. Operator   : NATTIKA                        Seq. Line :  11
Acq. Instrument : Instrument 1                    Location : Vial 80
Injection Date  : 6/14/2016 3:34:30 PM                 Inj :   1
                                                Inj Volume : 10.000 µl
Acq. Method     : C:\CHEM32\1\DATA\NATTIKA\140616 1ST CO CALIBRATION CURVE 2016-06-14 13-32-
                  46\NATTIKA SIMULTANEOUS 50 50.M
Last changed    : 3/8/2016 5:05:56 PM by NATTIKA
Analysis Method : C:\CHEM32\1\METHODS\PARACETAMOL.M
Last changed    : 9/4/2013 3:23:30 PM by NAIB
min0 1 2 3 4 5 6 7 8 9
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 VWD1 A, Wavelength=246 nm, TT (C:\CHEM32\...16 1ST CO CALIBRATION CURVE 2016-06-14 13-32-46\0000000010.D)
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=====================================================================
                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: VWD1 A, Wavelength=246 nm, TT
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   2.982 VB    0.4779 2932.44238   93.57441  31.8737
   2   4.660 BB    0.1269 2258.15015  257.92606  24.5446
   3   5.823 VB    0.1147 4009.60303  528.94226  43.5817
 
Totals :                  9200.19556  880.44273
 
 
=====================================================================
Data File C:\CHEM32\...KA\140616 1ST CO CALIBRATION CURVE 2016-06-14 13-32-46\0000000010.D
Sample Name: 50MCG/ML
Instrument 1 10/3/2017 10:38:16 AM PLERNTA Page 1 of 1
Acq. Operator : NATTIKA                        Seq. Line : 2
Acq. Instrument : Instrument 1                    Location : Vial 2
Injection Date  : 8/7/2016 8:33:55 PM                  Inj :   1
                            Inj Volume : 10.000 µl
Acq. Method : C:\CHEM32\1\DATA\NATTIKA_EE\070816 BLANK FORMU TO STUDY INTEFERENCE 2016-
         08-07 20-11-01\NATTIKA SIMULTANEOUS 50 50.M
Last changed   : 3/8/2016 5:05:56 PM by NATTIKA
Analysis Method : C:\CHEM32\1\METHODS\PARACETAMOL.M
Last changed    : 9/4/2013 3:23:30 PM by NAIB
min0 1 2 3 4 5 6 7 8 9
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 VWD1 A, Wavelength=246 m, TT (C:\CHEM32\...NK FORMU TO STUDY INTEFERENCE 2016-08-07 20-11-01\002-0201.D)
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=====================================================================
                         Area Percent Report                         
=====================================================================
 
Sorted By             :      Signal
Multiplier:                   :      1.0000
Dilution:                     :      1.0000
Use Multiplier & Dilution Factor with ISTDs
 
 
Signal 1: VWD1 A, Wavelength=246 nm, TT
 
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   2.781 VB    0.3412 2154.95703   84.51225 100.0000
 
Totals :                  2154.95703   84.51225
 
 
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\...816 BLANK FORMU TO STUDY INTEFERENCE 2016-08-07 20-11-01\002-0201.D
Sample Name: DF=5 BLANK FORMULATION
Instrument 1 10/3/2017 10:50:44 AM PLERNTA Page 1 of 1
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Figure 4-7 HPLC chromatogram of liposomes consisting of DPPC, cholesterol and 
DOPE containing erlotinib 
 
 
Figure 4-8 HPLC chromatogram of liposomes consisting of DPPC, cholesterol and 
DOPE containing genistein 
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Figure 4-9 HPLC chromatogram of liposomes consisting of DPPC, cholesterol and 
DOPE containing erlotinib and genistein 
 Calibration curves for erlotinib, genistein and co-quantification of 
erlotinib and genistein 
In order to examine the linearity of HPLC methods for quantification and co-
quantification of erlotinib and genistein, serial dilutions of both standard solutions 
were prepared ranging from 1 to 70 µg/mL. Each graph was plotted as peak 
response (mAU) versus concentration of drug (µg/ mL), yielding an equation for 
the line as shown in Figure 4-10 to Figure 4-13. Based on the obtained analysis of 
the least-square regression, correlation coefficients that present the linear 
relationship between the peak areas of analyte and analyte concentrations were 
achieved with R2 > 0.999 for the determined calibration curves. This represents 
good linearity for the analytical procedures over the drug concentration range 
investigated (Sistla et al., 2005; Faivre et al., 2011). 
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Figure 4-10 HPLC calibration curve of erlotinib (n= 3) 
 
 
Figure 4-11 HPLC calibration curve of genistein (n=3) 
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Figure 4-12 HPLC calibration curve of erlotinib (in presence of genistein) (n= 3) 
 
 
Figure 4-13 HPLC calibration curve of genistein (in presence of erlotinib) (n= 3) 
 Analytical method validation 
The developed HPLC method for quantification of erlotinib and genistein did not 
require any buffer solutions throughout the analysis as compared to previous 
methods for erlotinib (Faivre et al., 2011; Bolandnazar et al., 2013; Latha et al., 
2017) and genistein (Supko and Phillips, 1995; Da Costa César et al., 2006; 
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Pandit and Patravale, 2011). The results for analytical method validation, which 
included linearity, precision, accuracy, LOD and LOQ were achieved according to 
ICH guidelines with short analysis times (Table 4-4). The LOD and LOQ values 
were calculated based on the slope and standard deviation of the Y-intercept of 
the regression analysis of linear curves, as opposed to alternatives used to 
determine these critical values; for example, the signal to noise ratio (Latha et al., 
2017).  
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Table 4-4 Regression characteristics, validation and system suitability for the 
analysis of erlotinib and genistein (n=4) 
Parameters 
Individual HPLC analysis 
Simultaneous HPLC 
analysis 
Erlotinib Genistein Erlotinib Genistein 
Retention time 
(min) 
4.6 5.8 4.6 5.8 
Linearity range 
(µg/mL) 
3-70 2-70 3-70 2-70 
Number of samples 
per curve 
10 11 10 11 
Limit of detection 
(µg/mL) 
0.78 0.18 0.34 0.25 
Limit of 
quantification 
(µg/mL) 
3.00 2.00 3.00 2.00 
Accuracy (% RE) 
97.60– 
108.69 
97.46- 
102.53 
94.76– 
101.63 
96.53- 
109.60 
Precision (%RSD, 
n=3) 
1.89- 7.52 0.55- 2.84 1.03- 9.86 1.26- 5.11 
Repeatability 
(%RSD) at 35 
µg/mL (n=9) 
2.70 3.27 3.29 1.32 
 
Table 4-5 shows that the intra-day and inter-day precisions determined by %RSD 
and the accuracy values (%RE) for individual and simultaneous HPLC analysis of 
erlotinib and genistein (8, 35 and 55 µg/mL), were within the acceptance criteria, 
being less than 5% SD (Sistla et al., 2005). 
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These HPLC methods show the similar retention time using a simpler 
composition of mobile phase compared with previous reports of the quantitative 
determination of erlotinib and genistein individually, providing a rapid, simple 
and cost-effective analytical method. Co-quantification of erlotinib and genistein 
has not been previously reported. This method can be used to simultaneously 
quantify erlotinib and genistein throughout the remaining studies. 
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Table 4-5 Inter-day and Intra-day variability of the HPLC method (n=4, mean± S.D) 
 
Nominal 
concentration 
(µg/mL) 
Intra-day Inter-day Intra-day Inter-day 
Measured 
concentration 
(µg/mL) 
%RSD %RE Measured 
concentration 
(µg/mL) 
%RSD %RE Measured 
concentration 
(µg/mL) 
%RSD %RE Measured 
concentration 
(µg/mL) 
%RSD %RE 
Individual analysis of erlotinib Individual analysis of genistein 
8 8.09± 0.10 1.19 -1.11 8.09± 0.24 2.94 -1.07 7.97± 0.09 1.19 0.32 7.93± 0.28 3.47 0.83 
35 34.91± 0.17 0.49 0.27 34.44± 0.93 2.70 1.61 35.15± 0.26 0.73 -0.43 34.71± 1.13 3.27 0.82 
55 54.09± 0.70 1.29 1.66 53.90± 1.27 2.36 2.00 55.16± 0.20 0.36 -0.29 54.05± 1.44 1.73 1.73 
 Co-quantification analysis of erlotinib Co-quantification analysis of genistein 
8 8.30± 0.18 2.11 -3.81 8.04± 0.28 3.50 -0.51 7.93± 0.08 0.97 0.89 7.89± 0.07 0.93 1.34 
35 34.74± 0.22 0.63 0.73 34.28± 1.13 3.29 2.05 35.02± 0.12 0.35 -0.07 34.81± 0.46 1.32 0.55 
55 54.30± 0.21 0.40 1.27 53.90± 1.26 2.34 2.01 54.55± 0.08 0.16 0.82 54.51± 0.62 1.14 0.89 
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 Characterisation of drug-loaded liposomes 
Saturated lipid hydrogenated soybean phosphatidylcholine (HSPC) and 
cholesterol have previously been used in the preparation of liposomes 
encapsulating either erlotinib or genistein (Phan et al., 2013; Mandal et al., 2016; 
Li et al., 2017; Zhou et al., 2018). However, co-encapsulation of erlotinib (log 
P=2.75) and genistein (log P=2.84) into liposomes has not yet been reported. This 
combination was studied as an interesting and rational challenge for pulmonary 
delivery.  
Dipalmitoylphosphatidylcholine (DPPC), which contains two 16-carbon 
(palmitoyl) chains as compared to a mixture of 16 and 18–carbon chains for 
HSPC, was chosen as the main phospholipid component in the liposomal 
formulations studied here (Monteiro et al., 2014). DPPC and HSPC are not 
commercially available in inhalation products, though DPPC has been used for 
delivering ciprofloxacin in clinical trials. The use of DPPC as a major lipid in 
liposomes for the delivery of erlotinib and genistein individually and in 
combination was investigated since it was challenging for preparation, 
characterisation and optimisation. Secondly, the phase transition temperature of 
DPPC (41° C) is above 37° C, ensuring that there is no rapid loss of drug at body 
temperature (Chen et al., 2014). Importantly, DPPC is a major component of lung 
surfactant and may be more suitable for pulmonary delivery than HSPC 
(Kaviratna and Banerjee, 2012; Joshi et al., 2014).  
 Effect of cholesterol concentration on the properties of DPPC 
liposomes containing either erlotinib or genistein 
A previous study demonstrated that the incorporations of cholesterol and DOPE 
into HSPC liposomes at the appropriate ratio improved the entrapment efficiency 
and stability of genistein-loaded liposomes compared with those of the HSPC 
alone (Phan et al., 2013). This was due to changes in the lipid packing and fluidity 
of the phospholipid bilayer (Phan et al., 2013). Initially in this study, 5% w/w 
Chapter 4 Liposomes loaded with erlotinib and genistein 
 173 
erlotinib or 5% w/w genistein in DPPC was fixed, and then cholesterol content 
was varied (ranging from 0 to 30 mol% of total lipid content), to study the effect 
of cholesterol concentrations on the properties of erlotinib or genistein-containing 
DPPC liposomes.  
DPPC liposomes in the absence of cholesterol and those containing 8 mol% of 
cholesterol showed the similar encapsulation efficiency of genistein (Figure 4-14, 
respectively; 45% and 38.5% EE). This suggests that adding cholesterol content 
up to 8 mol% in the presence of genistein had no measurable impact on the 
packing of genistein within the saturated hydrocarbon chains of DPPC. As the 
inclusion of cholesterol was increased from 8% to 30%, a decrease in entrapment 
efficiency of genistein was seen (p<0.05). This may be because greater 
concentrations of cholesterol cause phase separation in the bilayer with a 
formation of cholesterol domain and/or a reduced free volume of the hydrocarbon 
chains, resulting in an exclusion of genistein from the liposomal bilayer and a 
decrease in genistein entrapment as described previously for other hydrophobic 
drugs (Elhissi et al., 2006b; Kępczyński et al., 2008). Cholesterol thus plays an 
important role in the molecular interaction of all other molecules present in the 
lipid bilayer, resulting in changes in bilayer properties and having a consequent 
effect on the incorporation of hydrophobic drugs (Chountoulesi et al., 2017).  
 
Figure 4-14 Effect of cholesterol content (mol%) on entrapment efficiency (%EE) of 
a) erlotinib and b) genistein in DPPC liposomes (n=3, mean ± S.D.) 
The entrapment efficiency for erlotinib did not change with increasing cholesterol 
content (range 3.50 – 8.86 % EE), indicating no significant effect of cholesterol 
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on entrapment efficiency for erlotinib over the range investigated. This could be 
due to the differences in partitioning and orientation between erlotinib and 
cholesterol in the liposomal membrane (Zhao et al., 2007). Erlotinib may be 
predominantly located near the polar head groups of DPPC liposomes, whereas 
cholesterol was oriented within the bilayer (Monteiro et al., 2014). Moreover, 
entrapment efficiency of erlotinib was comparatively lower than genistein for all 
loading concentrations (p<0.05).  
The incorporation of therapeutic agents into the liposomal bilayer depends on the 
nature of drugs (e.g. its molecular structure, polarity and oil/water partition 
coefficient) and the properties of lipid (hydrocarbon chain length, packing density 
and bilayer fluidity). These can all determine the localisation of drugs within the 
bilayer and their incorporation into liposomes, especially for hydrophobic drugs 
(Bozzuto and Molinari, 2015). This is because hydrophobic molecules tend to 
reside in the acyl chain regions within the bilayer rather than near the polar head 
groups of phospholipids in the liposomes (Bozzuto and Molinari, 2015). 
Cholesterol in DPPC bilayer modifies liposomal membrane properties particularly 
molecular packing and bilayer fluidity and consequently impacts drug 
incorporation into the bilayer especially for genistein. Differences in the 
molecular structures of erlotinib and genistein seem to affect the orientation of the 
drug molecules within the DPPC-based bilayer, reflected in differences in drug 
incorporation for the two drugs at the same cholesterol contents. Specifically, 
genistein appears to partition deeper than erlotinib within the bilayer in the 
hydrocarbon chain region, such that changes in packing order of the DPPC bilayer 
by cholesterol highly affected genistein incorporation. 
Inclusion of 8 mol% cholesterol significantly reduced the variability in the 
entrapment efficiencies for both drugs, indicating a more reproducible and stable 
liposome production. Previously, research has shown cholesterol has a great effect 
on bilayer and thermal properties in a concentration dependent manner (Demetzos, 
2008; Monteiro et al., 2014). Cholesterol increases the number of gauche 
configurations (kinks) in the phospholipid hydrocarbon chains at or below Tc (less 
rigid), which is associated with an increased lipid mobility and permeability in the 
gel phase compared to bilayers of the pure phospholipid (Cortijo and Chapman, 
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1981; Monteiro et al., 2014). By contrast, there is a decrease in the changes from 
trans to gauche configuration in lipids above the Tc, causing a reduction in bilayer 
fluidity and permeability in the fluid state (Cortijo and Chapman, 1981). The 
steroid rings of cholesterol are dense, and incorporation of cholesterol into the 
bilayer increases the density of hydrocarbon chains, decreases the fluidity, leading 
to higher rigidity of the liposomal bilayer (Monteiro et al., 2014). This effect was 
dependent on cholesterol concentration. At very high cholesterol concentration 
(i.e. 50 mol%) and greater, the phospholipid phase transition is effectively 
abolished (Cortijo and Chapman, 1981; Taylor and Morris, 1995).   
 Effect of cholesterol concentration on particle size distribution of 
liposomes containing either erlotinib or genistein 
Mean particle size was not significant different for sonicated liposome 
formulations in the absence of cholesterol and those containing 8 mol% of 
cholesterol (Figure 4-15, p>0.05). However, there was an increase in mean size 
when cholesterol content was greater than 8 mol% for formulations containing 
either erlotinib or genistein (p<0.05). These findings were in accordance with 
previous reports of sonicated DPPC liposomes containing various cholesterol 
concentrations, indicating a concentration-dependent effect on mean size (Lopez-
Pinto et al., 2005; Pattni et al., 2015). There was considerable variability in 
measurement of the hydrodynamic diameter for higher cholesterol contents (15% 
and 30% mole) particularly for erlotinib formulations. Moreover, some 
aggregation was apparent at ambient temperature for 30 mol% of cholesterol for 
both preparations, and also found for 15 mol% of cholesterol for erlotinib 
formulations within 5 min. These observations may suggest a phase separation, 
with a formation of cholesterol-rich domain. By contrast, there was no difference 
in PDI values (p>0.05). These results show that 8 mol% cholesterol in bilayer 
provides a restriction on the radius of vesicles that can be achieved by sonication.  
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Figure 4-15 Effect of cholesterol concentration on mean hydrodynamic diameter 
(nm) of DPPC liposomes containing erlotinib or genistein after 30 min sonication 
(n=3, mean± S.D.) 
Cholesterol is frequently included in liposome bilayers to control drug release or 
increase their in vivo and in vitro stability by stabilising the bioactive agent in the 
core of the liposome (Taylor and Morris, 1995; Monteiro et al., 2014)). Based on 
the findings for size stability and drug incorporation, a formulation including 8 
mol% cholesterol was taken into further studies. 
 Effect of including DOPE on the properties of DPPC/Cholesterol 
liposomes loaded with either erlotinib or genistein 
The degree of fatty acid saturation influences the permeability and packing of the 
phospholipid bilayer (Monteiro et al., 2014). Unsaturated lipids can have 
increased spaces between the tightly packed hydrocarbon tails within a bilayer. 
This may cause an increased bilayer fluidity and permeability compared with 
saturated hydrocarbon chains (Monteiro et al., 2014).  
DOPE has previously been used as an unsaturated lipid to alter the bilayer 
packing and fluidity, thereby increasing the diffusivity and partitioning of 
exogenous compounds (Phan et al., 2013; Joshi et al., 2014). Formulations 
comprising DPPC and DOPE were not toxic upon inhalation, since DOPE acts as 
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a surfactant and is similar to the surfactant Protein-B (SP-B) present in 
endogenous lung surfactant (Joshi et al., 2014). Furthermore, fusogenic lipid like 
DOPE is usually used as a helper lipid in liposomes for enhancement of 
membrane permeability and improvement in intracellular drug delivery, due to its 
structural features. Consequently, DOPE, was considered in this study. 
No studies have so far investigated the use of DPPC, cholesterol and DOPE for 
the incorporation of erlotinib and/or genistein into liposomes for delivery by 
pulmonary route. In this study, 20 mol% DOPE was initially studied based on a 
previous report of genistein incorporation (Phan et al., 2013). Encapsulation 
efficiency of erlotinib increased by approximately 16% (p<0.05) compared to 
those without DOPE (Figure 4-16). Differences in drug incorporation between the 
two drugs due to the inclusion of DOPE may be resulted from the orientation of 
drug molecules and DOPE, as found for inclusion of cholesterol. This suggests 
that the presence of 20% mole of this flexible unsaturated phospholipid (DOPE) 
enhanced incorporation of both drugs and would potentially be advantageous for 
the co-incorporation of erlotinib and genistein. However, the mole ratios between 
DPPC, cholesterol and DOPE should be further investigated to allow 
accommodation of both erlotinib and genistein molecules within the bilayer. 
 
Figure 4-16 Effect of including DOPE on entrapment efficiency of 5% w/w erlotinib 
or 5% w/w genistein in DPPC: cholesterol (92:8) liposomes (n=3, mean ± S.D.) 
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 Effect of sonication time on encapsulation efficiency of erlotinib or 
genistein in liposomes 
The mean size of DPPC: cholesterol: DOPE (72:8:20) liposomes containing either 
erlotinib or genistein was reduced using probe-sonication from the initial size of 
approximately 7µm. From 15 min to 30 min sonication, encapsulation efficiencies 
of erlotinib and genistein evidently increased before remaining almost the same 
level (Figure 4-17). Consequently, 30 min sonication was chosen based on the 
high encapsulation efficiency of both drugs.  
 
Figure 4-17 Effect of sonication time (min) on encapsulation efficiency (%EE) of 5% 
w/w erlotinib or 5% w/w genistein in DPPC: cholesterol: DOPE (72: 8: 20) 
liposomes (n=3, mean ± S.D.) 
 Characterisation of liposomes co-loaded with erlotinib and genistein 
The inclusion of cholesterol (8 mol%) and DOPE (20 mol%) into DPPC bilayers 
gave improvements in drug entrapment for both drugs individually (5% w/w drug 
in total lipid). Since hydrophobic molecules are located within phospholipid 
bilayer, not only lipid composition but also the drug-to-lipid ratio will impact 
encapsulation efficiency (Bozzuto and Molinari, 2015; Chountoulesi et al., 2017). 
In this study, the weight ratio of total lipid: drug was investigated to identify the 
maximum drug incorporation for erlotinib and genistein when incorporated 
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individually or co-loaded into liposomes. Both individual and co-encapsulation 
formulations with the drug content of 2.5% w/w showed the highest entrapment 
efficiency of the three concentrations investigated (p<0.05, Table 4-6).  
The encapsulation efficiencies of genistein in co-loaded DPPC formulations were 
the same as those for genistein alone (p>0.05), whereas the entrapment efficiency 
was lower for erlotinib in co-loaded liposomes. This may indicate drug-drug 
and/or drug-lipid interactions within phospholipid bilayers, resulting in the 
changes in the fluidity of phospholipid bilayers and physical drug entrapment, as 
previously described (Section 4.5.2.1).  
The mean hydrodynamic diameter for all preparations was smaller than 200 nm 
except for 10% w/w co-loaded liposomes, while preparations were relatively 
polydispersed (PDI >0.3) except erlotinib-containing liposomes. The surface 
charge was in the range +0.66 to +4.78 mV. The formulation of erlotinib and 
genistein (2.5% w/w each drug in DPPC or 5% w/w total drug in DPPC) was 
further studied to identify the optimal DOPE content. It is noted that cholesterol 
content was maintained at 8 mol% and the drug concentration in total lipid was 
constant (5% w/w). 
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Table 4-6 Effect of drug-to-lipid ratio (%w/w) on the properties of DPPC liposomes (n=3, mean± S.D.) 
Concentration (%w/w 
drug in lipid) 
Formulation Entrapment 
Efficiency (EE; %) 
Mean particle 
size (nm) 
Polydispersity Index 
(PDI) 
Zeta Potential 
(mV) 
2.5% Erlo (Ind.) 32.53± 6.05 106.37± 1.84 0.25± 0.02 +4.78± 0.99 
Erlo (Comb.) 14.65± 3.42 159.22± 19.42 0.44± 0.09 +2.42± 1.82 
Gen (Ind.) 84.66± 2.70 139.03± 11.70 0.43± 0.02 +1.34± 0.77 
Gen (Comb.) 90.03± 10.99 159.22± 19.42 0.44± 0.09 +2.42± 1.82 
5% Erlo (Ind.) 13.20± 5.53 99.68± 2.18 0.22± 0.01 +4.78± 1.63 
Erlo (Comb.) 7.02 ±1.13 200.07± 45.81 0.50±0.12 +2.35± 0.43 
Gen (Ind.) 58.54± 8.06 158.17± 7.27 0.43± 0.05 +0.74± 0.46 
Gen (Comb.) 71.48± 9.03 200.07± 45.81 0.50±0.12 +2.35± 0.43 
10% Erlo (Ind.) 11.45± 10.70 106.67± 23.80  0.35± 0.17 +4.47± 2.09 
Erlo (Comb.) 3.09± 0.87 317.8± 57.06 0.86± 0.16 +3.54± 0.26 
Gen (Ind.) 24.05± 3.92 146.03± 16.49 0.51± 0.04 +0.66± 0.28 
Gen (Comb.) 41.24± 6.74 317.8± 57.06 0.86± 0.16 +3.54± 0.26 
*Ind = Individual formulation and Comb= Combination formulation 
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Based on preliminary experiments, the incorporations of 20 mol% of DOPE and 8 
mol% of cholesterol into DPPC liposomes improved the entrapment efficiency for 
erlotinib alone compared with the formulation without DOPE (p<0.05). Therefore, 
the content of DOPE (0-40 mol% of total lipid contents) was varied to determine 
the effect on co-loading of the two drugs. As seen in Table 4-7, there was no 
significant difference in encapsulation efficiency for genistein when DOPE was 
increased (p>0.05). By contrast, the highest drug entrapment (p<0.05) for 
erlotinib (23.16%) was achieved in the presence of 20 mol% DOPE before 
decreasing to approximately 12.5% EE (p<0.05). This may be because the 
inclusion of DOPE at lower contents increases the fluidity of the bilayer and 
consequently enhances drug incorporation. However, as higher concentrations of 
DOPE (>20 mol%), the internal volume to accommodate both drugs is reduced 
due to its localisation within bilayer. Hence, the formulation (DPPC: cholesterol: 
DOPE, 72:8:20) was considered optimal and used for further studies. In terms of 
mean hydrodynamic diameter, all formulations had mean size< 200 nm as desired.  
Co-encapsulation of more than one drug into the same phospholipid bilayer may 
alter the liposome properties such as drug entrapment, mean size and the 
lipophilicity of membrane (Ingebrigtsen et al., 2017). There were significant 
increase in mean hydrodynamic diameter and particle size distribution when 
comparing liposomes co-loaded with erlotinib and genistein with those containing 
erlotinib (p<0.05). Considering drug entrapment, encapsulation efficiencies of 
erlotinib in co-loaded liposomes containing cholesterol (8 mol%) and DOPE (20 
mol%) were significantly higher than co-loaded formulations without those two 
molecules (p<0.05), suggesting that the incorporation of genistein in the presence 
of cholesterol and DOPE into lipid bilayer may significantly alter the mobility and 
permeability of the lipids within bilayer (Table 4-6 and Table 4-7). Genistein and 
the other two molecules were expected to have a stronger association with the 
lipid bilayer than erlotinib and be localised within both superficial and deep layer 
of hydrocarbon chains. Hence, this effect may cause a change in membrane 
properties, causing an enhanced incorporation of erlotinib within the aqueous part 
and/or first few layers of fatty acyl chains of the liposomes. 
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To sum up, the co-delivery of erlotinib and genistein in liposomes comprising 
DPPC, cholesterol and DOPE (mole ratio of 72:8:20) would be beneficial to 
reduce the excipients used in individually prepared composition and potentially 
simplify administration. This co-loaded formulation was therefore considered 
appropriate for further studies. 
Table 4-7 Effect of DOPE concentration (%w/w) on the properties of DPPC: cholesterol 
(92:8) liposomes co-loaded with 2.5% w/w erlotinib and 2.5% w/w genistein in total lipid 
(n=3, mean± S.D.) 
Concentration 
of DOPE 
(%w/w drug 
in lipid) 
Drug Entrapment 
Efficiency 
(EE; %) 
Mean 
particle 
size 
(nm) 
Polydispersity 
Index (PDI) 
Zeta 
Potential 
(mV) 
 
0% 
Erlotinib 12.87± 5.11  
139.3± 
16.18 
 
0.42± 0.01 
 
+1.88± 
0.84 
Genistein 88.26± 7.15 
 
10 % 
Erlotinib 11.96± 0.51  
147.03± 
38.41 
 
0.52± 0.15 
 
-2.18± 
1.28 
Genistein 99.34± 0.47 
 
20% 
Erlotinib 23.16± 2.08  
128.00± 
13.70 
 
0.44± 0.05 
 
-3.23± 
0.05 
Genistein 101.58± 
12.72 
 
30% 
Erlotinib 16.67± 2.64  
113.25± 
7.58 
 
0.37± 0.03 
 
-7.31± 
0.51 
Genistein 96.07± 2.51 
 
40% 
Erlotinib 12.50± 0.76  
102.69± 
6.71 
 
0.39± 0.02 
 
-8.97± 
0.54 
Genistein 98.22± 0.90 
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 Transmission electron microscopy 
TEM images of co-loaded liposomes, size reduced by probe sonication, showed a 
population of small spherical liposomes between 100 and 200 nm in diameter 
(Figure 4-18). This was in good agreement with other previous reports of 
multilamellar vesicles (MLVs) prepared by thin-film hydration method and 
reduced size by probe-sonication (Bozzuto and Molinari, 2015; Pattni et al., 2015; 
Rudokas et al., 2016).  
 
Figure 4-18 TEM images of erlotinib and genistein co-loaded liposomes (a.) 17500 x and 
(b.) 65000 x 
 Thermal analysis of liposomes 
Differential Scanning Calorimetry (DSC), a highly sensitive thermal analytical 
technique, has been used extensively to study liposomal systems, giving 
information on drug-liposome interactions that may impact entrapment efficiency, 
stability and drug release (Taylor and Morris, 1995; Budai et al., 2003; Demetzos, 
2008; Chen et al., 2014). DSC is a quick, simple and relatively low-cost technique 
compared with other thermoanalytical methods and provides accurate information 
about melting point and melting range, glass transitions, interactions, 
compatibility, decomposition, purity, and polymorphism based on changes on 
thermotropic properties (Demetzos, 2008). For liposomes, changes in the thermal 
a.) b.) 
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parameters of the lipid bilayers (i.e., Tm, HHW and ∆H) after incorporating drugs 
are associated with drug-lipid interactions, the stability of the formulation, and the 
percentage of active ingredient that can be incorporated into liposomal bilayer. 
This information allows for rational formulation design and development 
(Gardikis et al., 2006; Demetzos, 2008). In this study, calorimetric parameters, 
namely the pre-transition temperature (Tpre), main transition temperature (Tm), 
enthalpy (∆H) and half height width (HHW) were investigated to determine drug-
bilayer interactions and to determine the maximum drug incorporation into DPPC 
bilayers for both individual and co-loaded formulations.  
 Effect of lipid concentrations on the DSC thermogram of liposomes 
The lipid concentration was investigated to determine the lowest concentration of 
DPPC yielding consistent and reproducible DSC results with good peak resolution. 
This is beneficial to minimise the waste and cost for formulations with a high 
content of expensive synthetic lipids. However, high concentrations of lipid may 
be necessary to give a clear pre- and/or main transition peaks with measureable 
enthalpies. DPPC liposomes were prepared (Section 4.4.2.1) and their reduced 
size by probe-sonication to achieve final DPPC concentrations of 2.5, 20 and 40 
mg/mL. These were scanned in the DSC at a rate of 1ºC/min. There was no 
endothermic peak observed for the concentration of 2.5 mg/mL (data not shown). 
A main phase transition peak was evident at 20 mg/mL, though a clear pre-
transition of DPPC was not present (data not shown).  
Two different heating rates of 0.50 and 1.00°C/min with DPPC (40mg/mL) were 
employed to obtain high resolution of DSC thermograms to allow accurate 
calculation of Tpre, Tm, HHW and enthalpy. From previous reports, a slow scan 
rate is recommended for a highly purified phosphatidylcholines (PCs) as it yields 
high resolution and minimises broad and/or overlapping transitions (Sturtevant, 
1987). Slower heating rates may however lead to low sensitivity, resulting in the 
requirements for higher instrumental sensitivity (Sturtevant, 1987; Chiu and 
Prenner, 2011). High Sensitivity Scanning Calorimeter (HSDSC) was thus 
performed in this study to overcome these problems. Based on a preliminary study, 
0.5°C/min was determined to be a suitable scanning rate since it gave the 
Chapter 4 Liposomes loaded with erlotinib and genistein 
 185 
expected thermal events with peaks for the main and pre-transition evident 
(Figure 4-19), while there was no pre-transition apparent at 1.0 °C/min.  
 
Figure 4-19 DSC thermogram of DPPC liposomes (40 mg/mL) scanned at 0.5 ºC/min 
 Thermal properties of DPPC liposomes reduced size by probe-
sonication method 
As DSC is very sensitive and able to detect slight changes in bilayer properties, 
DPPC liposomes (40 mg/mL) before and after size reduction were studied by 
HSDSC with a scan rate of 0.5°C/min (Chiu and Prenner, 2011). For non-
sonicated DPPC liposomes, the values of thermal transitions such as a small broad 
pre-transition at 36 ºC and a sharp acyl chain melting transition at 41 ºC are in 
accordance with previous reports (Zhao et al., 2004; Wu et al., 2012; Hadian et al., 
2014).  
The pre-transition corresponds to a change in the orientation of the polar head 
groups of DPPC from a one-dimensional lamellar (Planar Gel Phase, Lβ’) to a 
two-dimensional monoclinic lattice (Rippled Gel Phase, Pβ’) (Taylor and Morris, 
1995; Beni et al., 2006; Elhissi et al., 2006b). Probe sonication of DPPC 
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liposomes prepared by the thin-film hydration method, resulted in a decrease in 
the enthalpy of the pre-transition and main transition (p<0.05; Table 4-8). The 
pre-transition temperature significantly increased from 36.55ºC to 39.36 ºC for 
sonicated liposomes (p<0.05) as shown in Table 4-8, implying decreased mobility 
in the head group region of DPPC (Beni et al., 2006).  
Table 4-8 Thermal properties of sonicated and unsonicated DPPC liposomes (n=3, 
mean± S.D.) 
Preparation 
method 
Pre-transition  Main transition 
1T pre 
(ºC) 
2ΔΗ 
(KJ/mol) 
 
3Tonset 
(ºC) 
4Tm (ºC) 
5HHW 
(ºC) 
ΔΗ 
(KJ/mol) 
 
Sonicated 39.36± 
0.29 
2.29± 
0.66 
41.36± 
0.09 
42.74± 
0.28 
1.68± 
0.16 
37.35± 
3.05 
Non-
sonicated 
36.55± 
0.51 
3.15± 
1.28 
41.54± 
0.00 
42.72± 
0.27 
1.62± 
0.03 
43.88± 
0.89 
1= The temperature of the pre-transition 
2= Enthalpy 
3= The onset temperature  
4= The main temperature of the main transition 
5= Half-height width 
 
The onset temperature of the main transition (T0) and the temperature at the peak 
(Tm), are commonly used to express the main lipid phase transition temperature 
(Tc) when carbon-carbon single bonds change from the gel phase (all-trans 
hydrocarbon chain configuration) to liquid-crystalline phase (some acyl chains 
present in the gauche (kinked) conformation) (Taylor and Morris, 1995; Elhissi et 
al., 2006b). In this study, T0 significantly decreased for sonicated liposomes  
(p<0.05). Furthermore, the enthalpy values (main transition endotherm) 
significantly decreased for both pre- and main transition when the size of DPPC 
liposomes was reduced (p<0.05), suggesting the modifications to the ordered lipid 
structure of the DPPC bilayers. These observations are in agreement with 
previous reports for sonicated vesicles, indicating packing differences within the 
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hydrocarbon chains between the two preparations (Chiu and Prenner, 2011; 
Hadian et al., 2014).  
The width at half-peak (HHW) of the main transition indicates the hydrophobic-
hydrophobic interactions within hydrocarbon hydrophobic regions during the 
transition. The increase in HHW of the main transition represents a reduction in 
the packing order within the lipid chains, or an increase in the bilayer fluidity, 
leading to a decrease in the overall transition cooperativity (Budai et al., 2003; 
Saunders et al., 2007). HHW values for liposomes before and after sonication 
were similar (p>0.05), indicating no measurable impact on the co-operative 
movement of the rigid hydrocarbon chains. 
Overall, liposomes reduced in size by probe-sonication showed some changes in 
the enthalpies of transition and the melting of the hydrocarbon chains. The data 
suggest that changes in thermal parameters result from the smaller radius of the 
sonicated liposomes and disrupted packing of the bilayers, given the highly 
curved membrane surface of the small sonicated liposomes. Changes in the 
intermolecular distance between carbon-carbon bonds may affect adjacent 
molecules, resulting in a reduction in main phase transition (Taylor and Morris, 
1995; Beni et al., 2006). 
 Thermal properties of sonicated DPPC liposomes containing 
different concentrations of erlotinib 
DSC thermograms of erotinib-loaded DPPC liposomes at various drug contents 
(2.5%, 5% and 10% w/w drug in lipid) and empty DPPC liposomes are shown in 
Figure 4-20, with calculated parameters in Table 4-9. Two thermal events; the 
pre-transition and main phase transition were measured for empty DPPC 
liposomes, at 39.36 ºC and 42.74 ºC, respectively. With 2.5% w/w erlotinib, 
thermograms still showed the pre-transition peak of DPPC liposomes at 39.21 ºC, 
whereas this transition disappeared at high contents of erlotinib. Since the pre-
transition is particularly sensitive when additives are included, the loss of this 
peak cannot be attributed to any specific molecular changes (Budai et al., 2003; 
Elhissi et al., 2006b; Zhao et al., 2007). The disappearance of this peak at 
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concentrations higher than 2.5% implies the presence of erlotinib in the 
phospholipid head group interfacial region. This observation was previously 
reported for DPPC liposomes after incorporating hydrophobic and amphiphilic 
materials  (Zhao et al., 2004; Elhissi et al., 2006b). 
 
Figure 4-20 DSC thermograms of a) 10%, b) 5%, c) 2.5% erlotinib-incorporated into 
DPPC liposomes and d) DPPC liposomes 
There was no significant change in Tc for all loadings of erotinib compared with 
DPPC liposomes (Table 4-9, p>0.05). The inclusion of erlotinib for the three 
concentrations investigated did not cause a change in enthalpy (p>0.05), 
indicating no significant impact on the main phase transition. The inclusion of 
2.5%, 5% and 10% w/w erlotinib significantly increased the HHW values of 
DPPC liposomes (p<0.05), suggesting a reduction in the overall transition 
cooperativity, though there was no difference in HHW between the concentrations. 
This parameter can be used to estimate the maximum level of drug incorporation 
by either the concentration above which phase separation occurs, or at which no 
further changes in the main phase transition (Elhissi et al., 2006b). This data was 
not sufficient to define the precisely maximum erlotinib incorporation; 
concentrations lower than 2.5% w/w require further studies. Increasing the 
amount of erlotinib to 10% gave the lowest enthalpy (p<0.05), possibly due to 
phase separation and/or generation of an unstable formulation. Based on these 
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DSC results, it seems that erlotinib may be located in the upper region of 
hydrocarbon chains in the bilayer, close to the polar head groups (Beni et al., 
2006). 
 
Chapter 4 Liposomes loaded with erlotinib and genistein 
 190 
Table 4-9 Thermal properties of erlotinib-loaded DPPC liposomes at concentrations between 2.5% and 10% w/w drug in total lipid (n=3, mean± S.D.) 
Erlotinib content 
(%w/w) 
Pre-transition 
temperature (ºC) 
Main transition    
 Tpre ( ºC) Tonset ( ºC) Tm (ºC) HHW (ºC)  ∆H 
(KJ/mol) 
%EE Mean particle 
size (nm) 
PDI 
DPPC 39.36± 0.29 41.36± 0.09 42.74± 0.28 1.68± 0.16 37.35± 3.06 - 109.05± 7.50 0.36± 
0.03 
2.5% 39.21± 0.28 41.50± 0.11 42.73± 0.27 2.26± 0.11 39.30± 1.50 32.53± 6.05 106.37± 1.84 0.25± 
0.02 
5% - 41.43± 0.21 42.54± 0.01 2.27± 0.18 36.73± 2.61 13.20± 5.53 99.68± 2.18 0.22± 
0.01 
10% - 41.25± 0.13 42.54± 0.01 2.39± 0.05 28.29± 2.06 2.23± 2.58 122.13± 
15.35 
0.37± 
0.23 
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There were no differences in mean size or size distribution for all vesicles 
containing erlotinib compared with empty DPPC liposomes. However, 2.5%w/w 
showed a significantly higher drug entrapment efficiency compared to other 
contents (p<0.05).  
Overall, it seems that erlotinib loaded in liposome bilayers may be predominantly 
located in the more polar region of the bilayer between C1 and C8 of the acyl 
chains with low interaction with the hydrocarbon chains of DPPC bilayer, and 
thus having a relatively minor effect on the main phase transition. 
 Thermal properties of sonicated DPPC liposomes containing 
different concentrations of genistein 
No pre-transition peak was observed in the presence of genistein at any of 
concentrations investigated (Figure 4-21), suggesting the location of genistein 
near the polar head group region of DPPC bilayer. The Tc shifted to a lower 
temperature (p<0.05) and the main transition of the DPPC (HHW) was 
significantly broadened (p<0.05) for 2.5% w/w genistein-loaded DPPC liposomes. 
A decrease in the main phase transition temperature suggests incorporation of 
genistein into the hydrophobic hydrocarbon region of the DPPC bilayer, leading 
to an increased fluidity with a greater rotational freedom of phospholipid 
hydrocarbon chains. A broadening of the main phase transition (HHW) also 
indicates an increase in the fluidity of the liposome bilayer with a reduction in the 
order of packing within the chains. The presence of genistein may lead to changes 
in the phospholipid packing by steric restrictions, related to its structure 
comprising multiple benzene rings. As a consequence, the bilayer structure was 
disrupted and the membrane fluidity was increased, though the enthalpy was 
similar to that of DPPC bilayers (p>0.05). Increasing the content of genistein 
higher than 2.5% did not result in any further disruption to the DPPC bilayers, 
suggesting the highest drug incorporation had been established in the DPPC 
bilayer, as previously reported for paclitaxel (Zhao et al., 2007).  
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Figure 4-21 DSC thermograms of a) 10%, b) 5% and c) 2.5% genistein-loaded DPPC 
liposomes 
Table 4-10 shows that the mean hydrodynamic diameter increased when genistein 
was incorporated into DPPC vesicles (p<0.05), suggesting that physically-
encapsulated genistein could expand the space within the DPPC bilayer. However, 
there were no differences in particle size and size distribution between the three 
genistein formulations. A content of 2.5% w/w gave the highest genistein 
encapsulation efficiency (p<0.05) and this may explain why particle size and size 
distribution of formulations loading at higher contents of genistein were similar 
(p>0.05) to that at 2.5% w/w.  
These DSC results suggest that the maximum drug incorporation into DPPC 
liposomes was 2.5% w/w. Furthermore, genistein is likely localised within 
hydrophobic interior of the lipid membrane and close to the polar head groups of 
DPPC since it significantly decreased the peak melting temperature of DPPC and 
the size of co-operative unit within bilayer and eliminated the pre-transition phase 
of DPPC vesicles. 
a) 
 
b) 
 
c) 
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Table 4-10 Thermal properties of genistein-loaded DPPC liposomes at concentrations between 2.5% and 10% w/w drug in total lipid (n=3, mean± S.D.) 
Genistein-
content (%w/w) 
Pre-transition 
(ºC) 
Main transition    
 Tpre ( ºC) Tonset ( ºC) Tm (ºC) HHW (ºC) ∆H 
(KJ/mol) 
%EE Mean particle 
size (nm) 
PDI 
DPPC 39.36± 0.29 41.36± 0.09 42.74± 0.28 1.68± 0.16 37.35± 3.06 - 109.05± 7.50 0.36± 
0.03 
2.5% - 39.81± 0.34 41.63± 0.22 2.29± 0.11 40.53± 1.01 84.66± 2.70 139.03± 
11.70 
0.43± 
0.02 
5% - 41.10± 0.22 42.34± 0.28 1.86± 0.08 41.68± 1.58 58.54± 8.06 158.17± 7.27 0.43± 
0.05 
10% - 40.67± 0.18 41.83± 0.27 1.88± 0.04 40.30± 1.28 24.05± 3.92 146.03± 
16.49 
0.51± 
0.04 
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 Thermal properties of DPPC liposomes containing co-loaded 
erlotinib and genistein of different concentrations 
No pre-transition peak was observed for formulations co-loaded with erlotinib and 
genistein investigated (2.5% and 5% of each), which may be attributed 
particularly to the inclusion of genistein (Figure 4-22). The onset and peak 
temperature of the main transition for 2.5% w/w co-loaded liposomes 
significantly decreased (p<0.05) compared with empty DPPC liposomes. A 
significant increase in HHW (p<0.05) was detected for the lower concentration of 
drugs. These suggest an increased fluidity of the DPPC bilayer with a reduction in 
the overall transition cooperativity. However, both concentrations of co-loaded 
DPPC liposomes had the same enthalpy for the main transition as DPPC (p>0.05). 
Including erlotinib and genistein beyond 2.5% w/w did not show any further 
changes in the main phase transition of DPPC vesicles, suggesting 2.5% w/w 
erlotinib and 2.5% w/w genistein were the maximum drug incorporations into the 
DPPC bilayer.  
 
Figure 4-22 DSC thermograms of a) 5% erlotinib and 5% genistein and b) 2.5% 
erlotinib and 2.5% genistein co-loaded DPPC liposomes and c) DPPC liposomes 
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Loading drugs into DPPC liposomes increased their mean hydrodynamic diameter 
(p<0.05, Table 4-11); however, the mean size and size distribution of both co-
loaded formulations were similar. These observations can be explained as for 
genistein-loaded DPPC formulations (Section 4.5.5.4). When considering drug 
entrapment, 2.5% of each drug showed greatest encapsulation efficiencies. These 
results suggest that 2.5% w/w each drug co-incorporated into DPPC was the 
maximum drug incorporation in the DPPC bilayer. 
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Table 4-11 Effect of erlotinib and genistein content (2.5% and 5% w/w each drug) on the thermal properties of co-loaded DPPC liposomes (n=3, mean± S.D.) 
Combined drug 
content (%w/w) 
Pre-transition 
(ºC) 
Main transition    
 Tpre ( ºC) Tonset( ºC) Tm (ºC) HHW (ºC) ∆H (KJ/mol) %EE Mean 
particle size 
(nm) 
PDI 
DPPC 39.36± 0.29 41.36± 0.09 42.74± 
0.28 
1.68± 0.16 37.35± 3.06 - 109.05± 7.50 0.36± 
0.03 
2.5%/ 2.5% - 39.42± 0.14 41.34± 
0.28 
2.40± 0.07 40.02± 0.69 14.65± 
3.42 (Erlo) 
90.03± 
10.99 
(Gen) 
159.22± 
19.42 
0.44± 
0.09 
5%/ 5% - 41.10± 0.20 42.04± 
0.00 
1.86± 0.05 42.74± 1.58 7.02± 1.13 
(Erlo) 
71.48± 
9.03 (Gen) 
200.07± 
45.81 
0.50± 
0.12 
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When the thermograms of DPPC liposomes containing erlotinib, genistein and co-
loaded (2.5% each drug) were compared, the shape of the DSC curve and phase 
transition behaviour for genistein and co-loaded formulations were similar (Figure 
4-23), suggesting that the inclusion of genistein had the more pronounced effect 
on the thermal properties of co-loaded liposomes. 
 
Figure 4-23 DSC thermogram of a) 2.5% erlotinib and 2.5% genistein co-loaded 
DPPC liposomes, b) 2.5% genistein-loaded DPPC liposomes, c) 2.5% erlotinib-
loaded DPPC liposomes and d) DPPC liposomes 
The mean hydrodynamic diameter and size distribution for genistein and co-
loaded liposomes (2.5% w/w of each drug) were similar (p>0.05, Table 4-12). 
The encapsulation efficiencies of genistein in individual and co-incorporated 
formulations were very similar (p>0.05), whereas drug entrapment decreased 
approximately two- fold for erlotinib in combined liposomes, from approximately 
33% to 15% EE (p<0.05). 
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Table 4-12 Effect of genistein and erlotinib alone or co-loaded at 2.5% w/w drug in lipid on the thermal properties of DPPC liposomes (n=3, mean± S.D.) 
Drug-to-DPPC ratio 
(%w/w) 
Pre-transition 
(ºC) 
Main transition    
 Tpre ( ºC) Tonset( ºC) Tm (ºC) HHW (ºC) ∆H (KJ/mol) %EE Mean 
particle size 
(nm) 
PDI 
2.5% Erlotinib 39.21± 0.28 41.50± 0.11 42.70± 
0.26 
2.27± 0.10 39.30± 1.50 32.53± 
6.05 
106.37± 1.84 0.25± 
0.02 
2.5% Genistein - 39.81± 0.34 41.63± 
0.22 
2.29± 0.11 40.53± 1.01 84.66± 
2.70  
139.03± 
11.70 
0.43± 
0.02 
2.5% Co-loaded - 39.42± 0.14 41.34± 
0.28 
2.40± 0.07 40.02± 0.69 14.65± 
3.41 (Erlo) 
90.03± 
10.99 
(Gen) 
159.22± 
19.42 
0.44± 
0.09 
 
Chapter 4 Liposomes loaded with erlotinib and genistein 
 199 
Due to the earlier findings that suggested genistein was localised both in the 
hydrophobic hydrocarbon chains of lipid bilayer and adjacent to the water-lipid 
interface (Section 4.5.5.4), this may limit penetration of erlotinib into the acyl 
chain region of the bilayer and/or the available polar head groups of DPPC. When 
the molecular structures of the two drugs are compared, the three –OH groups on 
the aromatic rings of genistein are easily protonated and will form a stronger ionic 
bonding with the amine and/or phosphate group of DPPC molecules, whereas the 
three nitrogen atoms and oxygen atom from quinazolinamine ring and 
methoxyethoxy chains of erlotinib will have weaker ionic interaction with the 
polar region of the phospholipids. These suggest the exclusion of erlotinib by the 
others. 
 Thermal properties of DPPC liposomes containing cholesterol and 
DOPE 
No pre-transition phase was observed for DPPC liposomes containing cholesterol 
and/or DOPE, implying the presence of these molecules at the interfacial region. 
The phase transition temperature shifted to lower values when 8 mol% cholesterol, 
20 mol% DOPE and 8 mol% cholesterol + 20 mol% DOPE were incorporated 
into DPPC liposomes (Figure 4-24), indicating greater freedom rotation of 
hydrocarbon chains within bilayer. The enthalpy decreased significantly and the 
main phase transition noticeably broadened (HHW) as reported in Table 4-13. 
This suggests that these molecules were inserted into the hydrophobic region of 
the DPPC bilayer. As cholesterol contains a tricyclic ring, hydrocarbon chains and 
hydroxyl group, the tricyclic ring was localised between the first few carbons of 
the fatty acyl chains into the hydrophobic core of DPPC bilayer and the 
hydrocarbon chains aligned parallel to acyl chains of DPPC phospholipid bilayer, 
while, its hydroxyl group orients towards the polar interface (Taylor and Morris, 
1995; Bhattacharya and Haldar, 2000; Monteiro et al., 2014). For DOPE, this 
molecule comprises two longer hydrocarbon chains as compared to cholesterol. 
DOPE acyl chains (18-C) would be expected to align across the acyl chains of 
DPPC bilayer, while its phosphatidyl ethanolamine head group would orient 
towards the aqueous phase. Consequently, the inclusion of 20 mol% of DOPE 
seems have more pronounced effect on hydrophobic hydrocarbon chains of DPPC 
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bilayer than 8 mol% cholesterol, due to stronger hydrophobic-hydrophobic 
interaction associated with their structures. 
 
Figure 4-24 DSC thermogram of a) DPPC, b) DPPC with 8% cholesterol, c) DPPC 
with 20% DOPE and d) DPPC with 8% cholesterol and 20% DOPE 
Table 4-13 Thermal properties of DPPC liposomes in the presence of cholesterol, DOPE, 
and cholesterol with DOPE (n=3, mean± S.D.) 
Formulations 
Pre-
transition 
(ºC) 
Main transition 
Tpre (ºC) Tonset (ºC) Tm (ºC) HHW 
(ºC) 
∆H 
(KJ/mol) 
DPPC 39.36± 
0.29 
41.36± 
0.09 
42.74± 
0.28 
1.68± 
0.16 
37.35± 
3.06 
DPPC + 8% 
cholesterol 
- 40.29± 
0.23 
42.54± 
0.00 
2.83± 
0.35 
27.93± 
1.21 
DPPC + 20% 
DOPE 
- 28.63± 
0.11 
36.54± 
0.00 
8.09± 
0.09 
18.86± 
0.62 
DPPC + 8% 
cholesterol + 
20% DOPE 
- 26.48± 
0.45 
36.37± 
0.58 
10.87± 
0.24 
12.14± 
1.42 
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 Thermal properties of erlotinib-incorporated into DPPC liposomes 
with and without genistein, cholesterol and DOPE 
A decrease in the main transition temperature and enthalpy was observed (Figure 
4-25), while DSC endotherm broadened in the presence of genistein (2.5% 
erlotinib and 2.5% genistein co-loaded DPPC liposomes), 8 mol% cholesterol+ 20 
mol% DOPE (2.5% erlotinib formulation) and genistein+ 8 mol% cholesterol+ 20 
mol% DOPE  (2.5% erlotinib and 2.5% genistein co-loaded formulation) within 
DPPC bilayer. These observations indicated modifications in the ordered lipid 
structure of the DPPC bilayer, which can result in the greater thermotropic 
changes in main transition phase. As the pre-transition phase was eliminated, 
these findings supported the molecular interactions of exogenous compounds with 
the DPPC head group. All combined results suggested that the inclusion of 
biomolecules into liposomes was located within hydrophobic hydrocarbon chains 
of the bilayer and/or adjacent to the interface of liposomes.  
 
Figure 4-25 DSC thermograms of a) 2.5% erlotinib-loaded DPPC liposomes, b) 2.5% 
erlotinib and 2.5% genistein co-loaded DPPC liposomes, c) 2.5% erlotinib-loaded 
DPPC/cholesterol/DOPE liposomes and d) 2.5% erlotinib and 2.5% genistein co-
loaded DPPC/cholesterol/DOPE liposomes 
The mean particle size and polydispersity index increased for 2.5% erlotinib-
loaded DPPC/cholesterol/DOPE liposomes, 2.5% erlotinib and 2.5% genistein co-
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loaded DPPC liposomes, and 2.5% erotinib and 2.5% genistein co-loaded 
DPPC/cholesterol/DOPE liposomes as compared to 2.5% w/w erlotinib-loaded 
DPPC liposomes (Table 4-14), supporting the incorporation of these biomolecules 
into bilayer. The entrapment efficiency of erlotinib in DPPC formulations 
significantly decreased when cholesterol and DOPE were included (p<0.05). As 
cholesterol and DOPE were expected to orient parallel acyl chains of DPPC 
bilayer and towards the interfacial region, this may lead to a reduced space within 
the bilayer to accommodate erlotinib. Also, the addition of only genistein (2.5% 
erlotinib and 2.5% genistein co-loaded DPPC liposomes) decreased the 
encapsulation efficiency of erlotinib as that of cholesterol and DOPE.  
By contrast, erlotinib incorporation noticeably increased when genistein, 
cholesterol and DOPE were included together (p<0.05). This observation suggests 
that genistein in the presence of cholesterol and DOPE had the greatest impact on 
bilayer properties in a fluid state (T>Tm), resulting in more mobile and flexible 
structure of acyl chains.  This fluid state of lipid membrane appears to have 
allowed incorporation of erlotinib within bilayer to a greater extent during the 
formation of liposomes. 
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Table 4-14 Characteristics of erlotinib liposomal formulations at 2.5% w/w drug in total 
lipids (n=3, mean± S.D.) 
Erlotinib in different 
formulations (2.5% w/w 
drug in lipids) 
Encapsulation 
Efficiency (% 
EE) 
Mean particle 
size (nm) 
PDI 
Erlotinib-loaded DPPC 
liposomes 
32.53± 6.05 106.37± 1.84 0.25± 0.02 
Erlotinib-loaded 
DPPC+cholesterol+DOPE 
liposomes 
14.20± 5.44 150.77± 37.28 0.36± 0.08 
Erlotinib and genistein 
co-loaded DPPC 
liposomes 
14.65± 3.42 159.22± 19.42 0.44± 0.09 
Erlotinib and genistein 
co-loaded 
DPPC+cholesterol+ 
DOPE liposomes 
23.16± 2.08 128.00± 13.70 0.44± 0.05 
 
 Thermal properties of genistein-incorporated into DPPC liposomes 
with and without erlotinib, cholesterol and DOPE 
For genistein, the trends in DSC endotherm were similar to those with erlotinib 
incorporation in DPPC/cholesterol/DOPE liposomes (Figure 4-26).  
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Figure 4-26 DSC thermograms of a) 2.5% genistein-loaded DPPC liposomes, b) 2.5% 
genistein and 2.5% erlotinib co-loaded DPPC liposomes, c) 2.5% genistein-loaded 
DPPC/cholesterol/DOPE liposomes and d) 2.5% genistein and 2.5% erlotinib co-
loaded DPPC/cholesterol/DOPE liposomes 
There was no significant difference in mean size, polydispersity index and 
encapsulation efficiency for all formulations shown in Table 4-15 (p>0.05). 
Encapsulation efficiency of genistein was similar for 2.5% genistein-loaded 
DPPC liposomes, 2.5% genistein-loaded DPPC/cholesterol/DOPE liposomes and 
2.5% genistein and 2.5% erlotinib-loaded DPPC liposomes (p>0.05). However, 
genistein entrapment showed the highest value when erlotinib, cholesterol and 
DOPE were included. 
 
.  
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Table 4-15 Characteristics of genistein-loaded liposomal formulations at 2.5% w/w 
drug in total lipids (n=3, mean± S.D.) 
Genistein in different 
formulations (2.5% w/w 
drug in lipids) 
Encapsulation 
Efficiency (% 
EE) 
Particle size 
(nm) 
Polydispersity 
Index (PDI) 
Genistein-loaded DPPC 
liposomes 
84.66± 2.70 139.03± 11.70 0.43± 0.02 
Genistein-loaded 
DPPC+cholesterol+DOPE 
liposomes 
83.78± 4.62 136.87± 13.19 0.45± 0.09 
Erlotinib and genistein 
co-loaded DPPC 
liposomes 
90.03± 10.99 159.22± 19.42 0.44± 0.09 
Erlotinib and genistein 
co-loaded 
DPPC+cholesterol+ 
DOPE liposomes 
101.58± 12.72 128.00± 13.70 0.44± 0.05 
 
Thus, the DSC results suggest that the co-incorporation of erlotinib and genistein 
into DPPC bilayer disrupted the packing order of the acyl chain region and 
increased the bilayer fluidity resulting in changes in the main phase transition (Tm, 
HHW and ∆H). Also, cholesterol and DOPE were incorporated within 
hydrophobic hydrocarbon chains of DPPC bilayer and the polar regions of both 
molecules was oriented towards the water phase based on their structures. The 
properties of lipids in liposomes in terms of their Tm   is a crucial parameter to 
consider for pre-formulation studies of these delivery systems. Tm for the 
optimised formulation was approximately body temperature and this can ensure 
that drug would not escape or leak out from bilayer before reaching the target site 
under physiological conditions (T ≈37ºC).  
All the combined data confirm the successful co-incorporation of erlotinib and 
genistein into DPPC /cholesterol/DOPE liposomes up to approximately 10% for 
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erlotinib and 100% for genistein. This developed formulation would be 
advantageous for further formulation development since excipients quantities are 
less than for two individual formulations. Consequently, DPPC/cholesterol/DOPE 
co-loaded liposomes with erlotinib and genistein were considered for further 
investigations in the following chapter. 
 Conclusion 
DPPC liposomes containing either erlotinib or genistein and in combination (2.5-
10% w/w) were successfully prepared by thin-film hydration and size reduced by 
probe-sonication. A validated HPLC analysis for the co-quantification of this 
combination was achieved following ICH guideline. The HPLC results showed 
that the maximum incorporation of individual and co-loaded drugs in DPPC 
liposomes was 2.5% w/w.  
DSC proved a valuable tool for understanding the interaction between formulation 
components in the liposome bilayers. The DSC thermograms of the drug-loaded 
liposomes showed changes in the main phase transition peak width, main 
transition and onset temperature, and the disappearance of the pre-transition peak 
compared to the empty liposomes. This suggests that both drug molecules were 
located close to the upper regions of the hydrophobic chains and polar head group 
of DPPC bilayers. Incorporation of 2.5% w/w drug individually and co-loaded 
into the liposomes resulted in higher HHW values and a decrease in phospholipid 
phase transition temperature. This suggests that the fluidity of bilayer was 
increased, caused by the reduced order of packing of phospholipid molecules in 
the presence of both drugs individually and in combination. Furthermore, 
genistein in the presence of cholesterol and DOPE have pronounced effects on 
bilayer fluidity and subsequently enhanced drug entrapment for erlotinib. 
Multichannel differential scanning calorimetry (MCDSC) was able to provide 
information for a better understanding of the molecular interactions between drugs 
and lipids within the phospholipid bilayer membrane. This analysis also helps to 
determine maximum drug incorporation for designing and optimising liposomal 
formulations.  
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 Introduction  
For delivery of liposomes, air-jet and vibrating-mesh nebulisers are considered 
more effective than ultrasonic devices, causing less disruption of the liposomal 
bilayers. (Elhissi et al., 2012; Elhissi et al., 2013). Air-jet nebulisers may result in 
significant leakage of entrapped hydrophilic drug from liposomes because of the 
shearing forces within the nebuliser, though drug losses can be reduced by 
incorporating cholesterol to make fluid-state bilayers more rigid, and by reducing 
the size of the liposomes being aerosolised (Bridges and Taylor, 2000; Cipolla et 
al., 2013; Lehofer et al., 2014). There are only minor losses of lipophilic drugs 
since hydrophobic materials remain incorporated within the liposome bilayer 
during air-jet nebulisation (Elhissi et al., 2011a; Cipolla et al., 2013; Elhissi et al., 
2013). Vibrating-mesh nebulisers have been reported to minimise hydrophilic 
drug loss from liposomes compared to other nebulisers, and thus have been 
proposed as particularly suitable devices for liposome delivery (Elhissi et al., 
2006a; Elhissi et al., 2012; Elhissi et al., 2013). 
As outlined in Chapter 1, the Andersen Cascade Impactor (ACI), the Next 
Generation Impactor (NGI) and the Multistage liquid impinger (MSLI) are full 
cascade impactors comprising a series of stages that fractionate aerosolised 
sample based on the aerodynamic size distribution of aerosols delivered by 
pMDIs and DPIs, though only the NGI is routinely used for the determination of 
the aerosol properties of nebulised aerosols. However, low dose formulations 
including formulations with potent drugs are challenging for analytical 
quantification due to the small amounts of drug deposited across the eight stages 
of the NGI. 
It has been proposed that the measurement of coarse and fine particle fractions 
obtained with an abbreviated impactor may be useful to describe the behaviour of 
aerosolised products, supplementing data from a full cascade impactor. 
Abbreviated Impactor Measurement (AIM) using an impactor with only 2 or 3 
stages representing coarse and fine particle doses/fractions, has been proposed for 
routine quality control as well as for product development applications of orally 
inhaled products. However, removal of the stages may possibly affect the whole 
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particle size distribution of an aerosol cloud due to particle losses to internal 
surface of an abbreviated impactor (Mitchell et al., 2009a).  
Three abbreviated impactors have been described (Figure 5-1); namely the Fast 
Screening Andersen (FSA), Reduced Next Generation Impactor (rNGI) and the 
Fast Screening Impactor (FSI).  
 
Figure 5-1 Commercially available abbreviated impactors 
 
Of the three abbreviated impactors, the Fast Screening Impactor (FSI; Figure 1-
15), which has been developed by Copley Instrument as a simple and labour-
saving approach for the in-vitro characterisation of FPD/FPF for pMDIs and DPIs, 
was investigated with nebulisers in this study, for two main reasons. Firstly, the 
FSI has only two collecting stages with the cut-off diameter of 5 µm between 
upper and lower stages, and there was no modification of the internal surfaces of 
the impactor as required for the rNGI.  However, the use of the FSI for aerosol 
characterisation has not been investigated widely and no abbreviated impactors 
are currently included in the European, United States or Japanese Pharmacopoeias.  
 Aims 
1. To investigate the FSI as an alternative impactor to the NGI for aerosol 
characterisation of nebulised liposomes co-loaded with erlotinib and genistein 
using the same operating conditions.  
Fast-Screening Andersen 
(C-FSA): A three-stage 
abbreviated system 
 
Fast-Screening Impactor 
(FSI): A two-stage system 
 
Reduced Next Generation 
Impactor (rNGI):  
Ø The filter-only 
configuration (rNGI-f)  
Ø The modified-cup 
configuration (rNGI-mc) 
 
Abbreviated Impactors 
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2. To investigate the effects of the method for aerosolisation (nebuliser system, 
flow rates), impactor conditions (temperature) and properties of co-loaded 
liposomes (size reduction by either probe sonication or extrusion) on the 
aerosol properties determined using the FSI. 
 Materials  
The materials used in the preparation of erlotinib and genistein co-loaded 
liposomes and for the reversed-phase HPLC method allowing simultaneous 
determination of this drug combination are outlined in Section 4.3. 
 Methods 
 Assessment of aerosol properties using the Next Generation Impactor 
(NGI)  
 Effect of lipid concentrations on measured aerosol properties 
The aim of this study was to investigate the optimal drug and lipid concentrations 
to allow accurate quantification of low drug contents when characterising 
nebulised liposomes using a full cascade impactor. Liposomal preparations: 2.5% 
w/w erlotinib and 2.5% w/w genistein co-loaded into DPPC, cholesterol and 
DOPE (72:8:20 % mole ratio) liposomes, were prepared using the thin-film 
hydration method described in Section 4.4.2.1. In this study, drug and lipid 
concentrations were increased proportionately in comparison with the formulation 
described in chapter 4. The lipid concentration was increased from 2.5 mg/mL to 
20 mg/mL, while the drug: lipid ratio was maintained (2.5% w/w erlotinib and 
2.5% w/w genistein in lipids). To ensure that increased concentrations did not 
affect formulation properties, the following were determined: hydrodynamic 
diameter, surface charge and encapsulation efficiency (as described in Sections 
4.4.3.1, 4.4.3.2 and 4.4.3.4, respectively). 
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 Effect of nebuliser fill volume on measured aerosol properties 
After cooling the NGI at 5± 3 °C for at least 90 min, 2 mL or 4 mL of the final 
liposome formulation (lipid concentration = 20 mg/mL) was added into Pari LC® 
Sprint air-jet nebuliser and nebulisation conducted for 5 and 10 min, respectively 
at a flow rate of 15 L/min generated by a Pari TurboBoy compressor (Section 
3.4.6). The duration of aerosolisation was based on the time to nebulise to dryness 
this fill volume using water (Section 3.5.5). Deposited erlotinib and genistein 
were collected by rinsing with absolute ethanol including the nebuliser reservoir, 
induction port, NGI collection cups and back-up filter as outlined in Section 3.4.7 
and then assayed by the simultaneous HPLC method as described in Section 
4.4.1.1. 
 Optimal conditions for characterising nebulised liposomes using the 
NGI 
The Pari LC® Sprint air-jet and Pari Velox® vibrating-mesh nebulisers were 
filled with 4 mL of liposomal suspension (containing 1.0 mg/mL erlotinib and 10 
mg/mL genistein) which was nebulised into the NGI at an air flow rate of 15 
L/min for 10 min, after cooling the impactor for at least 90 min at 5± 3 ºC. All 
collected samples from the induction port and collection cups across the impactor 
were made up to 5 mL with ethanol, whereas the volume of absolute ethanol for 
rinsing the nebuliser reservoir was 10 mL, prior to simultaneous HPLC assay. 
Aerosolisation parameters included mass balance, emitted dose (ED), Fine 
Particle Dose (FPD) and Fine Particle Fraction (FPF) were calculated as 
mentioned in Chapter 3. 
 Assessment of aerosol properties using the Fast Screening Impactor 
(FSI) 
The Fast Screening Impactor (FSI; Copley Scientific, UK) was employed using 
the same operating conditions as for the NGI. The effect of air-flow rate, impactor 
temperatures and nebuliser types on aerosol properties were studied as outlined in 
Sections 5.4.2.1 to 5.4.2.3. Nebulisation of liposomes co-loaded with erlotinib and 
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genistein (4 mL) was conducted using an air-jet nebuliser into the cooled FSI, 
through the induction port, at a flow rate of 15 L/min for 10 min. After 
nebulisation, the FSI was dismantled and quantification of deposited drugs was 
determined by HPLC analysis from the nebuliser reservoir, mouthpiece, 
mouthpiece adapter, induction port, additional insert of the FSI housing and back-
up filter together with the filter holder using appropriate volumes of absolute 
ethanol. 10 mL of absolute ethanol was used for rinsing nebulised liposomes in 
the nebuliser reservoir and the additional insert of the FSI, whereas the induction 
port and a back-up filter with filter holder required 5 mL of solvent. Fine Particle 
Dose (FPD) and Fine Particle Fraction (FPF) for the FSI were calculated as 
follows: 
Fine Particle Dose (FPD) = Drug mass from lower stage of the FSI                                        
Fine Particle Fraction (FPF) = 
Mass of drug from stage 2
Mass of drug from stage 1 and stage 2
 ×  100 %                       Eq. 5-1 
 Effect of flow rates on measured aerosol properties 
The FSI contains an additional insert calibrated at 30 L/min to give a cut-off for 5 
µm aerodynamic diameter. This insert was modified by alternately covering three 
of the six nozzles using wet glass microfiber filter when a flow rate of 15 L/min 
was employed (personal communication; Copley Instrument) as shown in Figure 
5-2. A cut-off diameter of 5 µm is used for calculation of Fine Particle Fraction 
(FPF) and Fine Particle Dose (FPD) at this lower flow rate (Johal et al., 2013; 
Mohan et al., 2017). Each individual experiment was determined after the 
impactor was cooled at 5± 3°C for at least 90 min.  
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Figure 5-2 Modification of additional FSI insert utilised at flow rate of 15 L/min 
 Effect of impactor temperature on measured aerosol properties 
The FSI was initially used in accordance with the European pharmacopoeia 
requirements for the NGI, i.e. cooling at 5± 3 °C for at least 90 min. In additional 
studies, a non-cooled FSI (at ambient temperature; 20 °C) was also employed. 
Both impactor temperatures were studied with the FSI operated at flow rates of 15 
L/min and 30 L/min, and the aerosol properties of the nebulised liposomes were 
determined. 
 Effect of nebuliser system on measured aerosol properties 
Experiments were conducted with an air-jet and vibrating-mesh nebulisers 
(respectively; Pari LC® Sprint and Pari Velox®, PARI Medical Ltd, Byfleet, UK) 
generating aerosols which were directed into the induction port of the FSI using a 
mouthpiece adaptor. The FSI measurements were undertaken after cooling the 
impactor at 5± 3°C for at least 90 min, at flow rates of 15 L/min and 30 L/min. 
 Size stability of liposomes before and after nebulisation 
The aim of this experiment was to study the effects of nebulisation on the physical 
stability of liposomes. After nebulisation, nebulisers and FSI stages were rinsed 
with 1 mL of HPLC water for particle size analysis. The Z-average mean 
hydrodynamic diameter and Polydispersity Index (PDI) were measured in 
triplicate by dynamic light scattering (DLS) as described in Sections 4.4.4.1 for 
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liposomal formulations before and after nebulisation. The mean values and 
standard deviation are reported. 
 Transmission electron microscopy (TEM) of liposomes before and 
after nebulisation 
The morphology and aggregation behaviour of freshly prepared liposomal 
formulations, liposomes remaining in air-jet and vibrating-mesh nebuliser 
reservoirs and those deposited on each stage of the FSI were determined by TEM. 
Samples were negatively stained with a drop of uranyl acetate (1% w/v) and 
observed using a transmission electron microscope (Philips Electron Optics BV, 
Netherlands) as described in Section 3.4.4.4. 
 Size reduction of liposomes co-loaded with erlotinib and genistein 
using membrane extrusion method  
The MLVs were repeatedly extruded through a series of polycarbonate membrane 
filters of reducing pore sizes (Cyclopore®, Whatman, UK) using nitrogen gas. 
The dispersion was extruded through 3 µm and 1 µm polycarbonate membrane 
filters of 47 mm diameter held in a stainless-steel holder at 10 psi. Preparations 
were further extruded through a 100 nm pore filter at 120 psi (LiposoFast-LF50 
extruder, Avestin, Ottawa, Canada). During extrusion the temperature was 
maintained at least 10°C above the main phase transition temperature of the 
mixture of phospholipids (i.e. at 50 ºC) (Hadian et al., 2014). The particle size 
distribution of extruded liposomes was measured using laser diffraction size 
analysis (Mastersizer 3000 laser diffraction particle size analyzer, Malvern 
Instrument Ltd, UK). The data are presented as volume median diameter (VMD) 
for micrometre-sized vesicles.  
For nanometre-sized vesicles, dynamic light scattering (DLS) was employed and 
size expressed as Z-average hydrodynamic diameter and polydispersity index 
(PDI) as described in Section 4.4.4.1. A PDI < 0.1 is typically considered as 
representing a monodispersed system, < 0.3 is a relatively monodisperse system, 
while > 0.7 is classified as a polydispersed system (ISO-22412, 2008; Kannan et 
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al., 2015; Holmkvist et al., 2016). The pore size of membrane filters and number 
of extrusions were optimised to achieve a final mean particle size between 100 
and 200 nm, with PDI <0.3.  
The final formulation was also characterised for encapsulation efficiency (Section 
4.4.4.4) using Eq. 3-5 and Eq. 3-6 (Section 3.4.4.3). The aerosol properties of 
extruded liposomes were characterised using the FSI under the same operating 
conditions as those for sonicated formulations (Section 5.4.2). 
 Statistical analysis 
All experiments were carried out in triplicate and data are expressed as the mean  
standard deviation (SD). The data were statistically analyzed by either Student’s t-
test or analysis of variance (ANOVA) and Tukey’s post hoc test, using IBM SPSS 
Statistic 22 software. A p value of < 0.05 was considered significant.  
 Results and discussion 
 Effect of drug and lipid concentrations on liposome properties for 
nebulisation 
The final liposome preparation intended for nebuliser delivery was chosen based 
on optimal liposome size and high content of encapsulated erlotinib and genistein. 
Table 5-1 shows the characteristics of the 2.5% w/w erlotinib and 2.5% w/w 
genistein co-loaded liposomal formulation at different lipid concentrations. Drug 
and lipid concentrations (2.5% w/w each drug in total phospholipids) were 
increased in comparison with the optimised formulation (lipid concentration of 
2.5 mg/mL) to enhance drug content (Section 5.4.1.1). The 2.5% w/w erlotinib 
and 2.5% w/w genistein co-loaded liposomal formulation (50 mg of total lipid 
content in 20 mL of dispersion or lipid concentration of 2.5 mg/mL) for loading 
into nebuliser reservoir contained 0.25 mg of erlotinib and 1.25 mg of genistein, 
based on their encapsulation efficiencies. A fill volume of 4 mL contained 10 mg 
lipid (2.5 mg/mL) and 0.05 mg of erlotinib and 0.25 mg of genistein. 
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Increasing lipid concentration to 20 mg/mL did not affect the liposomal properties 
in terms of mean hydrodynamic diameter, polydispersity index, surface charge or 
encapsulation efficiency of genistein compared to the formulation having lipid 
concentration of 2.5 mg/mL (p>0.05). However, encapsulation efficiency of 
erlotinib significantly decreased (p<0.05), possibly due to changes in the bilayer. 
Genistein may adopt more tightly pack within DPPC bilayer than erlotinib 
(Chapter 4), therefore changes in a formation of lipid bilayer have a more 
pronounced effect on erlotinib entrapment.  
Consequently, a lipid concentration of 20 mg/mL was chosen for further studies 
since it gave higher contents of both drugs than the previously optimal 
formulation, having the same mean size.  
Table 5-1 Characterisation of liposomes co-loaded with 2.5% w/w erlotinib and 2.5% 
w/w genistein at different lipid concentrations (n=3, mean± S.D) 
Lipid 
concentration 
(mg/mL) 
Mean 
hydrodynamic 
diameter (nm) 
Polydispersity 
Index 
Zeta 
Potential 
(mV) 
Encapsulation 
Efficiency (%) 
2.5 (Section 
4.4.2.1) 
128.00± 13.70 0.44± 0.06 -3.23± 
0.05 
23.16± 2.08 
(Erlo) 
101.58± 12.72 
(Gen) 
20  139.30± 2.42 0.56± 0.03 0.27± 0.05 8.57± 1.06  
(Erlo) 
100.13± 1.15 
(Gen) 
 
In preliminary studies, 2 mL and 4 mL of the final formulation (lipid 
concentration = 20 mg/mL) as shown in Table 5-2 for nebulisation were nebulised 
for 5 and 10 min, respectively and drug deposited within the NGI assayed by 
HPLC. When a 2 mL fill volume was nebulised and characterised by the NGI, all 
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concentrations of both drugs were below the limit of quantification (LOQ). The 
genistein concentration was above the LOQ for the 4 mL fill volume, but erlotinib 
concentration was lower than the LOQ for all stages of the NGI. Consequently, 4 
mL of liposomal formulation was used in further studies based on full 
quantification of genistein. 4 mL was nebulised for 10 min into the NGI and then 
deposited erlotinib and genistein were recovered from the NGI by rinsing with 
absolute ethanol prior to quantification by HPLC analysis. 
Table 5-2 Content of erlotinib and genistein in co-loaded liposomes (lipid concentration 
20 mg/mL) 
Initial content of 
drug (2.5% w/w 
each drug in 400 
mg lipids in 20 
mL of 
preparation) 
Encapsulation 
efficiency 
(EE) 
Content of 
drug in 20 
mL of 
dispersion 
(mg) 
Content of 
drug in 4 
mL of 
dispersion 
(mg) 
Content of 
drug in 2 
mL of 
dispersion 
(mg) 
10 mg     
(Erlotinib) 
8.57± 1.06 0.86  0.17  0.08  
10 mg     
(Genistein) 
100.13± 1.15 10  2  1  
 
 Comparison of aerosol properties of liposomal preparations delivered 
by an air-jet nebuliser determined using the Next Generation 
Impactor (NGI) and Fast Screening Impactor (FSI)  
Erlotinib deposited on each of the eight impaction stages of the NGI could not be 
accurately quantified by the validated HPLC analysis as concentrations of 
solutions collected from some stages were below the limit of quantification 
(LOQ). The two-stage abbreviated impactor (FSI) was subsequently evaluated as 
an alternative to overcome this problem. Table 5-3 shows that the values of mass 
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balance for genistein with both the NGI and FSI were within European 
Pharmacopeia acceptance limits, being in the range of 75- 125%. There was no 
significant difference in emitted dose (%ED) (p>0.05) as determined using both 
impactors, being approximately 30%. These results are in agreement with 
previous reports of in vitro aerodynamic characterisation of the dose emitted using 
Pari LC®, where %ED was in the range 15-40% (Sahib et al., 2010; Zhang et al., 
2014c; Mashat et al., 2016). The aerosol parameters for nebulised erlotinib could 
not be calculated due to the inability to quantify accurately drug deposition on 
each stage of the NGI. The aerosol parameters for genistein could be accurately 
calculated using both impactors and therefore, the performance of the NGI and 
FSI is best compared based on full quantification of genistein. 
Table 5-3 Aerosol parameters of liposomal aerosols delivered from an air-jet 
nebuliser into the NGI and FSI determined by the quantification of genistein (n=3, 
mean ± S.D.) 
Aerosol 
parameters 
NGI FSI 
Mass balance 
(%)     
85.44± 1.49 82.91± 2.28 
ED1 (%) 34.42± 0.92 34.31± 5.86 
FPD2 (µg) 328.33± 36.17 224.24± 10.14 
FPF3 (%) 58.33± 4.51 42.55± 6.28 
                                                     
1 ED= Emitted dose 
2 FPD= Fine particle dose 
3 FPF= Fine particle fraction 
 
The concentration of drug substance in the nebuliser chamber may increase during 
aerosolisation as a result of water evaporation (Pritchard et al., 2018), whilst 
disruption of liposomal bilayers may cause accumulation of large liposomes 
and/or aggregation of the vesicles, as discussed in Section 5.5.3.4. In addition, 
lipid composition may affect output. For example, beclometasone dipropionate-
loaded liposomes prepared from lipids with a higher Tm (DPPC) gave lower drug 
outputs than those containing phospholipids with a lower Tm, possibly due to an 
increased rigidity of vesicles, resulting in greater resistance to delivery from 
nebulisers (Darwis and Kellaway, 2001; Sahib et al., 2010; Elhissi et al., 2011b). 
The remaining fluid in the reservoir represents drug wastage, which can be 
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proportionately reduced using a higher fill volume as well as by modifying 
nebuliser fluid properties. 
There were differences in the calculated values of Fine Particle Fraction (FPF) 
and Fine Particle Dose (FPD) using the two impactors (Table 5-3). Using the NGI, 
the FPF and FPD for genistein was significantly higher than that obtained with the 
FSI (p<0.05). Differences in FPF and FPD values for the NGI and FSI may result 
from differences in the internal volume of the full cascade impactor and 
abbreviated impactor system. For the NGI, there is a longer distance and transit 
time as the aerosol passes through the impactor compared to the FSI. This allows 
an increase in heat-transfer related water evaporation from the nebulised droplets, 
resulting in the droplets shrinking (Dennis et al., 2008; Kuhli et al., 2009). Further, 
a difference in the internal volume of these two impactors could affect aerosol 
generation at the earliest stage of the evaluation when the air-flow rate quickly 
increased from zero to the constant value of 15 L/min. Another possible cause for 
differences in values is the method used for calculating FPF/FPD with the two 
impactors. For the NGI, values are determined by the interpolation of the plot of 
cumulative fraction or cumulative mass of active drug collected in all stages of the 
impactor versus cut-off diameter, whilst for the FSI the dose and fraction less than 
5 µm are based on the mass of drug deposited on the lower stage of the impactor. 
Under the same operating conditions, the two impactors produced different but 
comparable values for the key parameter of aerosolisation (FPF and FPD) with 
the same value for emitted dose (ED). Overall, the FSI had great utility as a 
relatively rapid method for formulation development and evaluation of nebulised 
liposomal formulations, and overcame the analytical quantification problems 
associated with erlotinib when using the full impactor. 
As differences in tidal breathing patterns (tidal volumes and flow rates) between 
patients may affect the delivered dose of nebulised drug, the use of a breath 
simulator for in vitro aerosol analysis may be used with a cascade impactor. 
Recently, using cascade impactors with breathing simulators, the breathing profile 
of an adult; for example, tidal volume= 500 mL, 15 breaths per minute with the 
inhalation and exhalation ratio of 1:1 has been recommended for delivered dose 
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testing and evaluating nebuliser performance (Copley, 2014). In this study, the 
experiments were conducted without this additional step for characterising the 
nebulised liposomes in order to keep the process simple, and to follow the 
requirements of and EMA guidelines (EMA, 2006; Ph. Eur. 9.0, 2017). 
 Aerosol characterisation using the FSI; effect of impactor operating 
conditions and nebuliser system 
Several factors such as air-flow rate through the FSI, impactor temperature and 
nebuliser systems were investigated to determine their influence on the measured 
aerosol properties. 
 The influence of flow rate through the FSI on measured aerosol 
properties 
The additional insert (Stage 1) of the FSI calibrated at 30 L/min with six nozzles 
was used in these experiments. Additionally, a flow rate of 15 L/min, as 
recommended by the Ph. Eur. for the NGI was investigated, with three of the six 
nozzles covered with wet microglass filter as described in Section 5.4.2. When 
comparing the two impactor flow rates, FPF increased almost two-fold, from 
approximately 40% to 70% for both drugs when using a higher flow rate (30 
L/min; Figure 5-3). As seen in Table 5-4, the FPD for both drugs delivered by the 
air-jet nebuliser through the FSI was higher at a flow rate of 30 L/min. This is 
because the higher flow rate can entrain relatively warmer air, causing enhanced 
evaporation effect and consequently droplet shrinkage prior to deposition within 
the impactor, as described in the previous studies of the NGI and Anderson 
Cascade Impactor (ACI) (Abdelrahim, 2011; Lewis et al., 2016). A decreased 
droplet size may yield higher values for FPF and FPD as shown in this study. A 
different value of FPD was observed for the nebulised aerosol of genistein 
(p<0.05), but not erlotinib, which demonstrated larger variability at the higher 
flow rate (p>0.05).  
The explanation for the differences between these two drugs is unclear. A 
decrease in temperature of aerosol leaving the air-jet nebuliser (T < Tc of 
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liposomes) during aerosolisation may not affect disruption of liposomal bilayers, 
causing no impact on drug solubility and loss of entrapped hydrophobic drug, 
since liposomal bilayers are rigid and stable when the temperature is lower than 
their Tc (36.37°C). However, the content of erlotinib on the lower stage of the FSI 
was slightly higher than the LOQ of the HPLC assay, though these values were in 
the middle concentration range of calibration curve for genistein. Accordingly, 
this may explain the differences between erlotinib and genistein for FPD values. 
However, both drugs showed the same trend in FPD and FPF when increasing air 
flow rate through the FSI. 
 
Figure 5-3 Aerosol parameters of co-loaded MLVs aerosols generated using an air-
jet nebuliser measured using a cooled FSI at 15 and 30 L/min (n=3, mean ±S.D.). 
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Table 5-4 Fine particle dose for co-loaded liposomal aerosols delivered by the air-jet 
nebuliser operated at 15 L/min and 30 L/min, using the cooled FSI (n=3, mean ±S.D.) 
Type of nebulisers Air-flow rate (L/min) Fine Particle Dose (µg) 
Air-jet 
15 
18.02± 2.51            (Erlo) 
224.24± 10.14        (Gen) 
30 
25.93± 9.17           (Erlo) 
326.87± 37.91       (Gen) 
 Effect of impactor temperature on measured aerosol parameters 
The FSI was cooled at 5± 3ºC as this is recommended in the Ph. Eur. for the NGI. 
Experiments were also conducted with a non-cooled FSI (ambient temperature, 
20 °C). The FPF values of erlotinib and genistein were not significantly different 
(p>0.05) at the two temperatures at a flow rate of 15 L/min (Table 5-5), whereas 
the measured FPD was relatively higher for both drugs at ambient temperature. At 
the flow rate of 30 L/min, a decrease in FPF for genistein was evident (p<0.05) 
when ambient temperature was employed, while the value of FPD was similar 
(p>0.05; Table 5-5). The FPD (which is a function of FPF and emitted dose) of 
erlotinib was comparatively higher for those collected from the non-cooled FSI at 
30 L/min, while there was no significant difference in FPF as compared to the 
cooled FSI (p>0.05).  
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Table 5-5 Aerosol parameters for co-loaded liposomal aerosols delivered by the air-
jet nebuliser at different FSI temperatures and flow rates (n=3, mean ±S.D.) 
 
The data revealed that the impactor temperature had less effect on the 
performance of the FSI, than the NGI which needs cooling as recommended by 
the Ph. Eur in order to avoid evaporation-related bias and to reduce the variability 
in the data when compared to use at ambient temperature (Dennis et al., 2008). 
Cascade impactor temperature has previously shown effects on heat transfer and 
droplet evaporation, especially for aqueous droplets produced by nebulisers 
(Bonam et al., 2008). Due to the latent heat associated with evaporation resulting 
from energy absorption, the temperature of nebulised aerosol is relatively cooler 
than the surrounding air (approximately 10°C) (Dennis et al., 2008). The cooled 
aerosol comes into contact with the warmer metal of the interior surfaces of the 
NGI. In order to maintain the moisture saturation, further evaporation takes place 
from the droplets, resulting in reduced droplet sizes throughout the non-cooled 
NGI (Dennis et al., 2008). However, omission of cooling nebulisers, air-stream 
Initial 
Temperature 
of the FSI 
Air-flow 
rate (L/min) 
Emitted Dose 
(%) 
Fine Particle 
Fraction 
(%) 
Fine Particle 
Dose (µg) 
5± 3°C 15 30.52±2.84 
(Erlo) 
34.31±5.86 
(Gen) 
45.55±6.16 
(Erlo) 
42.55±6.28 
(Gen) 
18.02±2.51 
(Erlo) 
224.24±10.14 
(Gen) 
Ambient 
temperature 
15 53.23±4.37 
(Erlo) 
47.57±1.96 
(Gen) 
48.03±9.57 
(Erlo) 
42.97±10.50 
(Gen) 
38.19±2.76 
(Erlo) 
327.66±91.77 
(Gen) 
5± 3°C 30 26.92±4.17 
(Erlo) 
27.93±1.81 
(Gen) 
73.37±11.83 
(Erlo) 
73.17±6.10 
(Gen) 
25.93±9.17 
(Erlo) 
326.87±37.91 
(Gen) 
Ambient 
temperature 
30 60.88±7.82 
(Erlo) 
56.99±7.16 
(Gen) 
55.17±7.15 
(Erlo) 
50.17±6.44 
(Gen) 
48.44±10.44 
(Erlo) 
420.74±101.61 
(Gen) 
Chapter 5 Aerosol properties of liposomes loaded with erlotinib and genistein 
 224 
and the impactor at a fixed temperature would increase simplicity, be labour and 
time-saving for aerosol characterisation and beneficial for routine quality control. 
Artefactual reduction in droplet size arising from thermal transfer-related 
evaporation may be less significant with the FSI since the FSI flight path is 
comparatively shorter than the NGI, causing a lower thermal capacity through the 
internal volume of the FSI; both impactors are made of stainless steel. By contrast, 
a larger headspace in the FSI may allow enhanced water evaporation when 
drawing nebulised liposomes through the cooled FSI using ambient air, leading to 
the similar results for nebulisation parameters at the two impactor temperatures 
(non-cooled and cooled FSI).  
The magnitude of the trend to the finer droplets caused by heat transfer-related 
evaporation is dependent on nebuliser type. This is because surface area, 
concentration and size distribution of the droplets initially produced by inhaler 
devices have a significant impact on mass transfer from liquid to vapour state 
(Dennis et al., 2008). Consequently, further studies such as the use of different 
formulations having various physicochemical properties and other nebulisers are 
required. A vibrating-mesh nebuliser was subsequently investigated further to 
allow comparison with an air-jet nebuliser under the same operating conditions.  
 Aerosol properties of liposomal aerosols delivered from a vibrating-
mesh nebuliser 
The trends in measured aerosol properties of both drugs in the liposomal 
formulation delivered by air-jet and vibrating-mesh nebulisers were similar when 
determined using an FSI at two air-flow rates. Figure 5-4 shows the performance 
of a vibrating-mesh nebuliser for delivering liposomal aerosols at flow rates of 15 
L/min and 30 L/min for a 10 min nebulisation period. When increasing the flow 
rate through the FSI from 15 L/min to 30 L/min, the FPF for erlotinib and 
genistein increased from approximately 20% to 40%, with the same emitted dose 
(p>0.05). Furthermore, FPD was higher for both drugs at the higher flow rate 
(p<0.05; Table 5-6). Thus overall, increasing the flow rate through the impactor 
using both types of nebuliser (air-jet and vibrating-mesh) affected measured 
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aerosol parameters, likely resulting from a decrease in droplet sizes, due to 
evaporative losses as outlined in Section 5.5.3.1. 
 
Figure 5-4 Aerosol parameters of co-loaded liposomes aerosols generated using a 
vibrating-mesh nebuliser determined using a cooled FSI at 15 and 30 L/min (n=3, 
mean ±S.D.). 
Table 5-6 Fine particle dose for co-loaded liposomal aerosols delivered by a vibrating-
mesh nebuliser operated at 15 L/min and 30 L/min, determined using the cooled FSI (n=3, 
mean ±S.D.) 
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The air-jet nebuliser appears more appropriate for delivering liposomal aerosols 
than the vibrating-mesh nebuliser based on a two-fold higher FPF of both drugs at 
both flow rates (Figure 5-3 and Figure 5-4). The values of FPD, a critical 
parameter for medical aerosols reflected FPF, and were more similar for these two 
nebulisers. This was because the emitted dose was significantly higher with the 
vibrating-mesh nebuliser (p<0.05), in good agreement with previous studies (Lass 
et al., 2006; Pitance et al., 2010). For both flow rates, the air-jet nebuliser 
produced significantly higher FPD for genistein (p<0.05; Table 5-4 and Table 5-
6), while there were no differences in FPD for erlotinib delivered using the two 
devices (p>0.05).  
Previously, vibrating-mesh nebulisers have been reported to give higher aerosol 
mass and drug outputs compared to air-jet nebulisers (Ari, 2014). However, the 
air-jet devices appeared superior in this study, which may be specific for this 
particular liposomal formulation. The physicochemical properties of the 
formulation including viscosity and surface tension, particle size distribution and 
zeta potential of dispersed systems have an impact on nebuliser performance and 
aerosol characteristics, particularly for both active and passive vibrating-mesh 
nebulisers (Chan et al., 2011; Carvalho and McConville, 2016). The lower 
efficiency of the vibrating-mesh nebuliser for delivering this specific formulation 
may be due to the absence of an ionic component (particularly a halide) or 
surfactant in the formulation as reported for curcumin-loaded genistein-mPEG 
polymeric micelles (Chapter 3). The presence of ions is also crucial for providing 
an enhanced output rate and for less variable aerosol characteristics (Carvalho and 
McConville, 2016). Moreover, vibrating-mesh technology could possibly cause 
the generation of heat over a 10 min aerosolisation period, resulting in the 
aggregation/degradation of liposomes as reported for thermobile proteins (Hertel 
et al., 2014; Beck-Broichsitter and Oesterheld, 2017). 
An additional concern is that the mesh aperture could possibly be blocked because 
of inappropriate properties of the liposomal formulation, drug crystallisation or 
repeated use, causing a decrease in the diameter of mesh pore and consequently 
higher resistance to aerosol generation (Chan et al., 2011; Manunta et al., 2011; 
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Carvalho and McConville, 2016). As a result of clogging, significant variations in 
output rate and delivered dose can be problematic.  
To further investigate the implications of these findings, the physicochemical 
properties of fluids; for instance, viscosity and surface tension, along with the 
influence of fluid constituents including electrolytes/halides and surfactants in 
formulations during aerosolisation should be studied in the future in relation to the 
measured aerosol properties and nebuliser performance for liposomal aerosols. 
 Particle size distribution of liposomes before and after nebulisation 
The particle size distribution of nebulised vesicles on individual stages of the 
impactor and in both nebuliser reservoirs was determined to evaluate liposomal 
size during aerosolisation. Table 5-7 shows the measured particle size of 
aerosolised liposomes delivered by air-jet and vibrating-mesh nebulisers. The 
mean size of sonicated liposomes remaining in the air-jet reservoir and on the 
additional insert (upper stage of the FSI) was approximately three-fold larger than 
the initial size (p<0.05), indicating liposome disruption, aggregation and/or fusion 
and consequent changes in the vesicle size (Manca et al., 2012). The PDI 
increased significantly (p<0.05), implying aggregation and/or fusion of the 
vesicles, broadening of the particle size distribution (Elhissi et al., 2012), which 
may be attributed to water evaporation during jet nebulisation, causing higher 
concentration of phospholipids and consequent vesicle aggregation within 
droplets (Elhissi et al., 2007). For the lower stage of the FSI (filter and filter 
holder), the measured mean size of liposomes was smaller than other regions but 
larger than those measured before aerosolisation (p<0.05). 
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Table 5-7 Mean hydrodynamic diameter (Z-ave) and Polydispersity Index (PDI) of nebulised sonicated co-loaded liposomes delivered to the FSI 
stages, and those remaining in the nebuliser reservoir (n=3, mean± S.D.) 
Type of nebuliser Before nebulisation After nebulisation 
   Nebuliser reservoir Upper stage of FSI Lower stage of FSI 
 Z-ave (nm) PDI Z-ave (nm) PDI Z-ave (nm) PDI Z-ave (nm) PDI 
Air-jet 139.3± 2.42 0.56± 0.03 363.50± 31.05 0.75 ±0.14 258.40± 14.4 0.83± 0.19 172.50± 18.36 0.35± 0.08 
Vibrating-mesh 146.2± 4.58 0.53± 0.01 210.90 ±22.78 0.77± 0.10 250.00± 88.02 0.72± 0.16 112.60± 13.51 0.37± 0.03 
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For the vibrating-mesh nebuliser, the mean particle size and PDI for nebulised 
liposomes remaining in the vibrating-mesh reservoir and on the upper stage of the 
FSI (stage 1 of the FSI housing) was significantly larger than the starting size 
(p<0.05), indicating that the accumulation of large liposomes and/or liposome 
aggregates can occur, which fail to pass through or be extruded through the mesh 
apertures during aerosolisation (Elhissi et al., 2011a; Carvalho and McConville, 
2016). However, liposomes collected on the lower stage of the FSI showed the 
smallest vesicle size (p<0.05). 
The mean size and size distribution of liposomes measured on the lower stage of 
the FSI was smaller than those remaining in both nebuliser reservoirs and on stage 
1 of the impactor. This may be due to water loss when aerosol droplets pass 
through the impactor or liposome disruption after being emitted from the devices 
(Elhissi et al., 2007). For both nebulisers, further studies are required to determine 
whether a marked size reduction of liposomes collected on the lower stage of the 
impactor causes drug leakage, though drug losses on size reduction are not usually 
a major issue for hydrophobic drugs unlike hydrophilic materials (Desai et al., 
2002). The impaction on metal surfaces and subsequent drying of the deposited 
droplets in the FSI may be a further possible reason leading to vesicle disruption 
and aggregation on the upper stage of the FSI. Overall, the physical stability of 
nebulised liposomal aerosols generated by air-jet and vibrating-mesh nebulisers 
was similar.  
Based on these findings particularly for FPF, the air-jet nebuliser was considered 
the more appropriate delivery device for delivering the developed liposomal 
formulation. The morphology of liposomes delivered using the air-jet nebuliser 
was studied by TEM (Figure 5-5 a and 5-5 b), revealing a population of small 
relatively uniform spherical vesicles (50-250 nm) before and after nebulisation. 
This observation was in good agreement with previous reports of multilamellar 
vesicles (MLVs) reduced in size by probe-sonication and nebulised (Bozzuto and 
Molinari, 2015; Pattni et al., 2015; Rudokas et al., 2016). The lamellarity of the 
vesicles did not change during nebulisation (Figure 5-5 c and 5-5 d), suggesting 
that air-jet nebuliser is a suitable device for delivering aerosols of the freshly 
sonicated liposomes. 
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It was noted that sonicated liposomes became cloudy within 30 min after 
preparation, suggesting poor physical stability. It has been reported that extrusion 
of MLVs through 1-µm polycarbonate filter improved physical stability of 
liposomes during air-jet nebulisation and enhanced drug output for air-jet and 
vibrating-mesh nebulisers (Carvalho and McConville, 2016). Therefore, 
membrane extrusion was investigated as an alternative size reduction method. 
 
Figure 5-5 TEM images of co-loaded liposomes prepared by probe-sonication before 
and after air-jet nebulisation (a) freshly prepared formulation (b) vesicles 
remaining in air-jet reservoir following nebulisation (c) liposomes deposited on 
stage 1 of the FSI and (d) liposomes deposited on stage 2 of the FSI. 
a) b) 
d) c) 
Chapter 5 Aerosol properties of liposomes loaded with erlotinib and genistein 
 231 
 Optimisation of liposome extrusion  
The composition of extruded co-loaded liposomes was the same as those 
previously size reduced by probe-sonication. The extrusion process would not be 
expected to affect drug encapsulation for both erlotinib and genistein since both 
drug molecules were incorporated within the liposome bilayers prior to this step 
(Morton et al., 2012). Consequently, optimisation of extrusion was initially aimed 
at improving the physical stability of liposomal formulations during their 
preparation. 
The initial mean volume median diameter (VMD) of freshly prepared erlotinib 
and genistein co-loaded liposomes (lipid concentration of 20 mg/mL) before 
extrusion was 7.83± 0.40 µm. Figure 5-6 a shows an exponential decrease in 
mean VMD (p<0.05) on repeated extrusion cycles through a 3 µm pore membrane 
and that there was only a small further reduction in VMD after 5 extrusion passes. 
In this case, VMD was less than the pore size which is contrary to previous 
reports whereby mean vesicle size is normally larger than the pore size of the 
filter used, due to a reversible elastic deformation of the liposomes when passing 
through the filter pores (Hinna et al., 2015). In this study, it is possible that lipid 
bilayers ‘squeezed off’ during extrusion and reformed vesicles having mean 
diameter smaller than the pore size of membrane filter. Another feasible cause is 
that extruded liposomes have large particles of unentrapped drug removed, during 
the extrusion process. The co-loaded liposomal formulation extruded 5 times 
through a 3 µm pore polycarbonate filter was then extruded further, through a 1 
µm pore filter. The trend for VMD was similar to that obtained with a 3 µm pore 
filter, 5 cycles was the optimal number of extrusion passes to reduce mean size to 
approximately 1 µm (Figure 5-6 b). 
Figure 5-6 c shows that when further extruded through a 0.1µm filter, a final 
constant value of approximately 0.13 µm was achieved. This was in accordance 
with previous reports using pore size < 0.2 µm (Morton et al., 2012; Ong et al., 
2016). Hence, 5 extrusion cycles using a polycarbonate filter with 0.1 µm pore 
size resulted in the desired mean size of 130 nm, when combined with the earlier 
extrusion steps at 3 and 1 µm. 
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Figure 5-6 Mean VMD of liposomes extruded through: a) 3 µm pore polycarbonate 
membrane filter and b) further extruded through a 1 µm pore polycarbonate 
membrane filter, and c) mean hydrodynamic diameter of liposomes further 
extruded through a 0.1 µm pore polycarbonate membrane filter (n=3, mean± S.D.) 
 
In summary, when membrane extrusion was used as a method of size reduction, 
the mean size decreased with an increasing number of extrusion cycles, as 
previously reported (Morton et al., 2012; Ong et al., 2016), reaching a size plateau 
after approximately 5 cycles for each membrane pore size (Figure 5-6 a, 5-6 b and 
5-6 c). Low nitrogen pressure was required to extrude liposomes through large 
membrane pores, whereas a higher pressure was required for extrusion through 
the smallest pore sizes and to increase the homogeneity of liposomes (Morton et 
al., 2012). The mean diameter of extruded liposomes passing through larger 
membrane pore size (5 and 3 µm) was smaller than or approximated the pore size 
of filter, while that of liposomes passed through 100 nm pore membranes was 
slightly larger than the nominal pore size, due to the flexibility of liposomal 
membranes, in accordance with previous reports of the relationship between 
liposome particle size and extrusion membrane pore size (Mayer et al., 1986; 
Hunter and Frisken, 1998; Ong et al., 2016). 
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 Comparison of the properties of liposomes, size reduced by probe-
sonication and membrane-extrusion  
In Chapter 4, size reduction of erlotinib and genistein co-loaded liposomes 
comprising DPPC, cholesterol and DOPE (72:8:20 mole %) was achieved using 
30 min probe-sonication, giving a final mean size of approximately 130 nm after 
removing free drugs (Table 5-8). In this chapter, membrane extrusion was used as 
an alternative method of size reduction to achieve vesicles with a mean size in the 
same range. 
Liposomes pre-filtration were cloudy and opalescent, due to non-incorporated 
drugs and/or liposome aggregates. Table 5-8 shows the mean particle size after 
passing sonicated or extruded liposomes through the cellulose acetate filters was 
smaller than the nominal pore size of 0.45 µm membrane filters, suggesting that 
only incorporated drugs in small liposomes remained in samples (Elhissi et al., 
2013). The mean measured surface charge for all liposome preparations were not 
significantly different (p>0.05), the value being approximately neutral as expected 
based on the individual bilayer components. Commensurately, extruded 
liposomes had a relatively homogeneous size distribution, with small PDI value 
(PDI<0.03) indicative of a monodispersed population (Castile and Taylor, 1999; 
Hadian et al., 2014).  
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Table 5-8 The effect of size reduction method on mean hydrodynamic diameter, 
Polydispersity Index (PDI), zeta potential and drug encapsulation for co-loaded 
liposomes after removing non-incorporated drugs by filtration (n=3, mean± S.D.) 
Size reduction 
method 
Hydrodynamic 
diameter (nm) 
PDI Zeta 
potential 
(mV) 
Encapsulation 
Efficiency (%) 
Probe-
sonication 
    Post-filtration 
 
139.30± 2.42 
 
0.56± 
0.03 
 
+0.27± 
0.05 
 
10.65± 1.69  (Erlo) 
98.69± 3.14  (Gen) 
Extrusion 
   Post-filtration 
 
125.60± 2.15 
 
 
0.13± 
0.05 
 
+0.43± 
0.22 
 
11.45± 1.13   (Erlo) 
105.30± 4.24 (Gen) 
 
Extrusion parameters were optimised using the chosen lipid composition, to 
generate liposomes in the desired size range with maximum incorporation of both 
drugs. The entrapment efficiencies of erlotinib and genistein-loaded liposomes 
prepared by probe-sonication and membrane extrusion were compared after 
removing unentrapped drugs using syringe-filtration. Previous research has 
demonstrated that the entrapment of sonicated hydrophobic steroid-containing 
liposomes was mainly dependent on lipid composition (Elhissi et al., 2013). The 
total content of erlotinib and genistein including free drug and drug-loaded 
liposomes for pre-filtered MLVs after 30 min probe-sonication compared with 
initial weight of drug in liposome preparation was 100%, indicating no drug was 
lost during preparation and sonication before non-incorporated drugs were 
removed by filtration. However, the total content of erlotinib and genistein 
including free drug and drug-incorporated liposomes after passing through a 
series of membrane filters was approximately 10% and 100% of initial weight of 
drug in formulations, respectively, indicating that unentrapped erlotinib was 
retained on the polycarbonate membrane filters during size reduction, while 
almost 100% of initial genistein was successfully incorporated into liposomes and 
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passed through the series of polycarbonate membranes. The entrapment 
efficiencies determined after separating non-incorporated drugs by passing 
through 0.45 µm cellulose acetate membrane filters did not show differences 
between sonicated and extruded liposomes for either drug (p>0.05). Thus, loading 
erlotinib and genistein (2.5% w/w each drug) into DPPC/cholesterol/DOPE 
liposomes (72:8:20 mol%) was not dependent on the method of size reduction 
since both encapsulated drugs were incorporated within the liposomal bilayer 
during preparation (Eckert et al., 2011; Rasti et al., 2012; Hadian et al., 2014). 
Considering the physical stability of liposomal formulations, the aggregation of 
liposomes was clearly observed within 30 min at ambient temperature for 
sonicated liposomes, and therefore freshly prepared formulations were used for 
determining the properties of nebulised aerosol. By contrast, there was no change 
in mean particle size (approximately 125 nm), but slightly increase in PDI of 
extruded liposomes, from 0.13 to 0.26 after 1-day; storage at 4ºC. However, no 
liposomal aggregates were observed. These combined observations suggested that 
membrane extrusion produced a more stable co-loaded liposomal formulation 
than sonication. 
Long-term stability studies are required; however, these findings support the 
development of liposomal formulation prepared by extrusion for enhanced 
stability. 
Overall, extruded liposomes comprising DPPC, cholesterol and DOPE (72:8:20), 
prepared by thin-film hydration with size reduction using extrusion represented 
the best manufacturing and formulation approaches in terms of particle size 
distribution and co-loading of drugs. 
 Aerosol characterisation of extruded liposomes aerosolised using air-
jet and vibrating-mesh nebulisers 
Aerosol properties of nebulised extruded liposomes were studied using the cooled 
FSI, operated at the air-flow rate of 15 L/min for 10 min to investigate whether 
the method of size reduction affected aerosol properties. The air-jet nebuliser 
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generated significantly higher FPF and FPD than the vibrating-mesh nebulisers 
(p<0.05) after 10 min nebulisation (Figures 5-3 and Figure 5-4, Table 5-4 and 
Table 5-6). Comparing the findings for sonicated and extruded liposomes (Figures 
5-3 and 5-4 for sonicated liposomes and Figure 5-7 for extruded liposomes), there 
were no significant differences in FPF for liposomes prepared by the different 
methods of size reduction using air-jet nebulisers (p>0.05), while vibrating-mesh 
nebulisers generated significantly higher FPF for extruded liposomes (p<0.05). 
However, the values of FPD of extruded erlotinib and genistein liposomes 
generated by both nebulisers were significantly higher than for sonicated 
liposomes (p<0.05) as seen in Tables 5-4, 5-6 and 5-9. This possibly resulted from 
the more monodispersed liposome population produced by membrane extrusion, 
passing more readily through the multiple aperture mesh of the nebulisers 
compared with those prepared by sonication.  
From these findings, the air-jet device would appear superior to the vibrating-
mesh device for delivering liposomes prepared by both methods of size reduction. 
Based on the combined results of FPD from Tables 5-4, 5-6 and 5-9, for the 
liposomal system, size reduction by extrusion, the air-jet nebuliser would appear 
preferable, with the aerosol properties less dependent on the properties of the 
liposomal formulations than the vibrating-mesh device. 
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Figure 5-7 Aerosol parameters of extruded co-loaded liposomes delivered by air-jet 
and vibrating-mesh nebulisers with the cooled FSI at 15 L/min (n=3, mean ±S.D.) 
 
Table 5-9 Fine particle dose for extruded co-loaded liposomal aerosols delivered by    air-
jet and vibrating-mesh nebulisers into the cooled FSI operated at 15 L/min (n=3, mean 
±S.D.) 
Type of nebuliser Fine Particle Dose (µg) 
Air-jet 
49.43± 5.88              (Erlo) 
480.36± 16.23          (Gen) 
Vibrating-mesh 
31.75± 5.05              (Erlo) 
307.62± 87.49         (Gen) 
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 Size stability of nebulised extruded liposome delivered by the air-jet 
and vibrating-mesh nebulisers 
For liposomes prepared by extrusion, there was a very small increase in mean 
particle size and PDI of liposomes remaining in the main reservoir of the air-jet 
and vibrating-mesh devices, upper and lower stage of the FSI compared with 
freshly prepared formulations (p<0.05; Table 5-10).  
When Table 5-7 and Table 5-10 are compared, liposomes sized reduced by 
extrusion process showed better size stability than those size-reduced by 
sonication during aerosolisation using both nebulisers in terms of changes in mean 
size after nebulisation, particularly for those remaining in the nebuliser reservoirs 
and deposited on stage 1 of the FSI. The mechanism underlying this is unclear and 
merits further investigation. In this study, liposomes were nebulised immediately 
after size reduction. Sonication is a physically much more disruptive and energy 
intensive process than extrusion, resulting in fracturing of vesicles and formation 
of new liposomes from bilayer fragments. With insufficient time for annealing of 
these newly formed structures, aggregation and fusion of vesicles may occur more 
readily than for extruded liposomes, which are size reduced by the relatively 
gentle process of squeezing through pores of defined size (Lawaczeck et al., 1976). 
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Table 5-10 Hydrodynamic diameter (Z-ave) and Polydispersity Index (PDI) of nebulised extruded co-loaded liposomal aerosols delivered to the FSI stages, 
and those remaining in the nebulizer reservoir (n=3, mean ±S.D.) 
 
Type of nebuliser 
 
Before nebulisation 
After nebulisation 
Nebuliser reservoir Upper stage of the impactor Lower stage of the impactor 
 Z-ave (nm) PDI Z-ave (nm) PDI Z-ave (nm) PDI Z-ave (nm) PDI 
Air-jet 
117.9± 2.27 0.08± 0.02 129.90± 0.87 0.25± 0.01 139.50± 10.21 0.28± 0.00 125.40± 5.55 0.22± 0.03 
Vibrating-mesh 
115.4± 1.97 0.14± 0.09 116.10± 4.78 0.10± 0.03 138.70± 6.60 0.29± 0.03 113.60± 3.27 0.15± 0.04 
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 Conclusions 
Sonicated and extruded co-loaded liposomes with potential for pulmonary 
delivery were successfully prepared by the conventional thin-filmed hydration 
method, followed by probe-sonication or membrane extrusion to reduce the mean 
size. The effects of probe sonication and membrane extrusion methods on drug 
incorporation and size stability during aerosol generation using air-jet and 
vibrating-mesh nebulisers has been studied and shown that the performance of air-
jet nebulisers was more effective than vibrating-mesh nebulisers for delivering 
liposomes reduced in size by both methods. The use of full impactors to 
characterise inhaler formulations may be limited by the need to accurately 
quantify deposited drug across multiple stages and they are labour intensive to use. 
The Fast Screening Impactor (FSI), comprising only two impaction stages with 
minor modifications, was found to be simple, labour and time-saving for aerosol 
characterisation, representing a useful alternative technique for characterising the 
aerosol properties of nebulised formulations, particularly when pre-cooled and 
used at 15 L/min. An air-jet nebuliser was found superior to a vibrating-mesh 
nebuliser, for delivering the co-loaded liposomes over a 10-min period, in terms 
of higher fine particle fraction. Extrusion was superior to probe sonication during 
preparation of formulations and aerosolisation process, giving greatest size 
stability of co-loaded liposomes as determined by size analysis before and after 
nebulisation.  
Overall, liposomes co-loaded with erlotinib and genistein prepared by extrusion 
were effectively delivered using an air-jet nebuliser. 
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 General discussion and conclusion 
Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related 
deaths worldwide (Zarogoulidis et al., 2013). Currently, oral and injected 
therapies for lung cancer are limited due to the systemic side effects and sub-
therapeutic levels of chemotherapeutic agents at the target site (Hu et al., 2013; 
Rudokas et al., 2016). Pulmonary drug delivery is an attractive route of 
administration and has been used to deliver drugs for local treatment of 
respiratory diseases including asthma, COPD and cystic fibrosis (Pilcer and 
Amighi, 2010). Thus, this delivery route may achieve effective localised treatment 
for NSCLC. 
Targeted therapy, one treatment approach in NSCLC, has been studied to treat 
specific molecular targets, including the epidermal growth factor receptor (EGFR) 
(Molina et al., 2008). Erlotinib, an epidermal growth factor receptor tyrosine 
kinase inhibitor (EGFR-TKIs), has been approved as 1st line treatment for patients 
who have EGFR mutations and as 2nd and 3rd line treatments for those with 
advanced-stage NSCLC. However, the toxicity of erlotinib is problematic 
(Thatcher et al., 2009; Zarogoulidis et al., 2013). Combinations of a 
phytochemical (e.g. genistein, curcumin, fisetin) and a chemotherapeutic agent 
have attracted a great deal of attention for reducing drug toxicity on normal cells 
and for their potentiation effects. Among a number of phytochemicals that have 
been studied on multiple targets in cancer cells, more than 60% are flavonoids, 
which can be found in fruits and vegetables. For example, the combination of 
erlotinib and genistein has shown synergistic anti tumour activity in three 
different NSCLC cell lines (Gadgeel et al., 2009).  
One factor that can limit the bioavailability for NSCLC treatment is the low 
aqueous solubility of many hydrophobic anticancer agents. Formulation 
approaches using colloidal drug carriers (e.g. polymeric micelles, liposomes, 
cyclodextrin, dendrimer) have been proposed to improve water solubility, which 
when administered by the pulmonary route may achieve drug dose uniformity, 
decrease the frequency of drug dosing and reduce the incidence of potential 
systemic side effects (Mansour et al., 2009). This PhD research explores a 
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potential strategy to enhance the treatment of lung cancer, by using polymeric 
micelles or liposomes for co-delivery of hydrophobic anticancer agents by the 
pulmonary route. Polymeric- and lipid-based carriers may be particularly suitable 
for pulmonary delivery, due to their biocompatibility and reduced drug toxicity 
(Li et al., 2015). 
For in-vitro aerosol characterisation of nebulised aerosols, the Next Generation 
Impactor (NGI) is routinely used. However, the quantification of nebulised low 
dose formulations is challenging, due to the small absolute amounts of drug 
deposited across many stages of a full impactor. Also, the use of full cascade 
impactors is time-consuming and labour intensive. Therefore, Abbreviated 
Impactor Measurement (AIM) using the Fast Screening Impactor (FSI), which 
yields limited information about the whole particle size distribution of an aerosol 
cloud was considered in this study. This was to investigate whether this faster 
method for aerosol analysis gave comparable results for key quality parameters 
for aerosolised drug carriers using medical nebulisers. 
This PhD investigated whether a hydrophobic drug-hydrophilic polymer 
conjugate could self-assembly to form micelles for delivering hydrophobic 
anticancer agents. Secondly, whether nebulisation of micelles and liposomes for 
the co-delivery of hydrophobic drugs delivered by air-jet and vibrating-mesh 
nebulisers could produce desirable aerosol characteristics, with high drug output 
and fine particle dose. Thirdly, this thesis studied whether the FSI could be used 
as an alternative impactor to the NGI, giving comparable values for key 
parameters for inhaler products including emitted dose, mass balance, fine particle 
fraction and fine particle dose. The work in this thesis was divided into three main 
sections; 1) synthesis and characterisation of drug-polymer conjugate, 2) 
preparation and characterisation of hydrophobic drugs-loaded polymeric micelles 
and liposomes and 3) aerosol characterisation of nebulised aerosols determined by 
the NGI and the FSI. 
The first part of this thesis studied a potential strategy for formulating 
hydrophobic drugs using hydrophilic polymer-hydrophobic drug conjugates. 
Drug-polymer conjugates have demonstrated a number of advantages including 
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enhancing the aqueous solubility of hydrophobic drugs (Hans et al., 2005; 
Khandare and Minko, 2006). In this approach, the drug-polymer conjugate forms 
micelles, encapsulating another drug for co-delivery. Recently, phytochemicals 
have received great attention as chemo-preventive agent. Genistein, one of the 
most extensively studied isoflavones, has shown synergistic anti-carcinogenic 
activities with both cytotoxic drug (i.e. erlotinib) and a herbal medicine (i.e. 
curcumin) against different cancer cell lines including lung, breast, ovarian and 
prostate cancer, without exerting toxic effects on normal cells (Liu et al., 2014b). 
Therefore, genistein was considered for co-delivery with a conventional cytotoxic 
drug; namely erlotinib in this study since co-delivery may allow the dose of 
cytotoxic drug to be reduced.  
The hydrophilic polymer, methoxy poly (ethylene glycol) (mPEG) has been 
frequently used in hydrophilic drug carriers. mPEG has been used in approved 
PEGylated biopharmaceutical products for clinical use namely mPEG-epoetin 
beta and mPEG-filgrastim (Turecek et al., 2016, BNF, 2018). Thus, mPEG was 
chosen to form a genistein- mPEG conjugate as described in Chapter 2 for 
producing drug carriers. Such carriers may retain the biological activity of 
genistein and be capable of delivering erlotinib or curcumin. The synthesis of 
amphiphilic genistein-mPEG conjugate involved two main steps: 1) oxidation and 
2) esterification. The successful synthesis of genistein-mPEG conjugate yielded a 
pale yellow powder, with a yield of 43.7% was confirmed by FT-IR, 1H-NMR 
and mass spectroscopy. 
Initially, this drug-polymer conjugate was studied to determine whether it could 
self-assembly to form micelles. The critical micelle concentration (CMC), 
measured using DLS was 1.35 mg/mL (2.56 x 10-4 M) as outlined at the 
beginning of Chapter 3, indicating self-assembly into micelles. The main body of 
the experimental work described in this chapter investigated the preparation and 
characterisation of genistein-mPEG micelles loaded with hydrophobic drug 
(erlotinib or curcumin). The aerodynamic characteristics of micelles delivered in 
aerosol generated by air-jet and vibrating-mesh nebulisers were measured using 
the NGI.  
Chapter 6 General conclusion and future work 
 245 
A preliminary study of erlotinib loading into the synthesized conjugate, showed 
an encapsulation efficiency of approximately 3%, with the generation of a turbid 
white suspension during preparation. This indicated that this conjugate was not 
appropriate for the delivery of erlotinib. On the other hand, curcumin was 
successfully incorporated into genistein-mPEG micelles, giving a transparent 
yellow solution with no precipitation. These observations suggest that the polymer 
was not suitable for erlotinib, possibly due to its molecular structure which limited 
drug incorporation into the micelles. Nevertheless, this new amphiphilic 
compound was a suitable drug carrier for curcumin. Curcumin was incorporated 
into genistein-mPEG at a range of concentrations to identify the optimal drug 
concentration (% w/w drug in total polymer content) for further studies.  
Based on effect of curcumin concentration on drug entrapment, surface charge, 
mean particle size and size distribution, 5% w/w drug in polymer was found to be 
the optimal content. This concentration gave the maximum solubilisation of 
curcumin, combined with other desirable properties; a high negative charge, mean 
size < 200 nm and PDI <0.3. Consequently, this final formulation was chosen for 
delivery by nebulisers. 
The aerosol properties of curcumin-loaded micelles (5%w/w drug in conjugate) 
delivered from air-jet and vibrating-mesh nebulisers, were determined using the 
NGI. The air-jet nebuliser produced significantly higher fine particle dose (FPD) 
and fine particle fraction (FPF) compared with the vibrating-mesh nebuliser. The 
predominant reason for the unexpected relatively poor performance of the 
vibrating-mesh nebuliser may be the physicochemical properties of the 
formulation investigated. Thus, further investigation is required to improve 
understanding to develop appropriate formulation strategies as outlined in future 
work.  
In summary, genistein-mPEG micelles incorporating curcumin at 5% w/w were 
successfully delivered using both nebulisers, with emitted dose greater than 50% 
(ED). The values of FPD and FPF for air-jet and vibrating-mesh nebulisers were 
in the range of 73-136 µg, and 33-48%, respectively. This indicates the potential 
of the micelle formulation approach for pulmonary co-delivery of anticancer 
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agents. Few studies of nebulised polymeric micelles have been previously 
reported; for instance, amphotericin B and budesonide micelles (Gilani et al., 
2011; Sahib et al., 2011; Moazeni et al., 2012). The drug-polymer conjugate 
developed in this thesis may have application for nebulisation of other 
hydrophobic molecules, which have similar structural properties to genistein. 
Since genistein-mPEG conjugate was not suitable for the delivery of erlotinib, 
another lipid-based formulation approach was explored for this drug in Chapter 4. 
Liposomes are lipid-based carriers used for various therapeutic applications 
including cancer treatment (Sercombe et al., 2015; Rudokas et al., 2016). These 
drug-carriers have more available space to accommodate exogenous compounds 
within different lipid bilayers compared to micelles, due to their size and 
lamellarity, and they are thermodynamically more stable than micelles following 
dilution (Bozzuto and Molinari, 2015), retaining incorporation and maintaining 
their size and structure better than micelles. Consequently, liposomes were 
considered for the co-delivery of erlotinib and genistein in Chapter 4.  
Erlotinib and genistein co-loaded liposomes were prepared by the traditional thin-
film hydration method, followed by probe-sonication. The in-vitro 
characterisation of the developed liposome formulation co-loaded with erlotinib 
and genistein was the major focus of this chapter. In order to develop 
formulations, an understanding of the effect of drugs and excipients on the 
properties of the lipid bilayer is important to optimise the quality attributes 
liposomal system especially entrapment efficiency, drug release and in-vitro 
stability (Demetzos, 2008; Chen et al., 2014). Thermal analysis using DSC, which 
is commonly employed to explore drug interactions with the phospholipid bilayer, 
is useful for liposomal formulation development. Two analytical methodologies 
(HPLC and DSC) were employed to study drug incorporation and the molecular 
interactions between drugs and lipids within the DPPC bilayer. 
A new HPLC analytical method developed and validated according to ICH was 
used to show that the maximum incorporation of erlotinib and genistein 
individually and co-loaded in DPPC liposomes was 2.5% w/w. DSC thermograms 
showed that the incorporation of both drugs into DPPC liposomes reduced the 
Chapter 6 General conclusion and future work 
 247 
packing of the acyl chain domain observed by a broadening of the main phase 
transition, measured as an increase in the half-height width (HHW), with a 
significant decrease in the main transition temperature of DPPC. This indicates an 
increase in the fluidity of the hydrocarbon chains and a reduction of cooperative 
unit within the phospholipid bilayer, suggestive of incorporation of the 
hydrophobic drugs close to the upper regions of the bilayer and polar head group 
of DPPC liposomes. The pre-transition was abolished on incorporation of the 
drugs. These combined results confirm that erlotinib and genistein were 
successfully incorporated into DPPC liposomes. 
The highest HHW value was found with 2.5% w/w erlotinib and 2.5% w/w 
genistein co-loaded liposomes, suggesting maximum drug incorporation. The 
final liposome formulation co-loaded with erlotinib and genistein in the presence 
of cholesterol (8 mol% of total lipid content) and DOPE (20 mol% of total lipid 
content) after 30 min sonication showed mean hydrodynamic diameter and PDI of 
approximately 136 nm and 0.45, respectively. The inclusion of cholesterol and 
DOPE caused a change in membrane properties, resulting in enhanced drug 
incorporation into the liposomes. The DSC data showed changes in the main 
phase transition (Tm, HHW and ∆H) as compared to formulations containing only 
drugs and DPPC, supporting that the incorporation of the two biomolecules into 
DPPC bilayer disrupted the packing order of the hydrophobic hydrocarbon chains 
and increased bilayer fluidity. The entrapment efficiency of genistein was 10 
times higher than for erlotinib, being approximately 100% and 10%, respectively. 
Thermal analysis using DSC showed that genistein had a more pronounced effect 
on the bilayer properties than erlotinib. Specifically, it seems that the three 
hydroxyl groups on the benzene rings of genistein are easier to protonate and can 
form stronger ionic bonding with the phosphate and/or amine group of DPPC 
compared with oxygen from the methoxyethoxy chains and nitrogen atoms from 
the quinazolinamide ring of the erlotinib molecule. Moreover, the rigid structure 
of erlotinib containing three benzene rings attached to alkyne may limit the 
rotation and penetration of erlotinib molecules into the bilayer. From this, 
differences in their molecular structure may be the main reason for differences in 
partitioning into the bilayer and consequently encapsulation efficiency. 
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Since DSC can provide information about energetic properties, this method plays 
an important role in the development of drug delivery systems such as for 
prediction of maximum drug incorporation into membranes (Casado et al., 2016). 
2.5% w/w erlotinib and 2.5% w/w genistein co-loaded liposomes were chosen for 
future studies based on these findings and optimal liposome size. In Chapter 5, 
nebulisation of 4 mL of this liposomal preparation for 10 min was considered 
optimal, to give high delivery of erlotinib and genistein.  
At the same flow rate of 15 L/min, the FSI (cooled at 5 ºC for 90 min) with 
modifications was evaluated as an alternative to the NGI to overcome the 
analytical drawbacks associated with the NGI for evaluating erlotinib delivered by 
an air-jet nebuliser. An additional insert calibrated at 30 L/min of the FSI was 
modified by covering three of six nozzles alternately with wet glass microfiber 
filter to maintain a cut-off for 5 µm at the employed flow rate of 15 L/min. This 
two-stage abbreviated impactor was found to be simple to use and labour-saving 
for simple aerosol characterisation, with similar performance compared to the 
NGI. This suggests the FSI may have great utility as a relatively quick method for 
formulation development and evaluation of nebulised liposomal preparations. 
There were differences in absolute values for FPD and FPF calculated using the 
two impactors, but trends for both drugs were the same. The NGI gave higher 
values for FPD and FPF compared to FSI (p<0.05).  
The differences in absolute values may result from the longer distance that the 
aerosol must pass as it travels through the full impactor, resulting in solvent loss 
from the nebulised droplets. There are also differences in the way FPF/FPD are 
calculated with the two impactors: by interpolation of cumulative fraction or 
cumulative mass of active substance versus cut-off diameter plot for the NGI, 
drug mass deposited on the lower stage for the FSI. The low absolute values for 
FPF and FPD reflect that large volumes of formulation were nebulised, not to 
dryness. Also, an internal dead space upstream of the FSI gives an internal 
geometry of the FSI dissimilar to that of the NGI, resulting in differences in 
particle deposition behaviour between the two impactors. Using the cooled FSI (5 
ºC) at a flow rate of 15 L/min for 10 min demonstrated that for the developed 
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liposomal formulation the air-jet, rather than vibrating-mesh nebuliser, was the 
more appropriate delivery device, giving higher FPF and FPD. 
Whilst the majority of studies reported were conducted with sonicated liposomes, 
the aerosol properties of nebulised extruded liposomes were also studied. Based 
on the results, the membrane extrusion method improved the size stability of 
liposomes during preparation and aerosolisation process as determined by particle 
size distribution before and after nebulisation.  
To conclude, the vibrating-mesh nebuliser was efficient; reaching dryness in a 
short time (3-10 min) for both sonicated and extruded preparations under the same 
operating conditions (Ari, 2014; Pritchard et al., 2018). However, the performance 
of these devices is dependent on formulation physicochemical properties; for 
example, ionic content, viscosity, surfactant, and particle size for dispersed 
systems (Chan et al., 2011; Carvalho and McConville, 2016). The lower 
efficiency of the vibrating-mesh nebuliser for delivering this specific formulation 
may be due to the lower energy input for atomisation and absence of an ionic 
component (particularly halides) or surfactant (Ghazanfari et al., 2007; Beck-
Broichsitter and Oesterheld, 2017). Pari GmbH has reported that nebulisation of 
2.5 mL of salbutamol sulfate solutions in the presence of 0.9% w/v NaCl for 3 
min using Pari Velox mesh nebuliser produced aerosol with MMAD and FPF, of 
3.8 µm and 74%, respectively. Consequently, the inclusion of the appropriate type 
and concentration of ionic solutions (usually chloride) and/or viscosity reducing 
agent should be conducted in future work.  
In terms of dose, formulations of curcumin, genistein and erlotinib for pulmonary 
delivery are not commercially available; therefore the appropriate local dose given 
via the pulmonary route should be evaluated. Clinical studies have suggested that 
1500 mg daily is the recommended oral dose of curcumin for patients with lung 
cancer (Gupta et al., 2013; Fadus et al., 2017). The dose required for the oral 
treatment of NSCLC using erlotinib is 150 mg once daily (Yeo et al., 2010b, BNF, 
2018). For genistein, an oral dose of 50 mg/kg body weight has been suggested 
based on in vivo studies (Spagnuolo et al., 2015). Based on the present findings of 
nebulised aerosols emitted from air-jet nebuliser, the fine particle doses of 
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curcumin in micelles, erlotinib and genistein in co-loaded liposomes are 123 mg, 
49 mg, and 480 mg, respectively. Since a decrease in drug metabolised prior to 
reaching the target site (pre-systemic metabolism) is one of the main benefits of 
pulmonary delivery, a lower dose is often required for inhalation compared to oral 
delivery for local lung co-delivery. In order to increase aerosol dosing, 
preparation of formulations as a dry powder by spray-drying or freeze-drying 
process, followed by reconstitution in a small volume of water is suggested. This 
is to increase the concentration of drug in the final dispersion before nebulisation. 
Also, dosing can be adjusted by increasing nebulisation time or frequency of 
administration to achieve the desired dose of drug in the deep lung.  
To sum up, all the findings of this thesis together support the development of two 
formulation approaches for the co-delivery of a herbal substance (genistein) and a 
cytotoxic drug (erlotinib) using liposomes and the combination of two herbal 
substances (genistein and curcumin) using micelles as suitable for delivery as an 
aerosol from a medical nebuliser. From previous reports of aerosol 
characterisation for DPIs and pMDIs, the utility of the FSI has shown equivalent 
performance to the NGI in terms of similar FPD and FPF (Mitchell and Nichols, 
2011). In this study, the FSI was found to be a useful alternative to the NGI based 
on the nebulised liposomal formulation containing genistein. The FSI is not able 
to provide all the information that the NGI or other full cascade impactors do, 
such as MMAD and GSD since these require plotting of multiple data points and 
interpolation of data, which is not available with the FSI. This applies also to the 
other two abbreviated impactors, namely the Fast Screening Andersen (FSA) and 
Reduced Next Generation Impactor (rNGI), which employ two or three-sized 
fractionating stages. However, the data obtained with abbreviated impactor is 
sufficient and adequate for routine quality control and inhaler product 
development including using ‘Efficient Data Analysis (EDA)’. Consequently, it 
may be beneficial to use the FSI as an alternative impactor for quality control 
where the purpose is to check for batch-to-batch variation as well as product 
development applications of nebuliser formulations.  
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 Future work 
The findings presented in this thesis have demonstrated that the two studied 
formulation approaches; micelles and liposomes can be considered for the co-
delivery of hydrophobic anticancer agents and their aerosol properties can be 
characterised by a full-cascade impactor or an abbreviated impactor, following 
nebulisation. There are four areas that future work could focus upon as listed 
below. 
1) Study of the biological activity of genistein in genistein-mPEG 
conjugate 
The aim of this study was to synthesize a new compound that may produce 
polymeric micelles, which retain the biological activity of genistein. The hydroxyl 
groups (-OH) attached to the benzene rings of genistein are responsible for its 
biological activities (Pavese et al., 2010; Rusin et al., 2010; Yoon and Park, 2014). 
For example, genistein can act as an antioxidant via protonation at –OH groups, 
thereby protecting against oxidative damage (Yoon and Park, 2014). The 
antiproliferative activity of genistein via inhibition of tyrosine kinase, 
topoisomerase II and G2/M block of the cell cycle is also related to the structural 
features of genistein. Consequently, the genistein-mPEG conjugate requires 
further investigation to determine whether the activity of genistein such as 
anticancer and antioxidant properties remain after being hydrolysed by 
carboxylesterase enzyme in bronchial epithelial cell (Mutch et al., 2007). 
Many studies have been carried out on the antioxidant activity of compounds 
found in natural substances and medicinal herbs. In vitro studies, the antioxidant 
activity of genistein in soybean can be determined by DPPH radical-scavenging 
activity and ABTS radical-scavenging activity in future since these two methods 
are sensitive to detect antioxidant activity within a short time (Mihaylova and 
Schalow, 2013; Lee et al., 2015a).  
To study the in vitro cytotoxic effect of genistein, A549 cells should be 
considered since this NSCLC cell line has been used to study the anticancer 
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activity of genistein in combination with erlotinib or curcumin. The assessment of 
cell viability can be determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT assay) to reflect the inhibition of cell growth 
for human lung carcinoma cells (Liu et al., 2014b; Yang et al., 2016; Zhang et al., 
2017). Moreover, other hydrophobic drugs for cancer-related diseases may be 
delivered using this conjugate. 
2) Study of the synergistic activity of curcumin-loaded genistein-mPEG 
polymeric micelles and liposomes co-loaded with erlotinib and 
genistein  
It should be noted that the genistein content in genistein-mPEG micelles could not 
be accurately determined in this study. This is because the ester bond of genistein 
and mPEG-COOH was not hydrolysed prior to HPLC determination. Further 
studies should consider the hydrolysis of genistein from genistein-mPEG (Qiu et 
al., 2010). Also, the potential synergistic anticancer activity in NSCLC may allow 
dose reduction in combinations of genistein and curcumin and for genistein and 
erlotinib. Therefore, a cell viability (A549 cell line) study should be carried out by 
MTT assay to determine the lowest dose needed in the two drug combinations. 
The data of in vitro cytotoxicity of combinations may suggest an appropriate 
formulation approach as well as suitable dosing and treatment durations for 
patients. 
3) Study of the effect of fluid properties on the discriminatory ability of 
the cascade impactors 
The concept of Abbreviated Impactor Measurement (AIM) has received attention 
from the pharmaceutical industry and instrument manufacturers as a quick method 
of measuring Aerodynamic Particle Size Distribution (ASPD) using a reduced 
number of stages in the impactor. The lower number of stages in the FSI as 
compared to a full cascade impactor makes it possible for higher accuracy due to 
low internal losses and less opportunity for analyst error, as well as for faster data 
acquisition (Mitchell et al., 2009b). Various studies have previously been 
conducted to compare the results obtained using the NGI or ACI and the FSI; 
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however, the use of FSI as an interchangeable impactor with the NGI for fluid 
nebuliser for routine quality control and product development has not been 
investigated widely.  
In this work, liposomes were studied to explore the comparability of the full and 
abbreviated cascade impactor methods. Future work should evaluate the effect of 
changes in formulation properties (e.g. viscosity and surface tension) and 
formulation strategies (solution, complexation, dendrimer etc.) on the 
performance of the two cascade impactors with respect to critical quality 
attributes such as emitted dose and fine particle dose to explore the relative ability 
of full and abbreviated impactors to determine differences in aerosol properties 
resulting from changes in fluid properties. Also, variations from multiple 
operators should be tested for sensitivity of the NGI and the FSI. 
4) Study of the effect of fluid properties on the performance of air-jet and 
vibrating-mesh nebulisers 
Based on the studies in this thesis, the air-jet nebuliser was found to be more 
efficient than vibrating-mesh nebuliser, with significantly higher FPD and FPF for 
curcumin-loaded genistein-mPEG micelles and for extruded liposomes co-loaded 
with erlotinib and genistein. These findings were at variance with some previous 
reports.  
There are a number of factors affecting the aerosolisation performance of 
vibrating-mesh devices. For example, components of the mesh itself (i.e. the size 
of pore, the mode of vibration, shape of mesh, material used and the 
aerosolisation mechanism) can vary widely between different manufacturers 
(Pritchard et al., 2018). Additionally, various physicochemical properties; for 
instance, surface tension, viscosity, salt and halide content and particle size in 
dispersed systems also have effects on drug output rate delivered by vibrating-
mesh nebulisers (Ari, 2014; Pritchard et al., 2018). As stated in Chapter 3 and 5, 
HPLC grade water was used to prepare micelles and liposomes to keep 
formulations as simple as possible. For aerosol properties of nebulised droplet 
delivered by air-jet and vibrating-mesh nebulisers, both formulations showed the 
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same trends. This may be because the particle size of drug-carriers (micelles and 
liposomes) and fluid viscosity were similar. 
The Velox mesh nebuliser used in this work, is based on the eFlow technology 
(active-mesh nebuliser) and was launched by Pari GmbH in 2015 (Pritchard et al., 
2018). A further systematic investigation of various drug-carriers and fluid 
properties should be considered for a better understanding of the droplet size, the 
dose emitted from a particular device and the nebuliser output efficiency.  
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